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ABSTRACT
The work described in this thesis was aimed at 
distinguishing between two possible mechanisms for the 
antiviral mode of action of pyrophosphate analogues.
Either, (a) they are converted into analogues of nucleo­
side triphosphates which inhibit the viral polymerase, or 
(b) they interact directly with the polymerase possibly 
by coordinating with an essential metal ion.
Several pyrophosphate analogues have been 
synthesised and screened for activity against herpesvirus 
DNA polymerase, influenza RNA polymerase and calf thymus 
DNA polymerase a. Characterisation of a number of these 
compounds was accomplished by chemical ionisation mass 
spectrometry. A number of reagent gases were tested and 
ammonia was found to be the most satisfactory.
The work carried out in this thesis suggests 
that the pyrophosphate analogues do not inhibit the viral 
polymerases by first being incorporated into the 6-y 
positions of nucleoside triphosphates. The proposed 
nucleoside triphosphate analogues have been synthesised 
and these are neither substrates for, nor inhibitors of the 
enzymes. Furthermore, when [2-^H]-phosphonoacetate was 
incubated with the standard polymerase assay mixtures, 
all the radioactivity recovered from the assays was in 
the form of starting material, none could be detected 
in the form of nucleoside triphosphate analogues.
However, it appears that the pyrophosphate 
analogues complex with an essential metal ion of 
influenza RNA polymerase. Dissociation constants (Kd i) 
for complexes formed between zinc ions and pyrophosphate 
analogues at pH 8.0 have been determined by gel 
filtration and there is a correlation between the Kd , of 
an analogue and its effectiveness as an inhibitor of 
influenza RNA polymerase.
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CHAPTER 1
GENERAL BACKGROUND
1.0 THE DISCOVERY OF VIRUSES
By the 1880’s the pioneering work of Pasteur, 
Koch and others had proved conclusively the microbial- 
aetiology of a number of disease states. However, there 
were a considerable number of infectious diseases that 
could not be attributed to bacteria or protozoa. It 
was originally assumed that these pathogens were extremely 
small bacteria which could not be cultured because of a 
lack of knowledge of their nutritional requirements.
experiment on the sap of tobacco leaves infected with 
mosaic disease to show the presence of infective bacteria. 
This involved passing the sap through a filter which 
had previously been shown capable of excluding the 
smallest of bacteria. The filtered material remained 
infectious but Ivanovsky refused to accept his results 
concluding that some contamination had taken place. In
unlike his predecessor recognised their importance. To 
describe this unprecedentedly small pathogen Beijerinck 
coined the phrase "contagium vivum fluidum" (contagious 
living fluid) or "virus".
In the same year Loeffller and Froscli demonstrated 
that cattle foot and mouth disease could be transmitted
1898 Ivanovsky's experiments and
X Dyson (1974)
2by a filtrate. They extended this work by proving 
conclusively that no toxin was involved and speculated 
that many other diseases might be caused by these very 
small reproducing agents. During the early part of this 
century diseases such as mumps, chicken pox, rabies, 
yellow fever and small pox were shown to be caused by 
viruses (Table 1.0), and viruses have since been found 
to be ubiquitous parasites of living organisms.
1•1 MEDICAL EFFORTS TO CONTROL VIRAL INFECTIONS
Bacteria are totally independent entities containing 
many enzymes and substrates which are unique to the 
prokaryotic cell and afford useful targets for anti-bacterial 
drugs. The success of the general screening approach in the 
discovery of anti-bacterials is on the whole a reflection 
of the large number of processes which are found only in 
the bacterial cell. Unlike bacteria, which can multiply 
in tissues in an extracellular position, viruses are 
obligate intracellular parasites and can only multiply 
within cells which provide the synthetic and energy 
yielding processes which they lack.
The intimate intracellular relationship between 
virus and host led to the belief that viral diseases 
could not be treated with chemical agents since any 
effect on viral multiplication would necessitate a toxic 
effect on host processes. Hence, early efforts to combat 
viral infections were largely directed to preventing the 
individual from contracting the disease through personal
T a b le  1 . 0  Im portant-  Viruses o f V erteb rates
N u c l e i c
A c i d
T y p e F a m i l y G e n u s V i r u s T y p e  o f  I n f e c t i o n  I n d u c e d
D N A A d e n o v i r i d a e M a s t a d e n o v i r u s N u m e r o u s  a d e n o  t y p e s R e s p i r a t o r y  a n d  o p h t h a l m i c
D N A H e r p e t o v i r i d a e H e r p e s v i r u s H e r p e s  t y p e s  l  a n d  2 O p h t h a l m i c ,  c e n t r a l  n e r v o u s
s y s t e m ,  g e n i t a l ,  c u t a n e o u s ,  
o r a l ,  u p p e r  r e s p i r a t o r y
C y t o m e g a l o G e n e r a l i z e d  o f  i n f a n t ,  r e s -
p i r a t o r y .  g l a n d u l a r
V a r i c e l l a N e r v o u s ,  c u t a n e o u s
( h e r p e s  z o s t e r )  
P s e u d o r a b i e s C e n t r a l  n e r v o u s  s y s t e m  o f
l i v e s t o c k
I n f e c t i o u s R e s p i r a t o r y  o f  l i v e s t o c k .
r h i n o t r a c h e i t i s f o w l
D N A P o x v i r i d a e O r t h o p o x v i r u s V a r i o l a  ( s m a l l p o x ) G e n e r a l i z e d
V a c c i n i a C u t a n e o u s
D N A P a p o v a v i r i d a e P o l x o m a v i r u s P o l v o m a .  S V 4 0 T u m o r s  o f  r o d e n t s
R N A O n h o m y x o v i r i d a e i n f l u e n z a v i r u s I n f l u e n z a R e s p i r a t o r y
R N A P a r a m y x o v i r i d a e P a r a m y x o v i r u s P a r a i n r i u e  n z a R e s p i r a t o r y
M u m p s G l a n d u l a r
N e w c a s t l e  d i s e a s e R e s p i r a t o r y  a n d  n e r v o u s  o f
f o w l
M o r b i l l i v i r u s M e a s l e s G e n e r a l i z e d
C a n i n e  d i s t e m p e r G e n e r a l i z e d  in  d o g s
P n e u m o v i r u s R e s p i r a t o r y  s y n c y t i a l R e s p i r a t o r y
R N A P i c o T i a v i r i d a e E n t e r o v i r u s P o l i o N e r v o u s
C o x s a c k i e R e s p i r a t o r y ,  n e r v o u s ,  c a r d i o -
v a s c u l a r
E c h o N e r v o u s ,  i n t e s t i n a l
R h i n o v i r u s N u m e r o u s  r h i n o  t y p e s R e s p i r a t o r y
F o o t  a n d  m o u t h  d i s e a s e G e n e r a l i z e d  o f  l i v e s t o c k
C a l i c i v i r u s F e l i n e  c a l i c i R e s p i r a t o r y  o f  c a t s
V e s i c u l a r  e x a n t h e m a G e n e r a l i z e d  o f  s w i n e
R N A R h a b d o v i r i d a e V e s i c u l o v i r u s V e s i c u l a r  s t o m a t i t i s G e n e r a l i z e d  o f  l i v e s t o c k
L y s s a v i r u s R a b i e s N e r v o u s
R N A C o r o n a v i r i d a e C o r o n a v i r u s C o r o n a R e s p i r a t o r y
I n f e c t i o u s  b r o n c h i t i s R e s p i r a t o r y  o f  f o w l
R N A T o g a v i r i d a e A l p h a v i r u s E a s t e r n .  W e s t e r n . N e r v o u s ,  r e s p i r a t o r y
V e n e z u e l a n  e q u i n e  
e n c e p h a l o m y e l i t i s
S e m l i k i  f o r e s t N e r v o u s
F l a v i v i r u s Y e l l o w  F e v e r N e r v o u s
N u m e r o u s  e n c e p h a l i t i d e s . N e r v o u s
i n c l u d i n g  J a p a n e s e  B .
S t .  L o u i s .
R u s s i a n  s p r i n g - s u m m e r  
D e n g u e J o i n t s ,  c u t a n e o u s
R u b w i r u s R u b e l l a S k i n ,  g e n e r a l i z e d .
n e r v o u s
R N A B u n y a v i r i d a c f f u n v a v i r u s N u m e r o u s  e n c e p h a l i t i d e s . N e r v o u s
i n c l u d i n g  B u n y a m w e r a
a m t  C a l i f o r n i a
R N A A r c n a v i r i d a e A r e n a v i r u s L y m p h o c y t i c N e r v o u s
c h o r i o m e n i n g i t i s
L u s x a G e n e r a l i z e d
R N A R e t r o v i r i d a e f  v p e s  l i  a n d  C N u m e r o u s  l e u k e m i a s . O n c o g e n i c  o f  l o w e r
O n c o v i n m i n c l u d i n g  F r i e n d .  G r i m .  
M o l o n e y .  K a u x c h c r
a n i m a l s
R o u s  s a r c o m a O n c o g e n i c  o f  f o w l
" Based on disease incidence or severity or on previous use in antiviral testing.
hygiene and immunisation and to the prevention of the 
spread of the disease through the community by the 
application of principles learned in the generalised study 
of epidemiology and public health.
1.1.1 Active Stimulation of the Immune Response
Prophylaxis by immunisation is an excellent 
way of preventing infectious disease and has been used 
in the control of many viral diseases using inactivated 
virus or live non-pathogenic virus and indeed the use 
of vaccinia virus immunisation has resulted in the 
eradication of smallpox. However, despite the undeniable 
success of vaccination in the fields of animal and human 
health not all virus diseases can be controlled in this 
manner. The reasons for this are many and varied; some 
are purely technical such as the purification in 
sufficient quantities of particular viral antigens, and 
may be overcome in due course but it is difficult to 
envisage how other, more fundamental problems may be 
overcome.
With some vaccines there is a small but not 
insignificant risk of complications such as the encephalitis 
which can follow smallpox immunisation. With live 
vaccines there is also the fear that the viral nucleic 
acid might be incorporated into the host genome or 
that the attenuated virus might revert to a pathogenic 
form.
Generally speaking, the risk of complications
is balanced against the probability of contracting the 
disease before any decision is taken by the health 
authorities to embark on a campaign of mass vaccination. 
However, the reluctance of some parents to allow their 
children to be vaccinated against a number of crippling 
and potentially fatal diseases has highlighted the 
public's fear of the adverse effects of some vaccines.
Infections of the upper respiratory tract are 
amongst the most common ailments of man (e.g. the 
common cold, influenza) yet the chances of producing 
adequate vaccines for such infections seem remote 
because of the large number of antigenic variants which 
are involved.
It is important to remember that immunisation is 
essentially a preventative measure; once a disease has 
been contracted vaccination has little hope of controlling 
its course in an individual unless, as in the case of 
rabies, the virus has a long incubation period. There 
is also a not insignificant percentage of the population 
who are immunocompromised and who cannot rely upon their 
immune systems to protect them from invading pathogens.
In such individuals even a normally very mild infection 
such as herpes labialis (cold sores) can prove fatal 
(Nahmias and Roizman, 1973).
When one considers the problems associated with 
the production and administration of vaccines, their 
purely preventative nature and the incidence of 
immunocompromised patients it becomes evident that 
there is a real need for antiviral compounds which can
be used both prophylactically and therapeutically.
1.1.2 Introduction to Chemotherapy
The problem of viral chemotherapy has undergone 
many positive changes in the past two decades. The 
conceptual position that no specific antiviral compounds 
would ever be found because of the intimate association 
between virus and host cell has been shattered by the 
discovery, through random screening techniques, of a 
considerable number of antiviral agents. More importantly, 
advances in molecular virology have provided a detailed 
knowledge of many virus-specific processes and enzymes.
Such information is clearly necessary if we are to 
develop, by rational means, specific antiviral drugs 
which have no effect upon the host cell.
1.2 VIRUS STRUCTURE AND REPLICATION
All known viruses contain either DNA or 
RNA, never both. The viral genome.which can be either 
single or double stranded, is enclosed and protected 
by a protein coat (capsid), which is made up of a 
number of identical subunits (capsomeres), often arranged 
in helical or cubical (or quasi-cubical) symmetry 
(Fig. 1.2). The protein coat is responsible for the 
majority of immunological responses that viruses 
induce in the host. The protein coat may itself be 
enclosed within an outer lipid membrane, which may
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contain viral proteins. Certain virus-associated proteins 
act to lend specificity to the virus for the purpose of 
absorption to a susceptible cell.
The processes by which viruses replicate within 
susceptible cells are complex and vary from virus type 
to virus type from the very moment they encounter the 
exterior of the cells which they invade. The work 
described in this thesis is largely concerned with 
influenza virus and herpesviruses and so the structure, 
composition and replication of these viruses will now 
be discussed.
1.2.1 Influenza Virus; Structure and Composition
The influenza viruses are members of the 
myxovirus group (Table 1.2.l.i). They form a large 
group of viruses which produce acute respiratory 
disease in man and other animals. The structure of 
influenza virus types A, B and C are similar (Fig. 1.2.1). 
Virus particles are roughly spherical or filamentous 
in shape and some ?5 to 120 nm in diameter bounded by 
an outer lipid membrane into which are inserted two 
glycoproteins which appear as spikes of different 
morphology. The haemagglutinin (H) appears as three-sided 
rods (14 x 4 nm) whereas the neuraminidase (N) is 
muchroom shaped with a head of four spheres and a tail 
(Varghese et al., 1983).

H o c m ag g lu tin in
Neuraminidase
Lipid membrane 
M a trix  protein 
Nuclcoprotein 
R N A
Fig. 1.2.1 Schematic diagram of influenza A virus 
(Laver and Valentine, 1969; Wrigley 
et at. , 1973) .
Internally the virus particle contains five 
non-glycosylated proteins (Table 1.2.1.11). The two 
major proteins are the nucleoprotein (NP) which is 
closely associated with the RNA genome and the matrix 
(M) protein which forms a shell underlying the lipid 
bilayer. Within the matrix shell and associated in 
some way with the genome are three high molecular 
weight proteins, designated P proteins, which form an 
RNA dependent RNA polymerase. The influenza virus type 
(A, B and C) is defined by the antigenicity of the 
ribonucleoprotein. Antibodies raised against the 
ribonucleoproteir.s of all type A viruses cross—react 
whereas no cross-reaction is observed with types B and 
C. Variation in the antigenicity of the H and N proteins 
is the basis of division of influenza type A viruses
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1 X ;SI« -  cuhir  
n :,,,o n  W eight
l'unet ion
range
,000 RNA-dependent 
! OOQ R N A - polymerase 
60,000 N eu ram inidase
N P  53,0 00 N u clco cap sid  
su b -u n it
H A t  *58,000 H acm ag g lu tin in  
H A 2  28,000 com ponents
M P  25,000 M a jo r, m atrix or 
m em brane protein
N S  1 23,000 Unknow n  
N S 2  11 ,0 0 0  >1
A pp ro xim ate  
no. of 
m olecules  
per virus  
particle
5 0
Assignm ent to structural 
and antigenic components 
o f virus
M in o r, internal non-glycosvlated  
proteins. U nkno w n antigenic sp eci­
ficity.
10 0 -2 0 0  Surface glycoprotein. M o rp h o ­
logically knob ; fibre. A ntigenically  
variable, subtype specificity
1000 In tern a l, non-glycosylatcd protein 
associated with R N A  to form helical 
n uclco cap sid , type-specific, an ti- 
g cn ica lly  stable
1000 Surface glycoproteins. M o rp h o ­
logically rods with triangular cross- 
section. H ea vy ( H A l )  and light 
(H  A 2 ) polypeptide chains linked by 
d isu lp h id e  bonds. A ntigcnically  
variable, subtype specificity
3000 M a jo r internal non-glycosylatcd
protein. A n tig cn ica lly  stable, type- 
spccific. Associated with inner sur­
face o f lip id layer of envelope
—  N o n -s ir u c tu ra l virus-coded pro-
—  teins. Syn th esized  in cytoplasm  and 
m igrate to nucleus of infected cells
• Haemagglutinin is synthesized os a single polypeptide of molecular weight 80,000 which is 
cleaved to H A l ami HA2 during virus maturation.
The values stated were determined for A Hong Kong 6S (H 3 N 2 ) virus, X 31 strain (Skchcl 
and Schild, 1971).
Table 1.2.1.11 The Polypeptides of Influenza Virus
Stuert-Harris and Schild, (1976)
into sub-types (WHO memorandum, 1980; Hinshaw et al.,
1982) .
The genetic material of influenza virus is 
single stranded, negative sense RNA which is segmented into 
8 unique fragments each of which acts as a monocistronic 
message for a virus polypeptide (McGeoch et al., 1976i.
The segmented nature of the virus genome is responsible
t Genes 7 and 8 code for spliced mP.NA's (McCauley and 
Mahy., 1983)
«mm i * .  4
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for the high frequency of genetic reassortment between 
influenza viruses which enables 'hybrid' viruses to be 
produced and may explain the appearance of new sub-types 
which occasionally cause pandemics (Webster, 1972;
Webster et al., 1982) since it can result in the appearance 
on the virus surface of new H and N glycoproteins to which 
populations have no immunity (Antigenic shift).
1.2.2 Stages of Influenza Virus Replication
The initial event in the infectious process is 
the absorption of the virus to the cell surface which is 
dependent upon two complementary structures; the 
receptor on the cell membrane and a region near the tip 
of the virus haemagglutinin. Synthetic oligopeptides 
which resemble the N-terminus of the haemagglutinin HA2 
sub-unit have been found to specifically inhibit the 
infectivity of influenza virus (Richardson et al., 1980). 
These synthetic oligopeptides may interfere with the binding 
of the haemagglutinin to specific cell membrane receptor 
sites and so prevent the absorption of virus to the cell.
The other virus glycoprotein, neuraminidase, does not 
appear to play a role in the initial interaction of 
virus and cell (Bucher and Palese, 1975).
The next step in the replication cycle is the 
penetration of the virus into the cell and there is 
considerable debate as to the precise mechanism by 
which this is achieved. There is some evidence to 
suggest that the virus particle enters by viropexis
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(endocytosis) (Dourmashkin and Tyrrell, 1974). However, 
Morgan and Rowe (1968) and WaterfieId et al. (1979) 
have proposed an alternative mechanism in which the 
virus and cell membranes fuse, thus allowing the release 
of virus 'core' material into the cell. Having gained 
entry to the cell the virus is then broken down into 
separated protein molecules and genetic material, a process 
known as uncoating. Again, controversy exists as to 
the actual mechanism by which this is achieved but it 
appears that cellular enzymes are involved. Two drugs,
1-adamantanamine (Amantadine) and a-methyl-l-adamantane- 
methylamine (Rimantadine) (Fig. 1.2.2.i), which are used 
clinically to treat influenza virus infections, seem
Fig. 1.2.2.1 Amantadine hydrochloride (a) and 
Rimantadine hydrochloride (b).
to exert their antiviral effect at the penetration and/or 
uncoating stage(s) (Hossman et al., 1965; Kato and 
Eggers, 1969; Skehel et al., 1977; Koff and Knight, 
1979; Miller and Lenard., 1981).
The structure and function of the influenza 
virus genome has recently been extensively reviewed by
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McCauley and Mahy (1983). Hence, only the salient points 
will be described.
Following uncoating the eight segments 
of vRNA are transcribed into two classes of RNA of 
positive polarity (Hay et al., 1978; Hay and Skehel,
1979). One class serves as viral mRNA's and is composed 
of incomplete transcripts of vRNA which are polyadenylated 
at their 3'ends and possess a cap sequence at their 
5'ends. The second class is composed of complete transcripts 
(cRNA), uncapped and non-polyadenylated which serve as 
templates for the replication of vRNA.
Transcription of RNA in infected cells is essen­
tially divided into two distinct phases. The first phase, 
primary transcription (Flamand and Bishop, 1973), proceeds 
independently of protein synthesis and results in the 
production of mRNA complementary to each segment of RNA 
in close to equimolar quantities (Hay et al. , 1977*5;
Barrett et al., 1979). Production of mRNA proceeds 
at a low level until approximately 90 minutes post 
infection after which it increases rapidly, probably 
as a result of the synthesis of new RNA polymerase 
molecules as this amplification does not occur in 
cells treated with cycloheximide (Barrett et al., 1979;
Hay et al., 1981).
In contrast to the RNA polymerase complex 
associated with reovirions and other viruses that 
synthesise capped mRNA's, the RNA polymerase of purified 
influenza virus includes no capping enzymes. Instead, 
caps on influenza mRNA's are derived preformed from
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heterologous capped cellular mRNA's (Bouloy et at. , 1979; 
Robertson et at., 1980; Plotch et at., 1981). This 
explains why transcription from cellular DNA is required 
for the synthesis of functional influenza mRNA (Barry 
et at. , 1962; Rott and Scholtissek, 1970; Mahy et at. , 
1972) .
A second phase of RNA synthesis (secondary 
transcription) is dependent upon protein synthesis 
(Barrett et at. , 1979; Hay et at. , 1980; Smith and 
Hay, 1982) and is necessary for the synthesis of template 
cRNA and for the subsequent synthesis of vRNA. The 
precise nature of the replicase responsible for this 
process is unknown. However, it seems likely that a 
modified form of the polymerase is involved (Barry 
and Mahy, 1979).
A scheme for influenza virus genome replication 
based upon models proposed by Hay et al.,( 1980); Smith 
and Hay, (1982) and Ghendon et at. , (1982) is depicted in 
Fig. I.2.2.Ü. The relative rates of synthesis of each 
of the virus specified polypeptides upon cellular 
polysomes is controlled in such a way as to ensure that 
sufficient quantities of each protein are produced for 
the construction of progeny virus (Lamb and Choppin,
1976). Control is largely exerted at the level of repli­
cation although it can also occur at the level of cRNA 
and mRNA synthesis and also by splicing of mRNA's 
(Hay et at., 1980; Smith and Hay, 1982; Ghendon et at., 
1982) .
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Fig. 1.2.2.Ü Scheme for influenza genome replication.
transcription from input genome RNA; 
transcription from cRNA or newly 
synthesised vRNAj
---- >  necessary interactions.
Step 1: primary transcription, which occurs 
in the absence of protein synthesis but 
requires host cell transcription.
Step 2: cRNA synthesis from input vRNA.
Step 3: vRNA synthesis directed by cRNA.
Steps 2 and 3 both require ongoing protein 
synthesis. Step 4: transcription of newly 
synthesised vRNA to form mRNA requires host 
cell caps. Step 5: Modification of mRNA's 
7 and 8 by splicing requires protein synthesis 
and undefined host cell functions.
(McCauley and Mahy, 1983)
Following synthesis, the virus polypeptides 
are transferred across the smooth and rough endoplasmic 
reticula where glycosylation of the haemagglutinin and 
neuraminidase takes place. The compounds D-glucosamine 
and 2-deoxy-D-glucose (Fig. 1.2.2.iii) have been shown 
to inhibit the glycosylation of virus proteins in
17
Fig. 1.2.2.iii D-Glucosamine (a) and 2-deoxy-D-glucose (b).
infected cells (Blough and Guitolini, 1979) which 
subsequently affects the functioning of these proteins 
(Chattergee et al., 1979). The virus specified proteins 
then migrate to the cell periphery where the haemagglutinin 
and neuraminidase are inserted into the cell membrane.
During the maturation process the haemagglutinin poly­
peptide is cleaved by a cellular protease into heavy 
HAj and light HA2 (Waterfield et al., 1979) which are 
linked together by a disulphide bond (Ward and Dophide, 1980; 
Waterfield et al., 1981).
The other virus proteins accumulate beneath 
the membrane at the site of glycoprotein insertion and 
progeny virus particles containing a full complement of 
vRNA are produced by membrane budding (Landsberger et al., 
1971). The control mechanisms which ensure that each 
progeny virus particle contains a complete copy of the 
virus genome, probably arranged in a precise organised 
sequence, are unknown.
Neuraminidase appears to mediate the release 
of newly formed virus particles from the infected cell
1 8
(Bucher and Palese, 1975) and as such is a target for the 
design of inhibitors of influenza virus replication. The 
most potent inhibitor of neuraminidase discovered to 
date is 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic 
acid (FANA) (Fig. 1.2.2.iv) which has been shown to 
inhibit the replication of influenza virus in culture 
(Schulman and Palese, 1975). However, this compound 
has shown little activity in animal models.
H
OH H
Fig. 1 .2.2.iv FANA
1.2.3 The Herpesviruses
Herpesvirus is the generic name for a group 
of large DNA containing viruses (150-200 nm diameter) 
which have very similar structures but few other 
properties in common. Members of the group include 
herpes simplex virus (HSV) types 1 and 2, varicella- 
zoster virus (VZV), cytomegalovirus (CMV), and 
Epstein-Barr virus (EBV) all of which infect man, and 
numerous animal viruses which are found in a wide 
variety of species.
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The herpesvirus genome is a linear double-stranded 
DNA molecule with a molecular weight of 100-150 x 106 
(Roizman, 1979). This places the herpesviruses amongst 
the genetically most complex with sufficient nucleotides 
to code for some 70-80 different polypeptides. To date 
some 48 proteins have been identified in infected cells 
(Roizman et al., 1974; Powell and Courtney, 1975), 24 
of these being referred to as structural proteins. The 
genome is wound on a protein structure formed of basic 
histones (Furlong et al., 1972), and is located in the 
centre of the nucleocapsid which measures 100 nm in 
diameter. The nucleocapsid exhibits icosahedral symmetry 
and is composed of 162 capsomeres (Wildy et al., 1960) 
which take the form of elongated hollow prisms of dimensions
9.5 x 12.5 nm. Separating the nucleocapsid from the 
envelope is the tegument (Roizman and Furlong, 1974) which 
is composed of fibrous proteins. Its function is as yet 
unknown. The lipid skeleton of the envelope is derived 
from budding from the inner nuclear membrane of the 
infected cell (Roizman and Furlong, 1974) (Fig. 1.2.3).
Seven virus-specified envelope glycoproteins (gA-gF and 
gY) have been found on the surface of the virion. At 
least one of which serves as a virus attachment protein 
(VAP) which recognises and binds to specific receptor 
sites on the surface of susceptible cells. Glycoprotein 
gB appears to be involved in the penetration of HSV 
and the oligosaccharide moiety of glycoprotein gC 
may play a role in modulating the hostb immune response
to HSV.
2 0
(  <$) )  ln*«ctiv« h e r p e *  sim ple« virion
M em bron e
Fig. 1.2.3 Schematic representation of HSV replication in a 
permissive cell (from J. D. Watson, Molecular 
Biology of the Gene).
A highly schematic representation of HSV 
replication in a permissive cell is depicted in 
Fig. 1.2.3.
Infections by viruses of the herpes group 
differ from those caused by other viruses in that the 
infecting agent is not necessarily eliminated from 
the body on recovery. Instead, the virus may persist 
in a latent state in the dorsal root ganglia which 
innervate the initial site of infection. This persistent 
infection is asymptomatic but the virus may become 
reactivated and pass along the nerve trunks to the 
site of initial infection and cause a 'recurrent' infection,
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which is often of a similar type to the initial infection.
1.2.4 Integration of Viral Nucleic Acid into the
Host Genome
The replicative cycles outlined above are 
examples of acute viral infections in which the rapid 
replication of progeny virus is followed by its release 
from the infected cell in most cases accompanied by the 
death of the cell. However, some viral infections 
follow another replicative path which leads to the 
integration of viral genetic material into the host cells 
chromosomes. Each time the host cell divides the viral 
genes are duplicated along with the host's genes and as 
such the viral genes can be passed on to the host's 
offspring. Once integrated into the host's chromosomes, 
the activity of the viral genes is usually altered or 
totally suppressed. Such 'latent' infections can be 
reactivated in a number of diverse ways (e.g. u.v. 
radiation, carcinogens and other chemicals) to produce 
a sudden outbreak of the viral disease or transform 
the cell into a neoplastic state.
Little is known of the mechanisms which cause 
a particular virus to follow either the replicative 
or integrative paths. However, in the case of the 
retroviruses, integration into the host's chromosomes is 
an essential part of their life cycle, being necessary 
for the replication of the viral genome (Bishop, 1978) 
(Fig. 1.2.4).
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Fig. 1.2.4 Schematic diagram of the major steps in the 
replication of an RNA tumour virus. 
(Watson., 1976)
1.3 THE INTERFERON SYSTEM
In addition to a variety of host defences such 
as antibody production, cell mediated immunity and 
macrophage action, viruses also induce the production 
and release of interferons by certain cells (Isaacs and 
Lindenmann, 1957). These glycoproteins can in turn 
elicit the setting-up of an "antiviral state” in other 
host cells by means of the mechanism outlined in 
Fig. 1.3.1 (Stewart, 1979). Two methods have been 
employed experimentally to increase the concentration 
of interferon in the body; the first and most obvious 
has been the administration of exogenous interferon.
-
ly  m o d *  
p ro re in
mrerreron molecules releosed
O  O\  by neighbouring cells
Fig. 1.3.1 Two pathways by which interferon can inhibit viral 
protein synthesis. Viral double-stranded RNA 
activates both the phosphorylating enzyme and the 
enzyme responsible for 2 ’,5 *-oligoadenylate 
synthesis. Viral double-stranded RNA is also 
an initial inducer of interferon production.
(Scott., 1983)
Research in this area has recently increased markedly 
by the possibility of producing large quantities of 
interferon using modern techniques, and initial clinical 
trials with interferon appear promising. The second 
mechanism to raise the bodily concentration of interferon 
has involved the administration of specific compounds 
such as double-stranded RNA with the aim of inducing 
the production of interferon (Kerr et al., 1974).
However, to date this approach has met with little success. 
Some of the antiviral activities of interferon are 
thought to be mediated by specific oligonucleotides 
which contain 2'-5' linkages rather than the normal
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3'-5' linkages (Hovanessian et al., 1977). These 2’-5' 
oligoadenylates (e.g. 5'-triphosphate of adenyl (2'-5')adenyl-
oligomers)have a powerful effect on cellular protein 
synthesis at very low levels (Hovanessian and Wood,
1980) and therefore oligoadenylic acids related to this 
structure would appear to have potential as antiviral 
agents. However, problems associated with production, 
uptake and stability do not make them promising antiviral 
agents for clinical use at the present time (Hutchinson 
et al., 1983).
with an efficient virus is the synthesis of new viral 
proteins and nucleic acid. Some viruses, such as 
certain members of the parvovirus group are entirely 
reliant upon the enzymes of the host cell to perform 
both these tasks. However, it is now known that a large 
number of viruses contain enzymes which are distinct
(2'-5')adenosine (ppp(A2p)2A) (Fig. 1.3.11) and higher
o o o
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1.4 NEW ENZYMES PRESENT IN INFECTED CELLS
The main metabolic activity of a cell infected
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from those of the host cell and/or carry the information 
in their genetic material for the synthesis in the 
infected cell of virus specific enzymes.
The basic premise concerning the intimate 
association between viral and cellular biosynthetic 
functions remains valid and even the most complex 
viruses depend at some stage on the proteins of the 
infected cell. The major reasons for the necessity 
of viruses to direct the synthesis of their own 
enzymes are outlined below.
(a) The synthesis of viral components may require 
a process which does not normally occur in 
the cell, e.g. all RNA viruses with a negative 
stranded genome contain an RNA dependent RNA 
polymerase since replication can occur only 
after transcription of the virus genome
into mRNA (Baltimore et al., 1970; Bishop 
et al. , 1971; Skehel, 1971) and there is no 
cellular enzyme which can carry out such a 
transcription.
(b) The virus replication cycle might involve a 
component which is not found in the cell, 
e.g. hydroxymethylcytosine in phage DNA 
(Mandel, 1968) .
(c) A necessary cellular enzyme might be located 
at a site removed from that of the replicating 
virus, e.g. Pox viruses replicate in the 
cytoplasm and hence cannot utilise the cellular 
RNA polymerase which is located in the nucleus
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(Katos and McAuslan, 1967; Schwartz and
Dales, 1971).
(d) The cellular enzyme may be controlled so that 
it is specific for regions of macromolecules
not present in the virus, e.g. o mediated
binding of E. coli RNA polymerase to regions
of DNA.
(e) The cellular enzyme might have a very low activity
e.g. non-dividing animal cells have only very low 
levels of thymidine kinase activity and several 
DNA viruses code for the synthesis of this 
enzyme.
Enzyme activities detected in intact RNA virions
or cells infected with RNA viruses are listed in Table 1.4.i 
and the DNA viruses and their associated enzyme activities 
in Table 1.4.ii. The lists contain enzymes for which the 
viral origin has not been proved conclusively (e.g. with 
the use of mutants) but is likely. Furthermore, the 
possibility must be borne in mind that some of the 
enzymes detected in enveloped virions may have a cellular 
origin.
1.4.1 Selective Inhibition of Viral Enzymes
be to select virus-specific processes and enzymes 
and then use whatever knowledge is available to design 
specific inhibitors (Mitchell, 1973; Becker, 1976). 
Assistance in this approach being provided by information
One rational approach to drug design would
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Table 1.4.i Enzymes Induced by RNA Viruses
Virus Enzyme activity Virus Enzyme activity
P icornaviruses N D V , mumps virus. neuraminidase, E C  3.2.1
Poliovirus, EM C, RNA-dcpcndcnt R N A  polymerase. Sendai virus
F M D V , rhinovirus EC  2.7.7 N D V adenosine triphosphatase (ATPase),
Poliovirus, F M D V endonuclease, E C  3.1.4 EC  3.6.1
Poliovirus, EM C, peptide hydrolase (protease), EC  3.4 R habdoviruses
F M D V VSV (guanine-7)-methyltransferase.
R eoviruses EC  2.1.1
Rcovirus (guanine-7)-mcthyltransferase, EC  2.1.1 VSV (adenine-2)-methyltransfcrase, EC  2.1.1
Reovirus, rotavirus RNA-dependcnt R N A  polymerase. VSV, rabies vims protein kinase, EC  2.7.1
E C  2.7.7 VSV nucleoside diphosphate kinase.
Rcovirus poly G  polymerase, E C  2.7.7 EC 2.7.1
Reovirus poly A  polymerase, E C  2.7.7 VSV, rabies virus. RNA-dependent R N A  polymerase.
Reovirus m RNA guanylyltransferase, EC  2.7.7 salmonid viruses EC 2.7.7
Reovirus nucleoside triphosphatase, EC 3.6.1 VSV m RNA guanylyltransferase, EC  2.7.7
Reovirus polynucleotide 5#>triphosphatase, VSV poly A  polymerase, E C  2.7.7
EC 3.6.1 VSV endonuclease, EC  3.1.4
Reovirus triphosphate-pyrophosphate exchange VSV nucleoside triphosphatase, EC  3.6.1
Togaviruses R etroviruses
Sindbis virus, Semliki protein kinase, E C  2.7.1 ASV. M u LV , M TV . protein kinase, EC 2.7.1
Forest virus RSV. FeLV. A M V
Sindbis virus, Semliki RNA-dependent R N A  polymerase. RSV, A M V , etc. RNA-dependent D N A  polymerase.
Forest virus EC  2.7.7 (reverse transcriptase), EC  2.7.7
Sindbis virus endonuclease, E C  3.1.4 RSV, A M V , etc. DNA-dependent D N A  polymerase.
O  room y xoviruses (reverse transcriptase), EC 2.7.7
Influenza A  virus protein kinase, E C  2.7.1 A M V , RSV endonuclease, EC  3.1.4
Influenza A  virus nucleoside diphosphate kinase. R LV RNase H. EC 3.1.4
EC  2.7.4 R LV protease, EC  3.4
Influenza A , B, C  virus RNA-dependent R N A  polymerase. A M V nucleoside triphosphatase, EC 3.6.1
EC  2.7.7 A renaviruses
Influenza A , B, virus neuraminidase, E C  3.2.1 Pichinde virus RNA-dependent R N A  polymerase.
Influenza A  virus nucleoside triphosphatase, EC  3.6.1 EC 2.7.7
P aram yxoviruses B unyaviruses
N D V (guanine-7)-methyltransferase, Uukunicmi virus RNA-dependent R N A  polymerase,
E C  2.1.1 EC 2.7.7
Sendai virus protein kinase, E C  2.7.1
N D V , mumps virus. RNA-dependent R N A  polymerase.
measles virus. EC  2.7.7
Sendai virus, SV5
N D V , Sendai virus, SV5 poly A  polymerase, E C  2.7.7
N D V m RNA guanylyltransferase, EC  2.7.7
Sendai virus endonuclease, E C  3.1.4
Avian myeloblastosis virus, A M V ; avian sarcoma virus, A S V ; cnccphalomyocardilis 
virus, EM C ; feline leukemia virus, FeLV ; foot and mouth disease virus, F M D V ; 
mammary tumor virus, M T V ; murine leukemia virus, M u LV ; Newcastle disease virus, 
N D V ; Rauchcr leukemia virus, RLV; Rous sarcoma virus, RSV; simian virus 5, SV5; 
vesicular stomatitis virus, VSV.
(Helgstrand and Oberg., 1 9 8 0 )
Table 1.4.11 Enzymes Induced by DNA Viruses
Virus Enzyme activity
P arvoviruses  
Kilham rat virus DNA-depcndent D N A  polymerase, 
E C  2.7.7
P apovaviruses  
Polyoma virus protease, E C  3.4
A den ov iruses  
Adenovirus type 2 
Adenovirus type 2
protein kinase, E C  2.7.1 
protease, E C  3.4
H erpesviruses  
H S V -l. HSV-2 
H S V -l, pseudorabies 
virus
H S V -l. HSV-2, V Z V , 
EB V , pseudorabies 
virus, H V T , EHV-1
ribonucleotide reductase, EC  1.17.4 
protein kinase, E C  2.7.1
nucleoside phosphotransferase 
(thymidine kinase), E C  2.7.1
Virus Enzyme activity
Vaccinia virus DNA-dependcnt D N A  polymerase, 
E C  2.7.7
Vaccinia virus poly A  polymerase, EC 2.7.7
Vaccinia virus m RNA guanylyltransferase, EC  2.7.7
Vaccinia virus DNase. EC 3.1.4
Vaccinia virus nucleoside triphosphatase, E C  3.6.1
Vaccinia virus polynucleotide S'-triphosphatase. 
E C  3.6.1
Vaccinia virus polynucleotide ligase, EC  6.5.1
H epatitis B viruses
Human hepatitis DNA-dependent D N A  polymerase.
B virus, woodchuck 
hepatitis B virus
EC  2.7.7
H S V -l
H S V -l, HSV-2, V Z V . 
H  V T , M D V , CM  V, 
E B V t pseudorabies 
virus, E H V -l  
H S V -l, HSV-2, V Z V . 
C M V , E B V  
H S V -l
thymidylate kinase, EC  2.7.4 
DNA-dependent D N A  polymerase, 
EC  2.7.7
DNase, E C  3.1.4
Dcoxycytidine deaminase, E C  3.5.4
/ ridoviruses  
Frog virus 3 
A S FV
Frog virus 3 
Frog virus 3 
Frog virus 3
protein kinase, E C  2.7.1 
DNA-dependent D N A  polymerase, 
E C  2.7.7 
DNase. E C  3.1.4 
RNase, E C  3.1.4
adenosine triphosphatase (ATPase), 
EC  3.6.1
P oxviruses  
Vaccinia virus
Vaccinia virus
Vaccinia virus 
Vaccinia virus
Vaccinia virus, 
rabbit pox virus
(guanin-7)-metbyltransferase,
EC  2.1.1
m RNA ribosc-2'-0-methyltransferase, 
EC  2.1.1
protein kinase, E C  2.7.1 
nucleoside phosphotransferase 
(thymidine kinase), EC  2.7.1 
DNA-dependent R N A polymerase, 
EC  2.7.7
African swine fever virus, ASFV ; cytomegalo virus. C M V ; Epstein-Barr virus. EBV; 
equine herpesvirus type 1, EHV-1; herpes simplex virus type 1, H S V -l;  herpes simplex 
virus type 2, HSV-2; herpes-virus of turkeys, H V T ; Marck’s disease virus, M D V ; 
varicella-zoster virus, V ZV .
(Helgstrand and Oberg., 1980)
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acquired on the general structures and in some cases 
modes of action, of compounds possessing antiviral 
activity. Another rational approach, the selective 
activation approach, involves searching for a compound 
which is a good substrate for the viral enzyme alone.
This compound is then activated by that enzyme to produce 
an inhibitor of viral multiplication but only in infected 
cells (Cheng et al., 1979>.
Viral enzymes can in general be regarded as 
isoenzymes of cellular enzymes. Although isoenzymes 
utilise identical substrates they can show considerable 
differences in their sensitivities to inhibitors. The 
classical example being the highly sensitive nature of 
bacterial and plasmodial dihydrofolate reductases to 
trimethoprim which shows virtually no activity against 
the human isoenzyme. A number of reviews concerning 
viral enzymes and inhibitors thereof have been published
II(Helgstrand and Oberg, 1980; Smith et al., 1980) and 
details on similar cellular enzymes can be found in 
standard works on enzymology.
1.4.2 Nucleoside Analogues as Antiviral Agents
A large number of the antiviral compounds 
developed to date are effective against herpesviruses 
and the antiviral specificity of these compounds largely 
relies on two virus induced enzymes, thymidine- 
(deoxycytidine) kinase (TK) and DNA polymerase.
Herpesvirus TK will accept a much broader
range of substrates than will the cytoplasmic and mitochondrial 
TK1s (De Clerq et al., 1977; Dobersen and Greer, 1978;
Cheng et al., 1979) and phosphorylate them to the 
corresponding 5'-phosphates. The phosphorylated nucleoside 
analogues subsequently effect virus replication by 
inhibiting the viral or cellular processes which support 
it (Fig. 1.4.2).
1.4.2.1 5-Iodo-2'-deoxyuridlne (Idoxuridine, 5-iodo-dUrd)
(Fig. 1.4.2) is phosphorylated in virus-infected and 
non-infected cells and is subsequently incorporated into 
both viral and cellular DNA (Prusoff and Goz, 1973) 
where it interferes with the process of replication and 
transcription. A number of analogues of 5-iodo-dUrd (e.g.
5-ethyl- 5-propyl-dUrd) do show selectivity against 
herpesviruses (De Clerq et al., 1978) probably due to 
a selective phosphorylation by the viral TK and eventual 
incorporation into the DNA of virus-infected cells.
1-4.2.2 E-5-(2-Bromovlnyl)-2'-deoxyuridine (BV-Urd)
(Fig. 1.4.2) and other E-5-(2-halogenovinyl)-dUrd 
derivatives (De Clerq et al., 1979; 1980a) are
specifically phosphorylated by the herpesvirus TK 
(Cheng et al., 1981), which restricts their action to 
the virus infected cell. BV-dUrd is a very potent 
inhibitor of HSV-1 but is less active against HSV-2 
possibly because HSV-1 TK phosphorylates BV-dUrd to the 
5'-mono- and diphosphates whereas HSV-2 TK does not 
phosphorylate beyond the monophosphate stage (Descamps
Fig. 1.4.2 Role of virus-induced thymidine(deoxycytidine) kinase 
and DNA polymerase in the selective anti-herpes 
activity of BV-dUrd, 5-iodo-dCyd, AraA, AI-ddUrd,
Ara-T, Acyclovir and FIAra-C.
For BV-dUrd, Ara-T, acyclovir and FIAra-C the selective 
antiherpes activity depends on both thymidine(deoxy­
cytidine) kinase and DNA polymerase for AI-ddUrd and 
5-iodo-dCyd it depends on virus-induced thymidine- 
(deoxycytidine) kinase only, and for Ara-A it depends 
on viral DNA polymerase only. In addition to the 
indicated pathway, FIAra-C may also be metabolised 
to the S'-mono-, di-, and triphosphates of FIAra-U, 
FAra-U, FAra-C and FAra-T and these 5 '—triphosphates 
may interact with DNA polymerase and eventually be 
incorporated into DNA.
(Adapted from De Clerq, 1982)

and De Clerq, 1981) further phosphorylation by cellular 
enzymes yields the 5'-triphosphate which interacts with 
the viral DNA polymerase to a far greater extent than with 
the cellualr enzyme (Allaudeen et al., 1981). BV-dUrd 
can also be incorporated into the DNA of virus-infected 
cells (Allaudeen et al., 1981) but the contribution which 
this makes to antiviral activity has not been determined. 
Initial clinical results with BV-dUrd are very promising 
(Maugdal et al., 1981; De Clerq et al., 1980b).
1.4.2.3 9-(2-Hydroxyethoxymethyl)guanine (Acyclovir)
(Fig. 1.4.2) As with other selective antiherpes drugs 
acyclovir does not become active until it has been 
specifically phosphorylated by a viral TK (Elion et al., 
1977; Fyfe et al., 1978). Analysis of herpesviruses which 
are susceptible to acyclovir suggests that it is a 
deoxycytidine kinase activity which is responsible for its 
initial phosphorylation. ForHSV-1, HSV-2 and VZV the 
deoxycytidine kinase activity resides on the same molecule 
as the thymidine kinase activity. However, the TK's 
of pseudorabies virus, infectious bovine rhinotracheitis 
virus and herpesvirus saimiri do not possess deoxycytidine 
kinase activity and these viruses are resistant to 
acyclovir. These viruses are susceptible to BV-dUrd 
suggesting that it is the thymidine kinase activity 
which is responsible for its initial phosphorylation.
The phosphorylation of acyclovir 51-monophosphate 
to 5'-diphosphate is accomplished by a cellular GMP 
kinase (Miller and Miller, 1980) and as its 5'-triphosphate
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it reacts specifically with the viral DNA polymerase 
(Furman et al., 1979). Acyclovir is also incorporated 
into DNA where it acts as a chain terminator as it 
does not have the 3'-OH necessary for chain elongation 
(Furman et al., 1980). Acyclovir has been shown to 
be clinically effective against a number of herpesvirus 
infections (Peterslund et al., 1981; Saral et al., 1981; 
Selby et al., 1981).
1.4.2.4 1-e-D-Ribofuranosyl-l,2,4-triazole-3-carboxa- 
midine (Ribavirin) (Fig. 1.4.2.4) has been shown to be 
effective against a broad range of both RNA and DNA 
viruses (Smith and Kirkpatrick, 1980). It can be
converted to the mono-, di- and triphosphate forms 
by cellular kinases (Miller et al. , 1977). As the 
5'-monophosphate form it inhibits inosine 5'-monophosphate 
(IMP) dehydrogenase which is an essential enzyme in the 
biosynthesis of GTP (Streeter et al. , 1973) . The 
biosynthesis of dTTP is also inhibited although the 
exact mechanism by which this is achieved remains
Fig. 1.4.2.4 Ribavirin
unknown (Drach et al. , 1981). It is this inhibition of 
nucleotide biosynthesis which has been assumed to be 
largely responsible for the antiviral activity of 
ribavirin.
Ribavirin 5 *-triphosphate has been shown to inhibit 
mRNA guanyltransferase which transfers GMP from GTP to 
the 5’-terminus of acceptor mRNA (Goswami et al., 1979). 
However, since both cellular and viral mRNA's (except 
picornaviral mRNA's) require capping it is difficult to 
envisage how this could result in antiviral specificity. 
Ribavirin 5'-triphosphate is a selective inhibitor of 
influenza RNA polymerase (Eriksson et al., 1977).
During the transcription of influenza RNA 5'-cap 
sequences are cleaved from cellular mRNA's to provide 
primers for viral RNA (Bouloy et al., 1978; Plotch et al., 
1979). The selective inhibition of influenza RNA 
polymerase by ribavirin 5'-triphosphate could well be due to 
an inhibition of the 5'-cap transfer reaction (Eriksson 
et al., 1977), and could explain the relatively specific 
activity of ribavirin against influenza virus although 
concomitant effects by inhibition of nucleoside biosynthesis 
should also be considered.
Ribavirin has been shown to be effective in 
experimental influenza A infection of mice but the 
compound produced no beneficial effects when administered 
by the oral route to humans during an outbreak of 
influenza A (Smith et al., 1980).
1.5 INHIBITORS OF VIRAL NUCLEIC ACID POLYMERASES
Several nucleoside analogues have antiherpes 
activity based upon their selective activation by a 
herpesvirus thymidine (deoxycytidine) kinase activity. 
However, one clinically important herpesvirus, CMV, 
does not induce such an activity in infected cells 
(Zavada et al., 1976) and furthermore, outside of the 
herpesvirus group only vaccinia has been shown to 
code for such an activity (Table 1.4.11). Consequently, 
the antiviral spectrum of these nucleoside analogues 
is restricted and as such they do not provide the broad- 
spectrum antiviral 'penicillin'.
The virus-specific nucleic acid polymerases are 
accessible for nearly all viruses (Table 1.4.1 and 1.4.il), 
are easily assayed in cell-free systems and afford 
good primary targets for antiviral agents.
The process of nucleic acid biosynthesis can be 
broken down into four distinct steps (Fig. 1.5).
(a) Template binding The polymerase recognises and 
binds to a specific nucleotide sequence on the 
template nucleic acid.
(b) Initiation A nucleoside 5'-triphosphate or 
primer oligonucleotide binds to the enzyme 
template complex at a site corresponding to 
the 5'-terminus of the nucleic acid to be 
synthesised. (The order of (a) and (b) has 
not been established.)
(c) Elongation Nucleoside 5'-triphosphates
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are added sequentially, in an order determined 
by the template, to the 3' end of the nascent 
nucleic acid with elimination of pyrophosphate.
(d) Termination On reaching a specific oligonucleotide
sequence on the template, synthesis of nucleic 
acid ceases and the complex of template, polymerase 
and nascent nucleic acid dissociates.
Interference with any one of these processes 
would result in an inhibition of nucleic acid polymerisation. 
However, if it is to be selectively inhibited, the viral 
polymerase must contain a different amino acid sequence 
from that of the host polymerase at an essential site on 
the enzyme. Suitable starting points for the design of
\G
Fig. 1.5 Elements of nucleic acid synthesis (from Helgstrand 
and Oberg, 1980).
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inhibition would be the substrates (discussed in 
Section 1.4.2) and the by-products of the reaction.
Viral templates or primers are also useful targets 
as are other essential elements of nucleic acid synthesis 
such as sulphydryl groups, other amino acids and metal 
ions.
1.5.1 Template and Primer Binding
Oligo(deoxy)ribonucleotides which have a structure 
complementary to a nucleotide sequence on the viral nucleic 
acid would be expected to hybridise with the viral nucleic 
acid and, depending upon its nature, inhibit replication, 
transcription or translation. The tridecanucleotide 
d(A-A-T-G-G-T-A-A-A-A-T-G-G) has a sequence complementary 
to the 3'-5'-terminal sequence of the Rous sarcoma virus 
genome and has been shown to inhibit both virus production 
and cell transformation (Zamecnik and Stephenson, 1978).
To determine the full potential of this approach 
information on the sequences of viral DNA and RNA primer 
and polymerase binding sites will be required.
1.5.2 Sulphydryl Groups
Several viral polymerases are affected by 
compounds which bind to SH groups. In particular.
Billard and Peets (1974) reported the inhibition of 
influenza virus RNA polymerase by selenocystine,
4-(2-propinyloxy)-B-nitrostyrene and acetylaranotin,
3 8
and reverse transcriptase is inhibited by gliotoxin 
and B-lapachone (De Clerq et al., 1978; Schuerch and 
Wehrli, 1978).
1.5.3 Other Amino Acid Groups
Reverse transcriptases contain an argininyl 
residue which is responsible for binding of the 
template primer to the active site (Borders et al., 1975). 
Pyridoxal phosphate forms a Schifi's base with this 
essential amino acid and is a strong competitive inhibitor 
of this class of viral enzymes (Modak, 1976).
1.5.4 Metal Ions
Oxford and Perrin (1974) detected the presence 
of zinc in highly purified preparations of influenza 
virus and have shown that many compounds which form very 
stable complexes with 'soft' heavy metal ions such as 
zinc (Pearson, 1966) are effective inhibitors of influenza 
RNA polymerase. The hypothesis has been postulated 
that these compounds inhibit the enzyme by forming an 
enzyme-zinc-ligand complex (Oxford and Perrin, 1974). 
Complexes formed from chelating agents and free metal ions 
in solution have also been shown to affect polymerases 
(Levinson et al. , 1973). In general, however, simple
chelating agents are not expected to exhibit any 
specificity.
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1.5.5 Pyrophosphate Analogues
Pyrophosphate (17) is a by-product of the 
polymerisation reaction (Fig. 1.5). Consequently, 
analogues of pyrophosphate might be expected to bind 
to a pyrophosphate binding site of the polymerase 
along the forward reaction coordinate or alternatively 
such compounds might reverse the polymerisation 
reaction resulting in a breakdown of nucleic acid. In 
either case the net result would be an inhibition of 
normal polymerase activity.
Such reasoning could have led to the discovery 
of phosphonoacetic acid (PAA (1) Fig. 1.5.5). However, 
the antiviral activity of PAA was discovered by random
O o
HO— P— CH5-C/
2 V m j
Fig. 1.5.5 Phosphonoacetic acid (PAA) (1)
screening of herpesvirus-infected WI-38 tissue culture 
cells (Shipkowitz et al., 1973). Consistent antiviral 
activity required a high concentration of drug (100 wg/ml) 
but the drug was tolerated well showing little or no effect 
on cell growth or division at levels several times that 
required to inhibit herpesvirus replication. The drug 
also appeared to have some potential as a clinical 
agent being effective against experimental herpesvirus
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infections of mice and rabbits.
These initial results prompted studies on the 
effect of PAA on molecular events in normal and HSV-infected 
human cells. Overby et al. (1974) showed that PAA did 
not produce any signi Scant changes in the rate of DNA,
RNA or protein synthesis in normal cells but in HSV-infected 
cells PAA completely inhibited the production of virus- 
specific DNA. Mao and co-workers (1975) extended this 
work by isolating the HSV-induced DNA polymerase from 
infected cells and demonstrated that PAA affects the 
synthesis of virus-specific DNA by a direct inhibition of 
this enzyme.
In an attempt to understand the antiviral 
activity of PAA it is helpful to compare the properties 
and functions of the normal cellular DNA polymerases 
to those of the herpesvirus-induced DNA polymerase.
1.6 CELLULAR AND HERPESVIRUS - INDUCED DNA
POLYMERASES
In many ways the DNA polymerase activities 
induced by herpesviruses are similar to the mammalian 
DNA polymerase a of uninfected cells (Table 1.6.1). The 
synthetic primer-templates (dG) Kj (dC) and (dT) (dA) n 
as well as double stranded DNA "activated" by digestion 
with pancreatic DNase are all copied efficiently by both 
enzymes (Wagner et al. , 1974; Weissbach et al., 1973).
The enzymes also have similar molecular weights and cannot 
be resolved on sucrose gradients (Hirai and Watanabe, 1976) 
and furthermore both enzymes are inhibited by N-ethyl
P M * M M M M tjy W R É É iM C’ <

maleimide (MalNet) (Wagner et al., 1974; Weissbach et al., 
1973). However, the virus-induced enzymes do differ from 
the cellular enzyme in some important respects (Mar and 
Huang, 1974) .
The herpesvirus-induced enzymes can be 
separated from cellular DNA polymerase a by phosphocellulose 
chromatography (Weissbach et al. , 1973) . With the 
exception of the DNA polymerase isolated from cells 
infected with Marek's disease virus (Boezi et al., 1974) 
all the virus-induced enzymes studied to date are most 
active at high ionic strength. At such salt 
concentrations the host cell polymerases are almost 
totally inactive (Weissbach et al., 1973). However, the 
most specific and useful method of classification is the 
reactivity of virus-induced and cellular polymerases to 
specific anti-sera (Table 1.6.Ü). Sensitivity of 
herpesvirus-induced but not cellular DNA polymerases to 
PAA has been used to distinguish between these enzymes 
but it is now clear that this specificiity is not absolute .
DNA Polymerase a but not 8 or y is inhibited by PAA, 
however, it is 15 to 30 times less sensitive than the 
herpesvirus-induced enzymes (Bolden et al., 1975; Miller 
and Rapp, 1976; Sabourin et al., 1978). The isolation 
and characterisation of PAA resistant herpesvirus strains, (Pr), 
by Honess and Watson (1977) and Powell and Purifoy (1977) 
have not only provided conclusive evidence that PAA inhibits 
herpesvirus replication by a direct interaction with the 
virus-induced DNA polymerase but have also cast further 
doubts on the validity of classifying a polymerase solely
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on its sensitivity to PAA. However, a combination of a 
number of the above criteria should lead to an unequivocal 
identification of polymerase type.
1.6.1 Structure-Activity Relationships
The simple chemical structure of PAA provides 
little opportunity for optimisation of antiviral activity 
by chemical manipulation. However, a number of analogues 
have been synthesised and tested as inhibitors of isolated 
herpesvirus-induced DNA polymerase and herpesvirus replica­
tion in cell culture and animal models (Table 1.6.1).
Herrin et al. (1977) reported the inhibition of 
HSV-l-induced DNA polymerase by low molecular weight 
carboxyl esters of PAA but these results have been 
questioned by Boezi (1979) who found such compounds to be 
inactive. This discrepancy has yet to be clarified but 
in general, esters of PAA are inactive.
Substitution of the phosphono group by carboxyl 
andsulphcno groups results in an abolition of activity 
against the herpesvirus of turkeys induced DNA polymerase 
(Leinbach et al., 1976). Replacement of the phosphono 
and/or carboxyl groups by arseno groups yields the 
compounds methylenediarsonate and arsenomethyl phosphonate, 
which Newton (1979) reports as being equally effective 
as PAA in plaque reduction assays involving HSV-1. She 
further states that the antiviral activity of these 
compounds was short-lived possibly due to their instability. 
However, Overby (1982) points out that organic arsenicals 
are normally very stable and postulates that the observed
Analog Reference
I. Carboxyl esters 
I'.lhyl: propyl: /-butyl 
Cyclohcxyl; octyl; benzyl
II. Monophosphate esters 
Methyl; propyl; hexyl
III. Tricstcrs 
Trimclhyl 
Tricthyl
IV MonophosphinR' acids
rhcnyl; 4-mct boxy phenyl; methyl
V. Phosphono analogs 
Siilfoacctatc 
Ma Innate 
Arscnoacetalc
VI. Carbox(vl analogs
Phosphononcclnldchydc 
Phosphonoacclamidc 
A/-Mcthylpho.sphonoacclamidc 
/V-Propyl-; N - butyl-; /V-cyclohcxyl-;
• N-amantylphosphonoacclamidc 
Acctonylphosphatc 
Aminomcthylphosphonatc 
or-Amino ethyl phosphonate 
yV-(phosphonoacctyl)-i -aspartate 
Methylene diphosphonate 
Methylene <liarsonalc 
A rsonomet by I phosphona te
VII. Methylene analogs 
Phosphonoformale 
Phosphonopropiona tc 
Phosphonobutyratc 
or-Phosphonopropionalc 
of-Mclhyl-2-phosphonopropionatc 
or-Phcnylphosphonoa éclate 
a-Aminophosphononcctnlc
VIII. Other related compounds 
Phosphoglycolatc 
Imidodiphosphonatc 
Carbamyl phosphate 
2 -Dcoxyribolhymidinc-.V- 
phosphnrophosphonoacctale 
Purinc-5-mono-cnrboxymclhyl- 
phosphonatc
Pvrimidinc-5'-mono-carboxvmclhvl-
phosphonate
I Ifrrin ct al. (1977) 
I It rrin cl al. (1977)
I It krin cl al. (1977)
I IT cl al. (1976) 
Siiii’KOWM/. cl al. (1971)
I h Rhin  et al. (1977)
l.FlNRAfH cl al. (1976) 
L 1-iNiiACTI cl al. ( 1976) 
Ni a v io n  (1979)
Hofzi (1979) 
Hofzi (1979) 
Hofzi (1979) 
von fiscil (1978)
Mof.7.1 (1979)
I JT  ct al (1976)
I.fiî cl al. (1976) 
Hofzi (1979) 
l.imct al. (1976) 
N f.w io n  (1979) 
N fvvton (197*))
R UNO ct al. (1978) 
Siiii’Ko w it z  cl al. (197.1) 
SiiiPKOwrrz ct al. (197.1) 
Li iNRArn ct al. (1976) 
Lf in iia o i ct al. (1976) 
Lr.iNiiAni cl al. (1976)
I .finbaoii ct al. (1976)
L k in iia o i ct ni. (1976)
Hofzi ( 1979)
Hofzi (1979)
Hofzi (1979)
IIfimfr and N iissmaum (1977) 
I I iimfr and N iisshaiim (1977)
Table 1.6.1 Analogues of phosphonoacetate tested for 
antiherpesvirus activity (taken from 
L. R. Overby, 1982).
activity of these aresno-analogues may be a manifestation 
of their cytotoxicity. Inhibition studies involving 
isolated virus-induced DNA polymerase are obviously needed 
to help delineate the true antiviral nature of these 
compounds. Substitution of the carboxyl group by 
moieties other than arseno generally result in an 
abolition of activity. The only exceptions to this rule 
are certain amide derivatives described by Von Esch (1978), 
but it would appear that a free carboxyl group is necessary 
for optimal activity.
Pyrimidine and purine nucleoside analogues 
of PAA have been shown to be effective against HSV 
infections in mice and cell culture but the mechanism of 
action has not been shown to involve a direct interaction 
with the virus-induced DNA polymerase (Heimer and 
Nussbaum, 1977).
Several studies have revealed that separation 
of phosphono and carboxyl groups is not necessary for 
antiherpesvirus activity as phosphonoformate (PFA(2)
Fig. 1.6.1) is as equally effective as PAA (Reno et al., 
1978). However, increasing the carbon chain length 
to produce the propionate and butyrate analogues or 
substitution on the methylene carbon of PAA by methyl,
0 o~ II '/ H O - P - C1 s OH OH
Fig. 1.6.1 Phosphonoformic acid (PFA)(2) .
amino or phenyl groups results in an abolition of anti­
herpesvirus activity in cell culture (Shipkowitz et al., 
1973; Leinbach et al. , 1976).
The study of analogues of PAA has revealed 
that the structural requirements for antiherpesvirus 
activity are rigorous and that an unsubstituted phosphono 
group and an unsubstituted carboxyl group either linked 
to one another directly or by an unsubstituted methylene 
group are required for optimal activity.
1.6.2 Spectrum of Activity of Phosphonoacetate
and Phosphonoformate
Table 1.6.2 shows the effects of PAA and PFA
on a number of polymerases of both viral and cellular
origin. The table clearly indicates that PAA and PFA
are equally effective as inhibitors of the herpesvirus-
induced DNA polymerase. Numerous studies have also
revealed that herpesvirus replication in culture is
inhibited to the same extent by equimolar concentrations
of the two drugs. The two drugs appear to inhibit
herpesvirus-induced DNA polymerase by binding to the same
site. Evidence for this being derived from detailed kinetic
analyses and from studies involving mutants where strains
of HSV resistant to PFA have also been found to be
•»resistant to PAA and vice-versa (Eriksson and Oberg, 1979; 
Hay and Subak-Sharpe, 1976; Reno et al., 1978). Cellular 
DNA polymerase a is also inhibited to the same extent by 
PAA and PFA, however, the sensitivity of this enzyme to 
inhibition seems to be related to enzyme concentration
Enzyme Concentration giving 50*/* inhibition,
p M
P FA(2) PAA(1)
R N A  polym erases
Influenza virus (Mg**) 20 300
Influenza virus (M n>#) 0.3 0.9
VSV 500 _
Reovirus >500 _
Calf thymus I >500 >500
Calf thymus 11 >500 >500
E. co li >500 >500
R everse  transcriptases
A M V 7 4,000
R M u LV 0.7 600
D N A  polymerases
H S V -l (strain C  42) 0.4 0.5
HSV-1 (strain 124) 3.5 7.0
Hepatitis B virus 20 >500
Calf thymus a (25 U/assay) 50 75
Calf thymus a ( 2.5 U/assay) 3.5 6.5
Calf liver y >500 >500
M icrococcus lu te us >500 >500
E . c o li >500 >500
Table 1.6.2 Inhibition of polymerases by PAA and PFA 
(Helgstrand and Oberg., 1980)
(Sabourin et al., 1978) which may explain the earlier 
conflicting results concerning the sensitivities of 
various enzyme preparations to PAA (Allaudeen and 
Bertino, 1978; Bolden et al., 1975; Hay et al., 1977; 
Mao et al., 1975; Overby et al., 1977).
Table 1.6.2 shows that the antiviral activity 
of PAA is restricted to members of the herpesvirus 
group whereas PFA is also an effective inhibitor of 
influenza RNA polymerase (Helgstrand et al. , 1978;
Stridh et al., 1979), hepatitis B DNA polymerase 
(Nordenfelt et al. , 1979; Hess et al., 1980), and 
reverse transcriptase from a number of sources (Sundquist
toi#*
and Oberg, 1979).
1.6.3 Metabolism and Toxicity of PAA and PFA
Studies utilising radiolabelled-PAA have shown 
that PAA is not metabolised to other compounds in herpes- 
virus-infected or uninfected cells (Boezi, 1979) or 
animals (Bopp et al., 1979). Virtually all of the drug 
that is administered to rabbits and rodents is rapidly 
excreted in a chemically unmodified form in the urine 
and faeces (Bopp et al., 1979; Rung et at., 1978) but 
a small amount is deposited in the bone (Rung et al.,
1978) again as the unmodified form where its turnover 
appears to be small (Boezi, 1979). PFA has also been 
shown to accumulate in the bones and cartilage of treated 
animals (Helgstrand et al., 1979). The effects of PAA 
and PFA on bone have not been thoroughly evaluated.
Although no systematic investigation into the 
toxicity properties of PAA and PFA has been undertaken 
the numerous animal studies reported in the literature 
contain the salient facts. Fitzwilliam and Griffith 
(1976) reported that the LD5Q of PAA for mice was 
1500 mg/Rg/day and at concentrations of up to half this 
figure no gross toxic symptoms were observed. A dose 
of 150 mg/Rg of PAA was well tolerated when administered 
intravenously to rabbits but a dose of 300 mg/Rg produced 
severe muscular spasms and frequently death (Meyer 
et al. , 1976) .
Epithelial tissues are irritated by concentrations 
of PAA above 2% but much higher concentrations of PFA do
not cause irritation. A 2%-5% solution of PAA is well
tolerated by rabbits when applied to the eyes but higher 
concentrations lead to the development of fine punctate 
lesions of the corneal epithelium which heal within 
48 hours of cessation of treatment (Gerstein et al. ,
1975; Meyer et al., 1976). PAA has been shown to be 
non-mutagenic in tests using Salmonella typhimurium 
and mouse lymphoma cells (Becker et al., 1976).
1.6.4 Clinical Evaluation
PFA is presently undergoing clinical trials 
as a topical drug for the treatment of herpesvirus 
infections. Encouraging results have been obtained 
with a 3% PFA cream in the treatment of herpes labialis 
and these studies will be extended to patients with 
genital herpes.
1.6.5 Mechanism of Action of PAA
Leinbach et al. (1976) and Mao and Robishaw
(1975) have suggested that PAA inhibits herpesvirus 
DNA polymerase by interacting with the proposed pyro­
phosphate binding site of the enzyme. Evidence for this 
mechanism being derived from several experimental 
observations: PAA and pyrophosphate are both non­
competitive inhibitors of the virus-induced enzyme 
with respect to the four deoxyribonucleotides and non­
competitive inhibitors with respect to DNA when the
deoxyribonucleotide concentration is low but (nearly) 
uncompetitive inhibitors when the deoxyribonucleotide 
concentration is high. The apparent inhibition constants 
being in the mM range for pyrophosphate and 1-2 pM for 
PAA. PAA is a competitive inhibitor of pyrophosphate 
in the pyrophosphate-deoxyribonucleoside 5'-triphosphate 
exchange reaction and in multiple inhibition analyses 
pyrophosphate and PAA function as mutually exclusive inhibitors, 
i.e. they both bind to the same site. In addition to these 
observations, strains of HSV resistant to PAA also show an
Ifincreased resistance to pyrophosphate (Eriksson and Oberg,
1979; Hay and Subak-Sharpe, 1976; Reno et at., 1978).
The observed inhibition patterns are best 
explained by an alternate product mechanism as outlined in 
Fig. 1.6.5 (Leinbach et at., 1976). In the normal 
polymerisation reaction, pyrophosphate is produced as 
the nucleoside 5'-triphosphates couple to the growing 
DNA chain. Pyrophosphate can act as a substrate for the 
reverse reaction, i.e. pyrophosphate-deoxyribonucleoside 
5’-triphosphate exchange. Leinbach et at. (1976) 
propose that PAA, which is a good substrate for the reverse 
reaction, binds to the enzyme at the pyrophosphate binding 
site and causes a reversal of the polymerisation reaction.
This mechanism predicts that some exchange of pyrophosphate 
for PAA should take place in the deoxyribonucleoside 
5'-triphosphates and that these altered nucleotides 
should serve as substrates in the polymerisation reaction.
This mechanism of inhibition has not been verified by 
direct experimentation; no altered nucleotides containing

and no suggestions as to the molecular mechanism of 
inhibition have been forwarded. Moreover, the precise 
mechanism of inhibition of herpesvirus DNA polymerase 
by analogues of pyrophosphate has not been totally defined 
with experimental verification even though some ten 
years have passed since the discovery of the antiviral 
activity of PAA. Hence, the aim of this project was 
to study the mechanism of inhibition of polymerases by 
pyrophosphate analogues.
There would appear to be essentially two possible 
modes of action of these compounds. Either (a) the compounds 
are incorporated in altered nucleotides of the type NMP-PAA* 
which subsequently inhibit the polymerase in a manner 
analogous to that proposed by Leinbach et at. (1976) or 
(b) they interact directly with the enzyme possibly by 
coordination to an essential metal ion (possibly zinc).
In order to distinguish between these two mechanisms it was 
necessary to design, synthesise, characterise and screen 
a range of pyrophosphate analogues for activity 
against a number of polymerases. Furthermore little has 
been published on the metal-complexing abilities of 
pyrophosphate analogues and hence it was also necessary 
to devise a rapid and efficient method for the determination 
of pyrophosphate analogue - zinc ion stability constants.
It was hoped that elucidation of the precise mechanism 
of inhibition might lead to the design of more effective 
inhibitors of viral polymerases.
•Where N is ribonucleoside or deoxyribonucleoside depending 
upon the type of polymerase involved.
CHAPTER 2
SYNTHETIC ROUTES
2.1 GENERAL BACKGROUND
Analogues of phosphate esters in which an 
oxygen atom has been replaced by another atom or functional 
group have been widely investigated as models which might 
display modified chemical and biological activity. In the 
main, attention has been directed to replacement of oxygen 
by a nitrogen or sulphur atom or a methylene group. Such 
substitutions can be either 'internal' leading to phosphor- 
amidates (Fig. 2.1 (a) X = NH or NR), thiolophosphates
(Fig. 2.1 (a) X = S) and phosphonates (Fig. 2.1 (a) X = CH2)
R— X —  P— OR
I
OH
(a>
0
II
R— O -----P— OR
1YH
(b)
Fig. 2.1 Analogues of phosphate esters.
or 'external' forming phosphoramidic acid (Fig. 2.1 
(b) Y = NH or NR), phosphorothioates (Fig. 2.1 (b) Y = S) 
and esters of methylphosphinic acid (Fig. 2.1 (b) Y = CHj). 
External substitutions are beyond the scope of this 
review and will not be discussed further. For further 
information see Engel (1977) and Blackburn (1981).
The most important difference between the methylene and 
nitrogen or sulphur containing analogues is the inherent
stability of the P-C bond compared to the P-O, P-N and 
P-S linkages. Consequently, the search for stable 
analogues of phosphate esters has focussed largely on 
phosphonates (Engel, 1977).
2.2 SYNTHESIS OF PHOSPHONATES
2.2.1 Pyrophosphate Analogues
Analogues of pyrophosphate (17) such as PAA (1), 
PFA (2) and methylenebisphosphonate (8) have been known 
for many years and can be prepared by either the Michaelis- 
Becker or Arbuzov reactions (Nylen, 1924; Kossolapoff, 
1955; Herrin et al., 1977) (Fig. 2.2.1(i))
RO.V*------ONa
RCT
RO.
+ R— X
RO
\H> Na-
R = alkyl, aryl, etc 
X -.C l.B r.l.
Fig. 2.2.1 (i) Arbuzov (a) and Michaelis-Becker (b) reactions.
The final step in these syntheses involves de-esterifi- 
cation to the parent phosphonic acids. Complete de-ester­
ification is usually accomplished under vigorous conditions 
(typically reflux with concentrated HC1) and often 
results in low yields. Recently, iodotrimethylsilane 
(Me^Sil) has been used to bring about the efficient 
dealkylation of phosphonate esters (Blackburn and 
Ingleson, 1980). The dealkylation proceeds in two 
stages with the initial formation of the silyl ester 
which is then hydrolysed in water or methanol (Fig. 2.2.1(ii))
R — P— O C H jR  
OAr
c : t O MeOH
R— P — OSiMe3 ------------
Fig. 2.2.1(ii) Dealkylation of phosphonate esters with Me^Sil.
The reagent has no effect upon aryl phosphate esters or 
alkyl carboxylate esters and so can be used to prepare 
C-ethyl esters of PAA and PFA. Rosenthal et al. (1975)
and Hata et al. (1975) have also reported the use 0f 
tvie (trimethylsilyl)phosphite in Arbuzov reactions to 
yield readily hydrolysable bis (trimethylsilyl)phosphonate 
esters. P,P-diethyl PAA (7) can be prepared from the 
fully esterified material by hydrolysis with one equivalent 
of NaOH (Clayton et al. 1979). Thus, derivatives of PAA 
and PFA modified at either acid function can be readily 
obtained (Fig. 2.2.1(iii).
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OI(EtO) P C H 2 COOEt
Fig. 2.2.1(iii) Preparation of derivatives of PAA.
The potential stabilisation of a negative charge
on a carbon atom with a phosphoryl substituent leads to 
greatly increased acidity of any hydrogen atom attached 
to that carbon. Consequently, phosphonates readily form 
anions on treatment with a variety of bases and these 
anions will then react with a wide range of electrophiles.
Thus, Quimby et al. (1968) have described the halogénation 
of tetraalkyl methylenebisphosphonate with aqueous hypohalite 
and alkylation via the metalated derivatives.
2.2.2 Nucleoside 51-Triphosphate Analogues
Analogues of nucleoside 5'-triphosphates in 
which a methylene group is substituted for the 6,y-pyrophosphate 
oxygen have been prepared by several methods (Engel, 1977)
(Fig. 2.2.2). Carbodiimides have been used successfully 
but the lack of specificity in effecting condensation 
between two dissimilar reactants often results in the 
formation of complex mixtures of products and hence low 
yields. Mindful of this problem, Chambers and Khorana
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Fig. 2.2.2 Preparation of nucleoside S'- [8, Y~methylene}triphosphates.
(1958) developed the use of nucleoside 51-phosphoramidates 
in which the phosphorus is rendered electrophilic and 
hence susceptible to attack by a second anion. The use 
of these activated derivatives effectively eliminates the 
self condensation of the second anion and other side 
reactions which are associated with syntheses involving 
carbodiimides and results in improved yields. The most 
widely used phosphoramidates are the phosphoromorpholidates 
which have been chosen because they offer the best 
compromise between the ease of formation, reactivity and 
solubility in anhydrous organic solvents (Moffatt and 
Khorana, 1961).
2.3 BIOLOGICAL APPLICATIONS
With the exceptions of the antiviral properties 
of PAA (1) and PFA (2), and the use of dichloromethyl- 
enebisphosphonate (9) and ethane-1-hydroxy-1,1-bisphosphonic 
acid (13) in the treatment of certain bone diseases 
(Fleisch and Felix, 1979), the use of pyrophosphate 
analogues has been mostly limited to the determination of 
binding requirements of inorganic pyrophosphatases of 
diverse biological origin (Kjellstrom and Bishop, 1970; 
Cooperman and Chin, 1973; Kelly et al. 1974). Similarly, 
the use of nucleoside 5'-[B,y-methylene)triphosphates 
has been restricted to mechanistic studies of ATP and 
GTP dependent processes.
The limited successful application of such 
compounds as biological models has been attributed in 
part to the differences in structural characteristics 
of the P-C grouping compared to the P-0 grouping which 
it replaces (Yount, 1975) (Table 2.3(D).
B o n d 0 ( P 0 3 ) 2Na.(h 2°) i0a
CH2(P03)2H4b H N  (P03 )2N a 4
<h 2°>ioc
P - X 1.612 8 1.79 8 1-6 7 8 X
P - 0  (average) 1.523 8 1.54 8 1-5 2 1 X
P-P 2.925 8 3.05 8 3-0 0 6  X
P - X - P 130.2° 117° 1 2 7°
^McDonald and Cruickshank, 1967 
“Lovell, 1964 
cLarsen et al. , 1969
Table 2.3.(i) Comparison of the geometries of sodium pyrophosphate,
methylenebisphosphonic acid and sodium imidobisphosphate 
(adapted from Yount, 1975).
However, a second and seemingly more important 
consideration (Blackburn, 1981) is the decrease in acidity 
of the phosphonic acid groups on introduction of an 
electron donating alkyl group which results in a different 
degree of dissociation for the phosphonate compared to 
the parent phosphate at physiological pH. However, by 
introducing electron withdrawing groups onto the a-CHj 
group of methylenebisphosphonic acid (8) the similarity 
of the phosphonate to the parent phosphate can be heightened 
(Grabenstetter et al., 1967; Blackburn et al., 1981)
(Table 2.3.(ii).
Compound X(P03H2)2 
where X = PKa4 PKa3 PKa2
(c h 3) 2c 12.10 8.04 3.16
c h 3c (H) 11.97 7.49 3.14
c h 2 10.96 7.44 2.87
CH3C(OH) 11.52 7. 31 2.89
NH 10.22 7.30 2.60
HC(OH) 10.56 7.05 2.74
BrC(H) 10.15 6.55 2.20
FC (H) 9.35 6.15 < 2.70
c i 2c 9.78 6.11 -
O■O 8.42 5.81 -
F2C 8.00 5.80 < 2.60
0 8.22 5.77 2.36
Table 2.3(11) Acid dissociation constants of pyrophosphate 
analogues.
Table 2.3(11) clearly shows that there is a 
progressive increase in acid strength in the series
X = CH2 < CC12 < CHF < C(OH)2 < 0 s CF2
and that difluoromethylenebisphosphonate can essentially 
be designated an 'isopolar' analogue of pyrophosphate. 
However, to date little has been reported on the 
biological activity of halogenated methylenebisphosphates 
or of nucleotide analogues derived from them.
2.4 MATERIALS AND METHODS
2.4.1 Materials
(i) Unless otherwise stated all compounds were
commercially available and were used as received 
(Appendix III).
(ii) The structures of all the pyrophosphate analogues
are shown on page 150.
(iii) All reagents were of analytical grade or were 
purified before use.
2.4.2 General Methods
(i) *H n.m.r. spectra were recorded using a Perkin-
Elmer R34 spectrometer. 31P n.m.r. spectra were recorded 
using a Bruker WH90 or WH400 spectrometer and were proton 
decoupled. 31P n.m.r. chemical shifts are quoted relative 
to an external standard in p.p.m., downfield shifts are 
positive.
(ii) Mass spectral analyses are detailed in Appendix
I.
(iii) Chromatography was performed by upward develop­
ment for t.l.c. plates and downward development for paper 
using the following solvent systems:
System Plate/Paper Solvent
I Whatman 3 MM EtOH:l M ammonium acetate (5:2)
II Whatman 3 MM Me0H:H20:Conc. ammonia (6:1:3)
III Cellulose F254 Iso-butvric acid:l M ammonium 
hydroxide : 0.1 M EDTA (100:60:1.6)
IV Cellulose F2^4 EtOH:0.5 M ammonium acetate 
(5:2)
Spots were visualised by fluorescence under 254 nm light 
in the case of t.l.c. plates. Paper chromatograms 
were visualised by the method of Mann et al. (1979).
(iv) Esters of halogenated methylenebisphosphonates 
were converted to free acids by boiling with an excess 
of concentrated hydrochloric acid and unless otherwise 
stated, were purified as described in the literature.
(v) Interconversion of salts and free acids was 
accomplished using Dowex 50 ion exchange chromatography.
(vi) Elemental analyses were performed by 
CHN Laboratories, Leicester, U.K.
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2.5 EXPERIMENTAL
2.5.1 Phosphonoacetlc Acid (1) was prepared by boiling 
triethyl phosphonoacetate with an excess of concentrated 
HC1 and was recrystallised from glacial acetic acid.
The white crystals were washed with ether and dried in 
a vacuum oven at 60-70°C overnight. 1H n.m.r. (DjO, DSS)
6 (p.p.m.) 3.0 (d, Jp_H 20 Hz, -CHjCOOH), 3lP n.m.r.
(D20, 85% H3P04) 6 (p.p.m.) 16.0, s, M.pt. 136°C (lit.
142°C).
2.5.2 [2-3H]-Phosphonoacetic Acid To anhydrous PAA (5 mg>
3dissolved in carrier free H^O (25 yl) was added concentrated 
HC1 (1 yl) and the mixture heated at 70°C for 5 hours.
Excess 3H20 was removed under reduced pressure and 
exchangeable tritium was removed by repeated addition 
and evaporation of water. The residue which co-chromatographed 
on paper with unlabelled PAA in solvent system I was dried 
in vacuo over P20,. to 9^ -ve (2-3H]-phosphonoacetic acid, 
specific activity 12 yCi/ymole.
2.5.3 P,P-Dlethyl Phosphonoacetic Acid (7) was prepared 
by the method of Clayton et al. (1979). Triethyl phosphono­
acetate (22.4 g, 0.1 mol) was dissolved in 1 M NaOH 
(100 ml) and the mixture was stirred for 18 hours at 
room temperature. The pH was adjusted from 9.5 to 1.5 
with dilute HC1, the solution saturated with NaCl and 
extracted with ethyl acetate (3 x 100 ml). The organic 
layer was dried and evaporated in vacuo to yield
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P,P-diethyl phosphonoacetic acid as a liquid (17.8 g, 91%).
*H n.m.r. (CDCl-j, TMS) 6 (p.p.m.) 9.3 (1H, s, COjH), 4.1 (4H,
octet, CH3CH2OP), 2.98 (2H, d, PCH2C02H), 1.3 (6 H, t, 
c h3c h 2>.
2.5.4 Trisodium Phosphonoformate (2) was prepared by the 
procedure of Nylen (1924) as described by Warren and 
Williams (1971). Freshly distilled triethyl phosphite
(90 g, 0.54 mol) was added to a solution of ethyl 
chloroformate (54 g, 0.5 mol) in toluene (200 ml). The 
mixture was heated under reflux for 3 hours and the 
toluene removed in vacuo. The residue was vacuum 
distilled (142°C/12 mmHg) to yield triethyl phosphono­
formate (79 g, 73%). *11 n.m.r. (CDClj, TMS) 6 (p.p.m.)
4.3 (2H, q, COCH2CH3), 4.05 (4H, q, POCH2CH3) , 1.33
(3H, t, COCH2CH3) 1.05 (6H, t, POCH2CH.j) .
To prepare trisodium phosphonoformate, NaOH 
(10 g, 0.25 mol) was dissolved in water (25 ml) and added 
dropwise without cooling to triethyl phosphonoformate 
(10.5 g, 0.05 mol). Heat was evolved and ethanol boiled 
away. On cooling, needles were obtained which were 
recrystallised from water to give trisodium phosphonoformate 
hexahydrate (2.85 g, 19%). 31P n.m.r. (DzO, 85% HjPO^)
6 (p.p.m.) 1.4, s. Descending paper chromatography,
solvent system II, single spot (Rf = 0.59).
2.5.5 C-Ethyl Phosphonoformate (6) Iodotrimethylsil- 
ane (3.4 ml, 25 mmol) was added dropwise, over a period
of 1 hour to a stirred solution of triethyl phosphonoformate
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(2.1 g, 10 mmol) in dry carbontetrachloride (10 ml) at
25°C. On completion of addition the mixture was stirred
for a further 1 hour. The solution was extracted with
water (2 x 10 ml) and the pooled aqueous extracts were
lyophilised. C-Ethyl phosphonoformate was obtained
as a colourless oil (1.51 g, 98%). XH n.m.r. (DjO, HOD)
6 (p.p.m.) 4.05 (2H, q, COCHjCH-j) , 3.05 (3H, t, COCH2CH3).
31P n.m.r. (d^-pyridine, 85% H3PC>4) 6 (p.p.m.) 28.2, s.
2.5.6 2-Phosphonopropionate (3) was isolated as its 
monocyclohexylammonium salt following the acid hydrolysis 
of the corresponding triethyl ester and was recrystallised 
from aqueous ethanol. Anal, for cgH20°5NP' calcd. (found),
C 42.74 (42.85), H 7.79 (8.13), N 5.47 (5.55). 3lP
n.m.r. (DjO, 85% H3P04) 6 (p.p.m.) 17.35, s. M.pt. 212-213°C.
2.5.7 Methylenebisphosphonic Acid (8) was prepared by
acid hydrolysis of the corresponding tetraisopropyl 
ester. The crude product was repeatedly evaporated to 
dryness from iso-propanol and dried in a desiccator over 
PjO,.. 31P n.m.r. (D20, 85% H3PC>4) 6 (p.p.m.) 18.2, s.
M.pt. 200-201°C.
2.5.8 Tetraisopropyl Dlchloromethyleneblsphosphonate
was prepared essentially as described by Quimby et al. 
(1968). Tetraisopropyl methylenebisphosphonate (6.37 g,
19 mmol) was added with vigorous stirring to a solution 
(140 ml) containing NaOCl (5%) and NaCl (4%). The mixture 
was stirred for 30 minutes on ice and then for a further
6 6
30 minutes at room temperature. The resulting white solid 
was removed by suction filtration and the aqueous solution 
was extracted with chloroform (3 x 20 ml). The white 
solid was dissolved in the chloroform extracts and the 
solution was extracted with water until a negative halide 
test was observed. The chloroform was removed under 
reduced pressure and the residue distilled. White crystals 
of tetraisopropyl dichloromethylenebisphosphonate were 
obtained upon standing. 3lP n.m.r. (CDCl^, 85% H^PO^)
6 (p.p.m.) 6.86, s. Free acid (9) 31P n.m.r. (DjO,
85% H^PO^) 6 (p.p.m.) 7.46, s.
2.5.9 Tetraisopropyl Dibromomethylenebisphosphonate
Tetraisopropyl methylenebisphosphonate (25 g, 0.072 mol) 
was added to a solution of potassium carbonate (250 g,
55%). Bromine (3.84 ml, 0.144 mol) in heptane (20 ml) 
was added with vigorous stirring over a period of 2 hours 
with the temperature maintained at 40°C. Water (100 ml) 
was added and the two layers were separated. The aqueous 
layer was extracted with chloroform (100 ml) and discarded. 
The organic portions were combined, extracted with water 
(2 x 100 ml) and dried. The organic solvents were removed 
in vacuo and a 31P n.m.r. assay of the residue revealed 
76% dibromo-, 16% monobromo- and 8% methylenebisphos­
phonate. The residue was recycled through the above 
procedure to produce tetraisopropyl dibromomethylenebis­
phosphonate, 96% pure by 3lP n.m.r. (CDCl^, 85* H3P°4‘* ^
(p.p.m.) 6.5, s. Free acid (11) 3lP n.m.r. (DjO, 85% H^PC^) 
6 (p.p.m.) 6.5, s.
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2.5.10 Tetraisopropyl Monohalomethylenebisphosphonates 
(10 and 12) were prepared from the corresponding dihalo- 
derivatives by the same general procedure (Nicholson and 
Vaughn, 1971). The preparation of monochloromethylene- 
bisphosphonate is described in detail below.
A solution of sodium hydrosulphide (2.8 g, 0.05
mol) in water (20 ml) was slowly added to tetraisopropyl
dichloromethylenebisphosphonate (20.3 g, 0.05 mol) in
methanol (20 ml). The temperature being maintained at
25°C throughout the addition. The solution was stirred
for 30 minutes and filtered to remove sulphur. The filtrate
was extracted with chloroform (50 ml) and the organic
portion dried. Removal of solvent left a colourless oil.
Vacuum distillation (165°C/2 mmHg) gave tetraisopropyl
31m o n o c h l o r o m e t h y l e n e b i s p h o s p h o n a t e . P (CDCl^# 85%
H^PO^) 6 (p.p.m.) 11.5, s. Free acid (10), 3lP n.m.r.
(DjO, 85% H^PO^) 6 (p.p.m.) 11.3, s. Tetraisopropyl 
dibromomethylenebisphosphonate 3lP n.m.r. (CDCl-j, 85%
H^ PO^ j) 6 (p.p.m.) 6.4, s. Free acid (12) 3lP n.m.r.
(DjO, 85% H^PO^) 6 (p.p.m.) 6.5, s.
2.5.11 Methanehydroxyblsphosphonate (14) was prepared 
according to Quimby et al. (1967). Tetrasodium mono- 
halomethylenebisphosphonate was refluxed with 1 M NaOH 
for approximately 8 hours. The resulting solution was 
titrated with dilute HC1 to pH 5 and disodium methane­
hydroxyblsphosphonate was precipitated in 73% yield by 
the addition of methanol. 3lP n.m.r. (DjO, 85% HjPO^)
6 (p.p.m.) 15, s.
2.5.12 Carbonylbisphosphonate (15) was prepared as
described by Quimby et al. (1967). Dichloromethylene- 
bisphosphonic acid (1.27 g, 5.2 mmol) was heated under 
reflux with NaOH (3.1 g, 78 mmol) in water (30 ml) for 
1*5 hours. Addition of methanol crystallised out crude, 
hydrated tetrasodium carbonylbisphosphonate which was 
recrystallised from aqueous acetonitrile (2.52 g, 88%).
^*P n.m.r. (D20, 85% H-jPO^ ) 6 (p.p.m.) 0.0, s. U.V.^max,
419 nm. I.R., C=0 str, 1612 cm 1.
2.5.13 Dlmethylaminomethylenebisphosphonate (19) The
free acid obtained from the acid hydrolysis of the 
corresponding tetraethyl ester (8.7 g, 26 mmol) was 
recrystallised from methanol to yield the desired product 
as a white crystalline powder (2.85 g, 50%). *11 n.m.r.
(D20, DSS) 6 (p.p.m.) 3.16 (6H, s, N(CH3)2), 3.72 (1H, t,
HC-N (CH3)2) .
2.5.14 Nucleoside 5'-triphosphate analogues (20, 21,
23 and 24) were prepared by the same general procedure which 
was essentially that of Moffatt and Khorana (1961). The 
synthesis of adenosine 5'-phosphorophosphonoacetate (AMP-PAA, 
20) is considered typical and is described in detail below.
4-Morpholine-N,N’-dicyclohexylcarboxamidinium 
adenosine 5'-phosphoromorpholidate (710 mg, 1 mmol) and 
PAA (1.4 g, 10 mmol) were dried by repeated evaporations 
from anhydrous pyridine. The two reactants were mixed 
as solutions in pyridine and co-evaporated (< 40°C).
The residue was taken up in pyridine (50 ml) and shaken at
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room temperature, the reaction being followed by t.l.c. in 
solvent systems III and IV (and also by 3lP n.m.r., 
see Section 4.2.7). On completion of reaction (1-2 hours), 
the pyridine was removed in vacuo, the residue taken up in 
water (200 ml) and applied to a DEAE DE52 column (CH^COO 
form, 2 x 4 5  cm). The column was washed extensively with 
water and then eluted with a linear gradient of triethyl- 
ammonium acetate (0.1 to 0.5 M, pH 4.7, 3L) . The eluate 
was monitored by u.v. absorption at 254 nm and the 
required fractions, as determined by t.l.c., were pooled 
and evaporated to dryness in vacuo (< 40°C). The residue 
was evaporated from water (x 6) to remove triethylammonium 
acetate, converted to the sodium salt, purified by gel 
filtration, lyophilised, and stored desiccated at -20°C.
Anal. for c i2H14°llN5Na3P2 calcd* (found),
C 26.93 (26.02), H 2.64 (2.67), N 13.09 (12.19), P 11.57 
(11.94). 31P n.m.r. (DjO, 85% H3P04> 6 (p.p.m.) 5.2 
(d, J 26.4 Hz, P6), -9.7 (d, J  25 Hz, Pa). T.l.c.
p - p  p - p
(III, Rf = 0.4; IV, Rf = 0.07). pH 1.0, Amax 260 nm 
(e 14500); pH 7.0, 257 nm (e 14300); pH 12.3,
IT ic iX
X 259 nm (e 16000). max
Analyses for the other nucleoside triphosphate 
analogues synthesised are given in Table 2.5.14.
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HEPES-buffered balanced salt solution. Viable cell 
counts were determined by means of trypan blue dye 
exclusion.
3.1.2 Preparation of Virus Stocks
The HFEM strain of HSV-1 and the 3345 strain 
of HSV-2 were employed. The PAA resistant strain (Pr)
was HSV-1 18 Clone I (Honess and Watson, 1977) originally 
supplied to Roche Products by R. Honness, N.I.M.R.,
Mill Hill, London. HSV stocks were crude suspensions 
prepared from confluent monolayers of HEp-2 cells in 
roller bottles which were infected at a multiplicity of 
infection (m.o.i.) of 0.001 plaque forming units (p.f.u.) 
per cell in maintenance media (10 ml). This low m.o.i. 
was employed to avoid the appearance of defective virus 
(Watson et al. , 1966). After absorption (2 hours/37°C), 
virus inocula were removed and fresh, warm maintenance media 
(50 ml) was added. The infected cells were incubated for 
3-4 days until cytopathic effect (c.p.e.) was clearly 
visible. The cells were scraped into the media using a 
rubber policeman and pelleted by low speed centrifugation 
(2000 rpm/15 minutes/4°C). The cells were then
resuspended in spent culture medium (1 roller bottle/5 ml) and 
sonicated (full power/1 minute, 0 to 4°C, MSE soniprobe) 
to release virus. The solution was clarified by 
centrifugation (2000 rpm/15 minutes/4°C). The supernatant 
was aliquoted, stored at -70°C and thawed once prior 
to use.
3.1.3 Plaque Reduction Assay
A confluent 175 cm"* flat culture bottle of 
vero cells was trypsinised. The detached cells were 
suspended in growth medium (9 ml) and a viable cell 
count was carried out. The cells were diluted to 
2 x 10^ cells/ml in growth medium and 24 well plates 
(Falcon or Costar) were inoculated with cell suspension 
(1 ml). After 24 hours at 37°C the cells were confluent 
and the growth medium was removed. Each well was 
infected with freshly diluted virus in maintenance medium 
(50 pfu in 0.2 ml). After absorption (1 hour/4°C) overlay 
(0.7 ml of maintenance medium containing 1% carboxymethyl 
cellulose) was added to each well. To this was added the 
various drug dilutions (0.1 ml) in duplicate wells.
After incubation for 3-4 days at 37°C in a humidified 
atmosphere of carbon dioxide (5%) in air, the monolayers 
were fixed with formal saline solution (<v 3 ml, 4% (v/v)
formaldehyde in phosphate buffered saline (PBS)/well/15 
minutes). The formal saline was removed and Giemsa was 
added as stain. The plates were washed with a constant 
stream of water and dried. Viral plaques were counted 
under a dissection microscope and the average number at 
each concentration of test compound was calculated as 
a percentage of that obtained for the drug free control. 
The drug concentration required to reduce the control 
figure by 50% (ID^g) was calculated by interpolation 
from a semi-logarithmic plot. Cytoxicity was observed 
as change in the microscopic appearance of the cells.
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3.1.4 Induction of DNA Polymerase Activity
in HSV-Infected Cells
The procedure employed was essentially that of 
Powell and Purifoy (1977). Confluent monolayers of HEp-2
Qcells in roller bottles (approx. 10 cells/roller bottle) 
were infected with HSV at a m.o.i. of 2-10 pfu/cell in 
maintenance medium (10 ml), or mock infected, and 
incubated (1 hour/37°C). At the end of the absorption 
period virus and mock inocula were removed and fresh 
warm maintenance medium (50 ml) was added. The cells 
were incubated until c.p.e. was just apparent (10-18 hours/ 
37°C). Monolayers were then washed with cold PBS 
(3 x 50 ml) and the cells were scraped into a small 
volume of cold PBS using a rubber policeman and pelleted 
by low speed centrifugation (2000 rpm/5 minutes/4°C).
Enzyme extracts were prepared immediately or the washed cell 
pellets were stored at -70°C and thawed once prior to use. 
Cell pellets stored in this manner retain DNA polymerase 
activity for several months (D. Purifoy, personal communi­
cation) . Enzyme extracts were prepared as follows, all 
procedures being carried out at 0-4°C; cells were 
resuspended in buffer (10 mM tria-HC1, pH 7.5, 3 mM
2-mercaptoethanol) at a concentration of 107 cells/ml.
The cells were then sonicated (1 minute/full power, MSE 
soniprobe). An equal volume of high salt buffer was 
added to give final concentrations of 1.7 M NaCl and 
5 mM EDTA and the mixture was allowed to stand for 
40 minutes. DNA and protein precipitates were removed by 
centrifugation (30,000 xg/20 minutes). The supernatant
was dialysed overnight against buffer (2 x 3 L, 10 mM 
trie-HC1, pH 7.5, 3 raM 2-mercaptoethanol, 10% (v/v) 
glycerol). The dialysate was clarified by centrifugation 
(100,000 xg/60 minutes), stored in aliquots at -70°C 
and thawed once prior to use.
3.1.5 Preparation of Activated DNA Template
A modification of the procedure of Schlabach
et al. , (1971) was employed. Native salmon sperm DNA
(2.5 mg/ml in 10 mM tris-HCl, pH 7.4, 5 mM MgCl2> was 
incubated with pancreatic DNase I (40 ng/mg DNA) at 60°C
for 5 minutes. Phenol (5 mg) was then added to the 
DNA solution to inactivate the DNase and the solution 
was dialysed overnight at 4°C against buffer (2 x 3 L,
10 mM tris-HCl, pH 7.4) to eliminate magnesium ions, 
small nucleotides and phenol. The dialysate was divided, 
stored at -20°C and thawed once prior to use.
3.1.6 DNA Polymerase Assays
The standard assay for HSV-induced DNA polymerase 
contained in a final volume of 200 p1: 50 mM tris-HCl,
pH 7.8, 5 mM MgCl2, 20 mM KC1, 110 mM (NH4)2S04, 200 pM 
EDTA, 6 mM 2-mercaptoethanol, 2 5 pM each of dATP, dCTP, 
dGTP, 6 pM [methyl-3H] -TTP (1000-2000 cpm/pmol), 375 pg/ml 
DNase I treated salmon sperm DNA and enzyme. 50 pi of 
enzyme extract incorporated about 20 pmol dTMP per 200 pi 
reaction mixture in 30 minutes.
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The standard assay for calf thymus DNA polymerase 
a contained in a final volume of 200 pi: 50 mM trie-HC1, 
pH 7.8, 1 mM dithiothreitol, 500 pg/ml BSA, 10 mM MgCl2,
20 mM KC1, 200 gg/ml DNase I treated salmon sperm DNA,
20 pM [^H-]dTTP (sp. act 400-1000 cpm/pmol) 100 pM each 
of dATP, dCTP, dGTP and enzyme (0.01 unit). One unit 
incorporated 10 nmol of dTMP into acid precipitable 
material in 60 minutes under the conditions employed.
Reaction mixes were maintained at 0°C until 
zero time. The reactions were initiated by the 
addition of enzyme and the tubes were incubated at 37°C 
for 30 minutes in the case of HSV-induced DNA polymerase 
and for 60 minutes for calf thymus DNA polymerase a, 
during which time incorporation of radionuclide into 
acid-precipitable material increased linearly. Reactions 
were stopped by the addition of cold TCA (200 pi, 20%
(w/v)) and the mixtures were kept on ice for at least 2 
hours. Acid-insoluble material was collected by suction 
filtration onto GF/C discs (Whatman) wetted with 10%
(w/v) TCA. Each tube was rinsed with 10 ml of cold 
10%(w/v)TCA. Discs were washed once with cold 10% TCA, 
twice with 5% TCA, once with ethanol and then oven dried 
at 80°C. Radioactivity was measured by scintillation 
counting in a toluene based scintillant. In the case of 
HSV-induced DNA polymerase assays the counts for 
the mock infected system for each assay were subtracted 
from those of the virus system. All tests were run in 
duplicate. Unless otherwise stated, test compounds were 
added to reaction mixes before the addition of virus.
50% Inhibition values were obtained from the dose-
response curve for each compound.
3.2 EXPERIMENTAL AND RESULTS
3.2.1 Effect of Pyrophosphate Analogues on
HSV-Induced DNA Polymerases
Table 3.2.1 lists the pyrophosphate analogues 
examined and summarises their corresponding inhibition 
of isolated HSV-induced DNA polymerase of both type 1 
and type 2. The table shows a systematic variation in 
structure in which the bridging oxygen of pyrophosphate 
has been replaced with a methylene group or omitted, as 
in the case of PFA and phosphonoformamide(5) , and the 
acid groups are either phosphono or carboxyl. PAA 
gave 50% inhibition of HSV-induced DNA polymerase at 
concentrations of 2 and 7 wM for type 1 and type 2 
respectively. Shortening the distance between the two acid 
groups as in PFA produced an equally effective inhibitor. 
However, increasing the carbon chain length (3-phospho- 
propionic acid (4)) or substitution on the methylene 
group (2-phosphonopropionic acid (3)) resulted in a 
decrease in activity.
Of the compounds containing two phosphono groups 
linked by a group other than oxygen only carbonylbis- 
phosphonate (15) produced any inhibition, causing a 50% 
reduction in type 1 and type 2 polymerase activity at 
180 wM.
A m o n g s t  t h e  n u c l e o s i d e  t r i p h o s p h a t e  a n a l o g u e s
Table 3.2.1 Effects of Pyrophosphate Analogues on 
Isolated HSV DNA Polymerases and in 
Plaque Reduction Assays
Concn. Producing 50% Inhibition3
Compound HSV-1 (HFEM) HSV-2 (3345)
Plaque Redn. DNA Pol. Plaque Redn. DNA Pol. 
(pg/ml) IpM) (pg/ml) (pM)
1 30 (215 pM) 2 40 (285 pM) 7
2 85 (280 pM) 3 50 (185 uM) 4
3 > 500 150 > 500 150
4 > 500 > 500 > 500 > 500
5 > 500 > 500 > 500 > 500
6 > 500 > 500 > 500 > 500
7 > 500 > 500 > 500 > 500
8 > 500 > 500 > 500 > 500
9 > 500 > 500 > 500 > 500
10 > 500 > 500 > 500 > 500
11 > 500 > 500 > 500 > 500
12 > 500 > 500 > 500 > 500
13 > 500 > 500 > 500 > 500
14 40% inhibn. at > 500 > 500 > 50050 pg/ml
15 > 500b 180 > 500b 180
16 > 500 > 500 > 500 > 500
17 > 500 > 500 > 500 > 500
18 > 500 > 500 > 500 > 500
20 190 300 115 180
(300 pM) (190 pM)
19 > 500 > 500 > 500 > 500
21 > 500 > 500 > 500 > 500
22 » 500 > 500 > 500 > 500
23 > 500 > 500 > 500 > 500
24 > 500 > 500 > 500 > 500
Calculated from dose-response curve for 
each compound.
bObservable cytoxic effect at 500 pg/ml.
examined only AMP-PAA (20) was found to possess any 
activity causing a reduction of 50% in type 1 and 
type 2 polymerase activity at 190 yM and 300 yM 
respectively.
3.2.2 Effect of Pyrophosphate Analogues on HSV Plaque
Formation
Both PAA and PFA reduced plague formation of 
HSV type 1 and type 2 by 50% at a concentration of 50 yg/ml 
(200-300 yM). Methanehydroxybisphosphonate (14) also 
affected plaque formation to a slight extent at 500 yg/ml. 
AMP-PAA was effective in culture producing a 50% reduction 
of type 1 plague formation at 190 yg/ml (300 yM) and 
type 2 plaque formation at 115 yg/ml (190 yM). None of 
the other compounds studied produced any significant 
inhibition of plaque formation at 500 yg/ml (Table 3.2.2).
3.2.3 Effect of Pyrophosphate Analogues on a PAA
Resistant (Pr) Strain of HSV-1
Fig. 3.2.3 shows the dose-response curves 
obtained for PAA against the activity of DNA polymerases 
derived from cells infected with Ps strains of HSV 
types 1 and 2 (HFEM and 3345 respectively) and a 
Pr strain of HSV type 1 (18 Clone I). The diagram shows
that the DNA polymerase derived from the Pr strain is 
approximately 100 fold more resistant to PAA than the 
parent Ps strain. Table 3.2.3 summarises the effect of 
some pyrophosphate analogues on the induced DNA
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Fig. 3.2.3 Specificity of PAA to various DMA polymerases.
DMA polymerases were assayed as described under 
methods. The inhibition is expressed as the 
percentage of uninhibited DNA polymerase 
activity remaining at various concentrations of 
inhibitor. The symbols used are: HSV-1 (HFEM) 
( • )» HSV-2 (3345) (X)» Calf thymus DNA
polymerase a (A) and HSV-1 (18 Clone I) (O).
polymerase and on the formation of plaques in 
culture.
3.2.4 Effect of Pyrophosphate Analogues on Calf
Thymus DNA Polymerase a
Table 3.2.4 lists the effects of pyrophosphate 
analogues on calf thymus DNA polymerase a. Only
"I, v.
Table 3.2 .3 Effect of some Pyrophosphate Analogues on
HSV-1 18 Clone I (Pr) Isolated DNA Polymerase 
and in Plaque Reduction Assays
Compound
Concn. Producing 50% Inhibition3 
Plaque Redn. (pg/ml) DNA Pol. (pM)
1 > 500 250
2 > 500 250
3 > 500 > 500
14 > 500 > 500
15 > 500b > 500
20 > 500 > 500
Calculated from relevant close-response 
curves.
^Observable cytoxic effect at 500 pg/ml
Table 3.2..4 Effect of Pyrophosphate Analogues on 
Calf Thymus DNA Polymerase a3
Compound Concn. Producing 50% Inhibition (pM)
1 45
2 50
11 350
15 100
23 350
aAll other compounds examined were inactive at 
a concentration of 500 pM.
one of the compounds active against HSV-induced DNA 
polymerase was more active against calf thymus DNA 
polymerase a, namely carbonylbisphosphonate producing 
50% inhibition at 100 pM. AMP-PAA had no effect on the 
cellular enzyme at 500 pM. PAA inhibited HSV type 1 
DNA polymerase by 50% at a concentration of 2 pH 
whereas 50 pM was needed to inhibit calf thymus DNA 
polymerase a to a similar extent. Two compounds which 
produced no inhibition of HSV-induced DNA polymerases 
at 500 pM were however active against the cellular 
enzyme. Dibromomethylenebisphosphonate (11) and 
AMP—PC(Cl)jP (23) produced 50% inhibition at 450 pM 
and 350 pM respectively.
3.2.5 Effect of Substrate Concentration on
Inhibition of HSV-1 (HFEM) DNA Polymerase
by PAA and AMP-PAA
To characterise the nature of inhibition further 
the effect of substrate concentration on PAA and AMP-PAA 
inhibition was studied. In the experiment the four 
deoxyribonucleoside triphosphates were used as the 
variable substrates and activated DNA was at saturating 
concentration (375 pg/h\L). When the data was plotted 
employing the method of Lineweaver and Burk (1934)
(Fig. 3.2.5), straight lines could be drawn intersecting 
in the lower left hand quadrant which, using the 
nomenclature of Cleland (1963), is described as linear 
non-competitive inhibition. The k^'s for PAA and 
AMP-PAA were calculated as 6 and 360 x 10 6 M respectively.

3.2.6 Time-Course of AMP-PAA Inhibition
AMP-PAA to a final concentration of 500 pM was 
added at zero time, 15 or 30 minutes after the initiation 
of DNA synthesis. As seen from Fig. 3.2.6, under the 
assay conditions employed radioactive substrate was 
incorporated into acid-precipitable material for at least 90 
minutes. AMP-PAA caused an instantaneous inhibition of 
identical extent whether added at the time of initiation 
or after the initiation of polymerisation.
3.2.7 Generation of PAA Containing Nucleotides in
Polymerisation Reactions
The reaction mixture contained in a final 
volume of 1 mL:50 mM trie-HC1, pH 7.8, 5 mM MgClj»
20 mM KC1, 110 mM (NH4>2S04, 200 pM EDTA, 6 mM 
2-mercaptoethanol, 25 pM each of dATP, dCTP, dGTP and 
dTTP, 375 pg/ml activated DNA, 20 pM [2-3H)-PAA 
(sp. act. 600 cpm/pmol) and enzyme (HSV-1 (HFEM) DNA 
polymerase). Reaction mixes were incubated (30 minutes/ 
37°C) and terminated by the addition of EDTA to a 
final concentration of 200 mM. Reaction mixes were 
applied to a column of DEAE DE52 cellulose (0.6 x 20 cm, 
CHj.COO- form). The column was washed extensively with 
water and eluted with a linear gradient (100 ml) of 
0 to 0.5 M triethylammonium acetate, pH 4.7. The flow 
rate was adjusted to approximately 0.2 ml/minute and 
fractions (2 ml) were collected. The radioactivity
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of aliquots (100 ul) of each fraction was determined 
by liquid scintillation counting (Fig. 3.2.7). The 
elution positions of [2-3H}-PAA and dAMP-PAA (24) 
were determined by DEAE DE52 chromatography of a sample 
containing 50 mM trio-HC1, pH 7.8, 20 uM [2-3H]-PAA 
(sp. act. 600 cpm/pmol) , 5 mM MgCl2» 20 mM KC1, 110 mM 
(NH4)2S04, 200 mM EDTA and 5 mM dAMP-PAA. Recoveries 
of [2—3H]-PAA from the column were at least 85%.
PAA dAMPPAA
Fig. 3.2.7 Recovery of [2-3H]-PAA from HSV-1 (HFEM) DNA
polymerisation reactions. Experimental details 
are described in the text.
3.2.8 dAMP-PAA As A Substrate for HSV-1 (HFEM) DNA
Polymerase
It was shown that dAMP-PAA could not serve as 
a substrate in place of dATP in the HSV-1 (HFEM) DNA 
polymerase assay as follows: The enzyme was assayed in
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standard reaction mixtures in the absence of dATP, in 
the presence of increasing amounts of dAMP-PAA and in 
the presence of saturating amounts of dATP (Table 3.2.8).
Addition (wM) Cpm incorporated 
into acid-precipitable 
materialdAMP-PAA dATP
0 0 1510
5 0 1606
10 0 1451
25 0 1490
50 0 1570
100 0 1503
500 0 1485
0 100 38245
Table 3.2.8 dAMP-PAA as a substrate for HSV-1 (HFEM) DNA
polymerase. The assay procedure was essentially 
as described under Methods but with the omission 
of dATP.
3.3 DISCUSSION
The initial problem encountered in this study 
was the choice of test system. A number of contradictory 
reports have appeared in the literature concerning 
changes in the sensitivity of HSV DNA polymerases to 
PFA during the course of their purification (Ostrander 
and Cheng, 1980; Derse et al., 1982). Rationalisation 
of these observations is made difficult by the 
differences in biological origin of the polymerases
and the experimental conditions employed. It can be 
argued that whereas a crude extract of infected 
cells may contain components which might interfere with 
the assay procedures, the purification procedure may 
remove some components which confer sensitivity to an 
inhibitor. The ease of preparation coupled to the 
availability of a number of specific controls, in 
particular the well characterised inhibitors PAA and 
PFA and PAA resistant (Pr) strains of HSV, led to the 
choice of crude extracts of HSV-infected cells as test 
systems.
Infection of HEp-2 cells with HSV leads to the 
induction of a new DNA polymerase activity which 
increases linearly for at least 12 hours and remains 
at this elevated level for at least a further 12 hours 
(Purifoy and Benyesh-Melnick, 1975). Monolayer cultures 
of HEp-2 cells were infected at a m.o.i. of 2-10 pfu/cell 
to ensure a synchronous infection of as large a number 
of cells as possible. Cells were harvested at approximately 
16 hours post-infection and the crude suspensions obtained 
by sonic oscillation of cell pellets were extracted using 
the high salt procedure of Powell and Purifoy (1977) which 
solubilises proteins bound to DNA and removes the bulk 
of DNA from solution. This latter point was confirmed 
by the finding that the activity of HSV DNA polymerase 
preparations was dependent upon exogenous template. The 
crude extracts so obtained were assayed under high-salt 
conditions which stimulated the HSV DNA polymerase and 
produced almost total inhibition of cellular DNA
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polymerases, which is in agreement with previous work 
(Weissbach et al. , 1973). The high ionic strength of 
the assay procedure is thought to mimic the action 
of polyamines in infected cells which activates HSV DNA 
polymerase and inhibits the HSV (exo-endo)DNase 
(Ostrander and Cheng, 1980) which co-purifies with HSV DNA 
polymerase (Knopf, 1979; Ostrander and Cheng, 1980). It 
should be noted at this point that storage of the extract 
at -70°C for 7-10 days results in total abolition of the 
viral DNase activity (Grossberger and Clough, 1981;
R.Honness personal communication). Under conditions 
optimal for cellular DNA polymerases all extracts derived 
from both infected and mock-infected cells were shown to 
possess some activity indicating that cellular enzymes were 
extracted along with viral polymerases.
The DNA template used in the various assays was 
an 'activated' DNA prepared by treatment of salmon sperm DNA 
with bovine pancreatic DNase I. The procedure employed for 
its preparation was essentially that of Schlabach et al.
(1971) except that inactivation of DNase I was achieved by 
the addition of phenol rather than by heating which was 
found to be not fully effective. DNA treated in this manner 
contains an optimal number of 3'-OH groups and single 
stranded gaps which permit repair synthesis. It is 
pertinent to note that maximal levels of HSV DNA 
polymerase activity are not obtained in infected cells 
until replication of viral DNA is essentially over suggesting 
that HSV DNA polymerase may also play a role in 
recombination and/or repair (Powell and Benyesh-Melnick,
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1975).
The simple combination of a phosphono and a 
carboxyl group either linked directly (PFA), or joined by 
a methylene group (PAA), produced the most effective 
inhibitors in both the cell-free and cell culture systems. 
Esterification of either the phosphono or the carboxyl 
groups, increase in carbon chain length or substitution 
on the methylene group of PAA led to a decrease in, or 
abolition of activity. These findings being in good 
agreement with a number of previous studies (Eriksson 
et at., 1980; Leinbach et al., 1976). The nucleotide 
analogue AMP-PAA was found to possess slight inhibitory 
activity in both the cell-free and cell culture systems. 
The activity of this compound against HSV DNA polymerase 
would appear not to be a result of breakdown to release 
free PAA as 33Pn.m.r. and t.l.c. studies have shown the 
material to be stable under the assay conditions employed. 
However, the stability of AMP-PAA under the conditions 
employed in the cell culture model is unknown. Hence 
metabolism or simple degradation resulting in the 
generation of free PAA should also be considered as a 
possible route to inhibition in this case.
Analogues of methylenebisphosphonate which 
contain electron withdrawing groups on the methylene 
bridge have been found to be effective inhibitors of 
influenza RNA polymerase (Chapter 4). However, of 
such compounds examined, only carbonylbisphosphonate 
had any Inhibitory effect upon HSV DNA polymerase and 
this compound was ineffective in cell culture. The
inhibition of plaque formation by methanehydroxybisphosphonate 
did not correspond to its effects upon HSV DNA polymerase.
It seems likely that the activity of methanehydroxybis­
phosphonate in the cell culture model is a result of the 
cell-toxic effects of this compound (Stenberg, 1981).
It would appear therefore that the structural requirements 
for inhibitors of HSV DNA polymerase are more specific 
than those for inhibitors of influenza RNA polymerase which 
is presumably a manifestation of differences in the 
respective pyrophosphate binding sites.
The HSV DNA polymerase appears to be more 
sensitive to PAA, PFA and AMP-PAA than the cellular DNA 
polymerase a. However, carbonylbisphosphonate was a 
slightly more effective inhibitor of the cellular 
enzyme than the viral enzyme. The inhibition profiles 
obtained for PAA, PFA and carbonylbisphosphonate are 
in agreement with reports by Eriksson et at. (1980) on 
calf thymus DNA polymerase a and by Allaudeen and 
Bertino (1978) on DNA polymerase a from a murine lymphoid 
leukaemia cell line. Dibromomethylenebisphosphonate and 
AMP-PC(C1)2p have not previously been reported as being 
inhibitory towards calf thymus DNA polymerase a.
Further studies on their mode of inhibition have yet to be 
undertaken. It is pertinent to point out that biological 
activity cannot be attributed to the removal of free 
metal ions (Mg2+, K+) from solution by chelation as 
the compounds are active at concentrations which would 
not significantly affect the free metal ion
concentration
92
Compounds active against the DNA polymerase 
derived from cells infected with a strain of HSV-1 (HFEM) 
known to be sensitive to PAA (Ps) were also screened for 
activity against the DNA polymerase derived from cells 
infected with a PAA resistant (Pr) strain of HSV-1, 18 
Clone I. This polymerase was approximately 100 fold 
more resistant to each compound compared to the 'parent'
Ps strain, suggesting that these compounds all bind to 
the same site on the polymerase. No compound produced 
any significant reduction in plaque number at 500 ug/ml. 
Further evidence supporting the view that AMP-PAA and 
PAA bind to the same site on the polymerase comes from 
kinetic studies with HSV-1 (HFEM) DNA polymerase. Both 
compounds gave linear non-competitive inhibition when the 
dNTP's were present as the variable substrates. The 
results obtained with PAA are consistent with a number 
of previous reports (Mao and Robishaw, 1975; Leinbach 
et at. , 1976). The time-course of inhibition for AMP-PAA 
was also essentially similar to that reported by Mao and 
Robishaw (1975) for PAA.
The alternate product inhibitor mechanism proposed by 
Leinbach et al. (1976) to explain the inhibition of herpesvirus 
of turkeys DNA polymerase by PAA, predicts that altered 
nucleotides of the type dNMP-PAA would be formed in DNA 
polymerisation reactions containing PAA. Experiments 
designed to test the predictions of this hypothesis 
were performed but no supporting evidence was obtained.
No altered nucleotides containing [2-3H]-PAA were recovered 
from DNA polymerisation reactions containing [2-3H]-PAA
Mi Mi *•>
and furthermore, the nucleotide analogue dAMP-PAA 
was prepared and was found to be neither a substrate 
for nor an inhibitor of HSV DNA polymerase. Similar 
results but with no accompanying experimental details 
have been reported by Boezi (1979) using dTMP-PAA.
CHAPTER 4
INFLUENZA VIRUS
4.1 METHODS
4.1.1 Preparation of Virus Stocks
The influenza virus A/X49 was a cross between 
A/England/864/75 and A/PR/8/34 with the H3N2 surface 
antigens of the A/England strain. The virus was grown 
in the allantoic sacs of fertile hens eggs and was 
isolated essentially as described by Kelly and Dimmock (1974). 
Eleven day old embryonated hens eggs (5 dozen) were 
inoculated with infected allantoic fluid (0.1 ml of 
a 10  ^dilution in phosphate buffered saline, PBS).
The eggs were incubated (33°C/48 hours) and then chilled 
(-20°C/2 hours). The allantoic fluid was collected, 
carefully excluding blood and yolk, and centrifuged (3000 rpm/ 
20 minutes) to remove unwanted egg membranes. From 
this point onwards all procedures were carried out at 
0 to 4°C. The supernatant was removed and the virus was 
pelleted by centrifugation (21,000 rpm/90 minutes, 6 x 
250 ml rotor). The supernatant was discarded and the 
virus pellet was allowed to soak overnight in PBS.
The pellet was then resuspended in PBS and layered onto 
a velocity gradient of 10 to 40% (w/v) sucrose in
buffer (30 ml, 10 mM trro-HCl, pH 7.4) and
centrifuged (22,000 rpm/1 hour, 3 x 65 ml swing-out rotor).
The diffuse virus band was collected by bottom puncture 
and the sucrose was diluted out with PBS to a final 
volume of 30 ml. The virus suspension was then layered 
onto an equilibrium gradient of 30 to 70% (w/v> 
sucrose in buffer (30 ml, 10 mM fcris-HCl, pH 7.4) and 
centrifuged (20,000 rpm/overnight, 3 x 65 ml swing-out 
rotor). The virus band was collected, diluted with PBS 
and the virus pelleted by centrifugation (30,000 rpm/
2 hours, 8 x 50 ml rotor). The supernatant was discarded and 
the pellet was allowed to soak overnight in PBS. The 
virus was then resuspended in buffer (3 ml, 400 pM 
tris-HCl, pH 8.0) and frozen as aliquots at -70°C and 
thawed once prior to use.
4.1.2 Haemagglutination Assay
Serial two-fold dilutions of the virus 
preparation were made in PBS. Chick red blood cells 
(0.5 ml, 0.5% suspension) were added to each virus 
dilution (0.5 ml) and the test mixtures were incubated 
(room temperature/1 hour). The pattern formed by the 
red blood cells was noted. The last well giving definite 
agglutination was considered the end point which is 
expressed as the reciprocal of that dilution.
4.1.3 Influenza RNA Dependent RNA Polymerase Assay
The standard reaction mixture contained in a 
final volume of 200 pi: 50 mM trie-HCl, pH 8.0, 5 mM
96
magnesium acetate, 150 mM potassium chloride, 5 mM dithio- 
threitol (DTT) , 0.4 mM adenvlyl-(3'-5')-guanosine, 0.25% 
Nonidet P-40, 0.4 mM each of ATP, GTP, CTP, 0.005 mM 
[3H]UTP (5 pCi) and purified virus. Reaction mixes 
were maintained at 4°C until zero time. The reaction 
was initiated by addition of virus and the tubes were 
incubated at 30°C for 1 hour. The amount of virus 
added was such that the incorporation of [3H>UTP into 
acid précipitable product increased linearly during the 
incubation period. The reaction was stopped by the 
addition of ice-cold saturated sodium pyrophosphate 
(200 pi) followed by cold 10% (w/v) TCA (2 ml). The
tubes were vortexed and kept on ice for 15 minutes 
or longer. The precipitates were collected by suction 
filtration onto Whatman GF/C discs, which were washed 
several times with 10% TCA, once with ethanol and dried. 
The radioactivity of material precipitated on the discs 
was then determined by scintillation counting using 
a toluene-based scintillant. Pyrophosphate analogues were 
added to the reaction mixtures before addition of virus.
The concentration of analogue which inhibited the 
incorporation of I3H]-uridine into acid-insoluble 
material by 50%, was derived from the dose-response 
curve for each compound.
4.1.4 Determination of Pyrophosphate Analogue -
Zinc Ion Stability Constants
The stability constants were determined by
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the method of Hummel and Dreyer (1962) using a column of 
Sephadex G-10 (1.6 x 92 cm) which had been equilibrated
with zinc chloride (10 uM, Spectroscopic grade) in 
buffer (0.1 M triethanolamine-HCl, pH 8.0). The pyro­
phosphate analogues (100 nmol) were added in buffer 
(1 ml, triethanolamine/zinc) and the column eluted with 
the same buffer at a flow rate of 0.4 ml/minutes. The 
zinc content of individual fractions (2 ml) was 
determined by atomic absorption spectrometry and the 
stability constants determined as described by Hummel 
and Dreyer (1962).
A detailed description of this technique can be found 
in Appendix II which is a reprint of N. Yoza, J. Chem. Ed.,
S4, 247 (1977).
4.2 EXPERIMENTAL AND RESULTS
4.2.1 Dose-Response Curves
A typical dose-response curve is shown in 
Fig. 4.2.1. The strongest inhibitor amongst the compounds 
examined was dibromomethylenebisphosphonate (11) which 
produced 50% inhibition of influenza RNA polymerase at 
a concentration of 10 pM (Table 4.2.1). All halo-substituted 
methylenebisphosphonates, (9) to (12), were potent inhibitors
whereas methylenebisphosphonate (8) was ineffective. 
Replacement of the bridging oxygen of pyrophosphate with an 
imido (16) and a carbonyl (15) function also produced 
effective inhibitors. Of the compounds containing a
the method of Hummel and Dreyer (1962) using a column of 
Sephadex G-10 (1.6 x 92 cm) which had been equilibrated 
with zinc chloride (10 pM, Spectroscopic grade) in 
buffer (0.1 M triethanolamine-HCl, pH 8.0). The pyro­
phosphate analogues (100 nmol) were added in buffer 
(1 ml, triethanolamine/zinc) and the column eluted with 
the same buffer at a flow rate of 0.4 ml/minutes. The 
zinc content of individual fractions (2 ml) was 
determined by atomic absorption spectrometry and the 
stability constants determined as described by Hummel 
and Dreyer (1962).
A detailed description of this technique can be found 
in Appendix II which is a reprint of N. Yoza, J. Chem. Ed.,
54, 247 (1977).
4.2 EXPERIMENTAL AND RESULTS
4.2.1 Dose-Response Curves
A typical dose-response curve is shown in 
Fig. 4.2.1. The strongest inhibitor amongst the compounds 
examined was dibromomethylenebisphosphonate (11) which 
produced 50% inhibition of influenza RNA polymerase at 
a concentration of 10 wM (Table 4.2.1). All halo-substituted 
methylenebisphosphonates, (9) to (12), were potent inhibitors
whereas methylenebisphosphonate (8) was ineffective. 
Replacement of the bridging oxygen of pyrophosphate with an 
imido (16) and a carbonyl (15) function also produced 
effective inhibitors. Of the compounds containing a
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Fig. 4.2.1 Effect of pyrophosphate analogues on influenza 
RNA polymerase. Influenza RNA polymerase was 
assayed as described in Methods. The inhibition 
is expressed as the percentage of the uninhibited 
RNA polymerase activity remaining at various 
concentrations of inhibitor. The symbols used 
are AMP-PAA (X) , PAA (A) and PFA (•) . In the 
uninhibited reaction 'v 7500 cpm were 
incorporated.
phosphono and a carboxyl function, only PFA was 
an effective inhibitor. Increasing the distance 
between the two acid groups by the introduction of 
a methylene group, (PAA), caused a decrease in potency 
and this slight activity was destroyed by a further 
increase in the length of the carbon chain (3-phosphono- 
propionic acid, 4) or by substitution on the methylene 
group (2-phosphonopropionic acid, 3). Furthermore, 
esterification of either the carboxyl (6) or phosphono (7)
Table 4.2.1 Inhibitory effect of Pyrophosphate Analogues 
on RNA Polymerase from Influenza Virus and 
Calf Thymus DNA Polymerase a
Compound pKd.*
Concn. (uM) Producing 
50% Inhibition
Influenza RNA 
Polymerase
Calf Thymus 
DNA Polymerase 
a
1 5.5 275 45
2 VOm 35 35
3 — ' 5 > 500 > 500
4 < 4 > 500 > 500
5 < 4 > 500 > 500
6 < 4 > 500 > 500
7 < 4 > 500 > 500
8 5.3 > 500 > 500
9 > 6 75 > 500
10 > 6 85 > 500
11 > 6 10 350
12 > 6 45 > 500
13 > 6 > 500 > 500
14 5.2 350 > 500
15 5.4 20 100
16 5.7 50 > 500
17 5.7 125 > 500
18 > 6 > 500 > 500
19 ND > 500 > 500
20 ND > 500 > 500
21 ND > 500 > 500
22 ND > 500 > 500
23 ND > 500 > 350
24 ND > 500 > 500
♦Dissociation constant of complex formed 
with zinc ions, measured at pH 8.0 as 
described in text.
ND Not determined
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groups of PAA also destroyed activity.
4.2.2 Time-Course of Inhibition by PFA
PFA (500 pM) was added at zero time, 15 and 
30 minutes after the initiation of polynucleotide synthesis 
As seen from Fig. 4.2.2 the radioactive substrate was 
incorporated into polynucleotide at a linear rate for at 
least 60 minutes. Addition of PFA caused an instantaneous 
inhibition of identical extent whether added at the time 
of initiation or after the initiation of polymerisation.
4.2.3 Effect of Zinc Ions and a Reducing Agent
(DTT) on Inhibition by PFA
In o r d e r  to d e t e r m i n e  if i n h i b i t i o n  of 
i n f l u e n z a  R N A  p o l y m e r a s e  b y  P F A  w a s  c a u s e d  b y  i n t e r a c t i o n  
o f  the i n h i b i t o r  w i t h  z i n c  ions o r  s u l p h y d r y l  c r o u p s  
p r e s e n t  o n  t h e  e n z y m e ,  a s s a y s  w e r e  p e r f o r m e d  in t h e  
p r e s e n c e  a n d  a b s e n c e  o f  z i n c  ions, D T T  a n d  P F A  (Table 
4.2.3).
Addition
[■*H]-UMP Incorporated into 
Acid-Precipitable Material
Control* + 100 uM PFA
None 2925 571
5 mM DTT 4741 1445
100 wM Zn2+ 185 0
100 uM Zn PFA 851 -
Table 4.2.3 Effects of zinc ions and DTT on inhibition 
b y  P F A
• A s s a y  p r o c e d u r e s  w e r e  e s s e n t i a l l y  as d e s c r i b e d  u n d e r  
m e t h o d s  b u t  w i t h  the o m i s s i o n  o f  DTT.
1 • '* * * ' % J». •>»*•»•f  » ' "a  i * *
r j M
"* 1 ' - . I > V, l a

1 0 2
4-2.4 AMP-PAA as a Substrate for the Influenza
RNA Polymerase
It was shown that AMP-PAA could not serve as 
a substrate in place of ATP in the influenza RNA 
polymerase assay as follows: The enzyme was assayed 
in standard reaction mixtures in the absence of ATP, 
in the presence of increasing amounts of AMP-PAA and in 
the presence of saturating amounts of ATP (Table 4.2.4).
Addition
AMP-PAA
(liM)
ATP
cpm Incorporated 
into Acid-Precipitable Material
0 0 463
50 0 1034
100 0 598
250 0 281
500 0 840
1000 0 836
0 400 7507
Table 4.2.4 AMP-PAA as a substrate for influenza RNA 
polymerase. Influenza RNA polymerase was 
assayed essentially as described in Methods 
but with the omission of ATP.
Similar results were obtained for the ATP analogue 
AMP-PC (Cl)2P.
4.2.5 Recovery of [2-3H]-Phosphonoacetate from 
Influenza RNA Polymerase Assays
To the standard assay mixture (1 ml), containing
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0.4 mM UTP in place of [3H]-UTP, was added [2-3H]-PAA 
(0.5 umole) and purified virus. The reaction was 
incubated at 30°C for 1 hour then EDTA was added to a 
final concentration of 20 mM. The reaction mixture 
was applied to a DEAE DE52 column (CH^-COO form,
0.6 x 14 cm) which was washed with water and then eluted 
with a linear gradient of triethylammonium acetate 
(0.5 M, pH 4.7, 100 ml). The radioactivity of the fractions 
(1.5 ml) was then determined by liquid scintillation counting 
in a toluene based scintillant. The recovery of radioactivity 
from this experiment was almost 90%. The relative elution 
positions of l3H]-PAA and AMP-PAA were determined in a 
separate experiment (Fig. 4.2.5).
Fig. 4 . 2 . 5  Recovery of radioactivity from influenza RNA polymerase 
assays containing [ 2 - 3H]-PAA. Reaction conditions were 
as outlined in the text.
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4.2.6 Effect of Substrate Concentration on 
Inhibition of Influenza RNA Polymerase 
by PFA
The mechanism of inhibition of influenza RNA 
polymerase by PFA was studied by varying the concentration 
of substrate nucleoside triphosphates in the polymerase 
assay system. However, when the data obtained were 
transferred into double reciprocal plots according to the 
procedure of Lineweaver and Burk (1934), the lines obtained 
were curved and no conclusions could be made concerning 
the type of inhibition.
4.2.7 Preparation of ATP Analogues followed 
by 31 p n. m . r~
The reaction of adenosine 5'-phosphoromorpho- 
lidate with pyrophosphate analogues in pyridine (3 ml, 10 mM 
tubes) was followed by ^*P n.m.r. at 162 MHz using a 
Bruker WH400 spectrometer. Reaction conditions were 
essentially as described in Section 2.5.14. Spectra 
were recorded before mixing of reactants at the time 
of mixing and at various times thereafter. The 
results of the various experiments are depicted in 
Figs. 4.2.7.Ì and ii.
4.2.8 Effect of Combination of Inorganic 
Pyrophosphate and PFA on Influenza 
RNA Polymerase
To determine if inorganic pyrophosphate 
displayed a competitive or additive effect with PFA,
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102-5min
4 2 - 5 m i n
2 2 - 5 m i n
12- 5mi n
9
Fig. 4.2.7.
- l ________________i__________________i__________________i ■
8 7 6 5 4 £ Bam.
i Adenosine 5'-phosphoromorpholidate plus
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Fig. 4.2.8 Effect of combination of PFA and inorganic pyrophosphate 
on influenza RNA polymerase activity. Assay conditions 
were as described in Methods. The inhibition is 
expressed as percentage of uninhibited activity 
remaining at various concentrations of inhibitor. 
Additions: control, no addition (O), inorganic
pyrophosphate, 50 yM (A). Dotted line represents 
calculated plot for an additive effect.
influenza RNA polymerase was assayed in the presence of 
increasing concentrations of PFA both in the presence 
and absence of a fixed concentration of inorganic 
pyrophosphate (Fig. 4.2.8). The addition of various 
concentrations of PFA to a fixed concentration of 
inorganic pyrophosphate resulted in greater inhibition than 
was achieved with either PFA or pyrophosphate alone.
T h e  d e c r e a s e  in i n f l u e n z a  R N A  p o l y m e r a s e  a c t i v i t y  w a s  
n o t  s i g n i f i c a n t l y  d i f f e r e n t  f r o m  t h a t  c a l c u l a t e d  for 
an a d d i t i v e  eff e c t .
1
*». A *<■<■
-X * • ■> '
4.2.9 Effect of Pyrophosphate Analogues on free 
Metal Ion Concentration
The pyrophosphate analogues in this study
are acidic compounds and could conceivably exert their
antiviral effect by chelation to, and hence removal
2 +from solution of, metal ions (Mg ions) which have
been shown to be essential for activity of influenza
RNA polymerase. However, compounds were active at pM
2+ +levels whereas the concentrations of Mg and K ions 
present in the assays was 5 mM and 150 mM respectively.
Under such conditions no change in the level of free metal ion 
concentration would be expected and hence biological activity 
cannot be attributed to depletion of free metal ions.
4.3 DISCUSSION
Influenza RNA polymerase was assayed in detergent- 
disrupted virus preparations using endogenous RNA as 
template and in the presence of adenylyl-(3'-5')-guanosine 
(ApG) as primer, which has been shown to stimulate 
polymerase activity in vitro (Plotch and Krug, 1977).
This system was chosen as it is not yet possible to 
isolate active influenza RNA polymerase which is free 
from RNA and other proteins. Recently, a ribonucleoprotein 
consisting of PA, PBt and PB2 and associated with vRNA 
but free of other proteins has been isolated which is 
capable of transcribing vRNA in vitro (Kawakami and 
Ishihama, 1983). However, the total characterisation of 
the processes carried out by this complex remains to be
published.
The inhibition of the polymerase was followed by 
studying the effect of pyrophosphate analogues on the 
incorporation of radioactivity into acid-insoluble 
polynucleotide. The assay is technically simple but 
stringent precautions must be taken to prevent contamina­
tion of reagents with RNase which would result in virus 
preparations appearing to have little or no RNA polymerase 
activity. Hence, all heat stable reagents were autoclaved 
prior to use and an aseptic technique was employed.
There are essentially two possible mechanisms for 
the mode of action of the pyrophosphate analogues. Either 
(a) they are converted by the virus into analogues of 
nucleoside triphosphates which inhibit the influenza RNA 
polymerase, or (b) they interact directly with the polymerase, 
possibly by coordinating with an essential metal ion, 
possibly zinc.
Results suggest that these inhibitors do not act 
by being incorporated into the B~y positions of nucleoside 
triphosphate analogues. The ATP analogue AMP-PAA (20) is 
neither a substrate for, nor an inhibitor of influenza 
RNA polymerase. Dichloromethylenebisphosphonic acid (9) 
is an effective inhibitor of the viral polymerase but its 
ATP analogue (23) is again neither a substrate fiar, nor an 
inhibitor of this enzyme. Furthermore, when [2-')H)- 
phosphonoacetate was included in the standard polymerase 
assay mixture, all the radioactivity recovered was in the 
form of starting material. None could be detected in the 
form of nucleoside triphosphate analogues.
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The ATP analogue AMP-PAA is easy to prepare by 
the phosphoromorpholidate route. However, attempts to 
prepare the ATP analogue which contains PFA at the S-y 
position met with failure. All that was achieved was the 
rapid conversion of adenosine 5'-phosphoromorpholidate 
into AMP. To gain a greater insight into the course of 
these conversions the reactions were followed by ^1p 
n.m.r. With PAA there was steady decay of the phosphoro­
morpholidate signal at 7.8 ppm accompanied by an increase 
in intensity of a pair of doublets centred at 5.2 and 
-9.7 ppm due to the formation of the pyrophosphate 
residue in AMP-PAA. When PFA is used the phosphoromorpholidate 
signal decays as before but no doublets appear, only a 
singlet at 2.2 ppm due to AMP. When the C-ethyl ester of 
PFA, which is not an inhibitor of influenza RNA polymerase, 
is used, signals due to the phosphoromorpholidate at 7.8 ppm 
and the ester at 28.2 ppm are observed at the start of the 
experiment and with time, two doublets of equal intensity 
appear at 20.2 ppm and -9.4 ppm due to the formation of the 
ATP analogue.
It seems likely that PFA reacts with the phosphoro­
morpholidate to give an ATP analogue but that it rearranges 
rapidly to give a highly reactive mixed anhydride of 
adenosine 5’-phosphoric and formic acids which 
subsequently breaks down (Fig. 4.3.i) (Jaenicke and Koch,
1963). With PAA the nucleoside triphosphate analogue could 
still decompose by an intramolecular mechanism but here 
a six-membered rather than a five-membered ring would be 
involved and hence this breakdown should be comparatively
■
M, A.*»'
I l l1
OIPOP-O P CH,COO I I 1
( 20 )
° 0° „ > .  
RO ' |
« /  Ro p :
OH MO. .°PC.
H,O *ROP-O-C. /-J,
O  ilO
O
O
Fig. 4.3.1 Reactions of adenosine 5-phosphoromorpholidate 
with PAA and PFA.
R = adenosine
slow. Marked differences between the rates of intra­
molecular hydrolysis of phosphonate esters have been 
observed depending on the size of ring involved in the 
cyclic reaction. Thus, diethyl 2-carboxymethylphenyl- 
phosphonate undergoes intramolecular hydrolysis 105 times 
more slowly than diethyl 2-carboxyphenylphosphonate at 
pH 3.0 and 79.5°C (Fig. 4.3.Ü) (Blackburn and Brown, 
1969). The C-ethyl ester of P F A  cannot decompose via 
a cyclic reaction as the carboxyl group is blocked.
Hence, the formation of the pyrophosphate bond in the 
nucleoside triphosphate analogue can be observed.
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OEt
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UJ
O
 
O
V
h2c o o h COOH
(b )
Fig. 4.3.H (a) Diethyl 2-carboxymethylphenylphosphonate
(b) Diethyl 2-carboxyphenylphosphonate
Little data on the metal chelating properties 
of pyrophosphate analogues have been published. We have 
therefore, determined by gel filtration a dissociation 
constant pK^, (Table 4.2.1) for complexes formed 
between zinc ions and pyrophosphate analogues at pH 8.0, 
the pH at which the RNA polymerase assays are carried 
out. We do not attempt to specify which ligand species 
are involved in complex formation as more than one species 
may be present and pKd . is merely an indication of the 
strength of the interaction between the analogues and 
zinc ions at this pH. However, our pKd i values do not 
differ markedly from the pKd values reported for the 
fully ionised species of PAA (5.3) (Stunzi and Perrin, 
1979) and dichloromethylenebisphosphonic acid (6.7) 
(Dietsch et al., 1976). Thus, the gel filtration method
was found to be an efficient and rapid method for the 
determination of stability constants. Several other 
methods including 3lP n.m.r., potentiometry, ion exchange 
and spectrophotometry were also evaluated for the 
determination of pyrophosphate analogue - zinc ion
I «*. A«**' ■m»’*''
ft*»
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stability constants. However, difficulties with ease 
and rapidity of operation and reproducibility of results 
effectively precluded their use in this particular 
study. We find that there is a correlation between the 
pK^, of an analogue and its effectiveness as an inhibitor 
of the RNA polymerase activity of influenza (Fig. 4.3.iii). 
Thus, PAA and PFA have relatively high pK^g and are 
inhibitors of the polymerase whereas (3) to (7) have 
lower pK^ig and are ineffective inhibitors. Steric factors 
appear to be involved as PFA which can form a metal chelate 
with a five-membered ring is a more effective inhibitor 
than PAA which forms a chelate with a six-membered ring 
which in turn is a more effective inhibitor than
3-phosphonopropionic acid (4) which would form a chelate 
with a seven-membered ring. The correlation between 
chelate ring size and complex stability is as predicted 
from experience with other ligands.
A correlation between pK<ji and inhibitor 
effectiveness also seems to exist for methylenebis- 
phosphonates. Thus methylenebisphosphonate (8) which 
has a lower pK^i than the halogenated analogues (9) to 
(12) is an ineffective inhibitor whereas (9) to (12) are 
effective inhibitors. Interestingly, carbonylbisphos- 
phonate (15) is a more effective inhibitor of the 
polymerase than (8) though it has a similar pK,j • . Here, 
steric factors may be important as the P-C-P bond angle 
in these two compounds should be very different.
Inorganic pyrophosphate (17) and imidobisphosphate (16) 
have high pK^.g and are effective inhibitors.

Fig. 4.3.iii Relationship between pKd , (the ability of 
pyrophosphate analogues to bind zinc ions 
at pH 8.0) and their effectiveness as 
inhibitors of influenza (A/X-49) RNA 
polymerase.
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Although ethane-l-hydroxy-1,1-bisphosphonate (13) 
forms strong complexes with zinc ions in solution it is not 
an effective inhibitor of influenza RNA polymerase. This 
seemingly anomalous result can possibly be explained by 
the presence of a third chelation site. Analysis of 
x-ray crystallographic data (Barnett and Strickland, 1979) 
by molecular graphics indicates that the hydroxyl group 
of the hydroxyethyl moiety would be unable to bind to the 
zinc ion involved in the six-membered chelate ring but it 
could be involved in chelation to a second zinc ion in 
solution which would result in a stronger overall complex 
formation. This same rationale can also be applied to 
(18) .
The inhibition of some zinc metalloenzymes 
(e.g. bovine liver glutamate dehydrogenase and bovine 
carboxypeptidase) by chelating agents can be reversed 
by the addition of excess zinc ions (Vallee, 1960).
However, reversal of inhibition is highly dependent upon 
the relative stability constants of the inhibitor for 
polypeptide bound zinc and free zinc. Furthermore, 
systems containing metal ions and complexing agents 
in excess constitute metal ion buffer systems in which 
the free metal ion concentration is controlled by the 
other components. In particular, proteirs contain 
several metalion complexation sites (-NH2, -COO, -S ) 
which can effectively decrease the concentration of 
free metal ions and this may help to explain why it is 
frequently not possible to reverse the inhibitory 
effects of chelating agents by the addition of free
metal ions (Vallee, 1960).
The inhibition of influenza RNA polymerase by 
PFA could not be reversed by the addition of zinc ions 
to the reaction mixes and indeed in control reactions 
zinc ions themselves were found to be inhibitory. In 
a further attempt to reverse inhibition, PFA was added 
as its zinc salt (formed oy ion exchange chromatography). 
However, this was found to be an even more effective 
inhibitor than the free drug. It is possible that the 
inhibitory effect of ZnPFA is two fold: on dissolution 
in the reaction mixture the salt dissociates yielding 
free zinc ions which bind to metal complexation site(s) 
on the enzyme and free PFA which binds to the pyrophosphate 
binding site.
Billards and Peets (1974) demonstrated that an 
excess of dithiothreitol (DTT) was capable of reversing 
the inhibitory effects of selenocystine and postulated that 
the influenza RNA polymerase was very sensitive to 
compounds which react with -SH groups. In control reactions 
DTT at a concentration of 5 mM stimulated the incorporation 
of [3H)-UMP into acid-precipitable product by 50%. However 
no significant change in the inhibition profile of PFA was 
observed when DTT was omitted from the reaction mixes 
suggesting that -SH bonds do not play a major role in PFA 
inhibition.
The complexity of the assay system makes inter­
pretation of the enzyme kinetics of the polymerase reaction 
difficult (for example, Lineweaver and Burk plots of the 
inhibition of this enzyme activity were curved). Studies
with active preparations of influenza RNA polymerase 
free from RNA and other proteins might help to establish 
the exact mode of action of pyrophosphate analogues.
Upon the evidence amassed to date we suggest that 
pyrophosphate analogues inhibit influenza RNA polymerase 
by complexing with an essential zinc ion at the active 
site of the enzyme thus preventing the binding of nucleoside 
triphosphates or the release of inorganic pyrophosphate 
once the internucleotide bond has been formed by the 
enzyme. A possible reason for the differential sensitivities 
of various polymerases (e.g. DNA polymerase a) to these 
analogues may be that the environment around the essential 
zinc ion is such that an effective inhibitory complex 
cannot be formed in certain enzymes.
APPENDIX I
AMMONIA CHEMICAL IONISATION MASS SPECTRA 
OF ESTERS AND AMIDES OF OXYACIDS 
OF PHOSPHORUS
AI. 1 INTRODUCTION
The electron impact (El) mass spectra of esters 
of oxyacids of phosphorus have been widely studied and 
detailed fragmentation patterns for many esters have 
been published (Gillis and Occolowitz, 1972; Meyerson 
et al. , 1980). However, under standard El conditions the 
interaction in the ion source between energetic electrons 
and sample molecules having ionisation potentials of 7-10 eV 
produces molecular ions that contain a considerable amount 
of excess energy which is largely dispersed through 
fragmentation. Consequently, the ion current carried by 
the molecular ion and other high molecular weight ions in 
the El spectra of many phosphorus esters and amides is often 
much less than 1% of the total ion current, making 
identification and analysis of unknown compounds difficult. 
Chemical ionisation (Cl) mass spectrometry has been 
suggested as a means of overcoming this problem (Sass and 
Fisher, 1979).
In Cl mass spectrometry, a reagent gas such as
methane is introduced into the ion source so as to achieve
3 4a reagent gas to sample ratio of 10 to 10 to 1. Under 
such conditions the principal process carried out by the 
energetic electrons in the ion source is ionisation of
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the reagent gas. For methane, ionisation is followed by 
ion-molecule interactions which yield two dominant ionic 
species, CH,.+ and CjH,.*. These ions can then ionise 
sample molecules (M) present in the source by means of 
proton transfer [1],
M + CH5+ -* MH+ + CH4 [1]
Ionisation by proton transfer is a considerably less 
energetic process than ionisation by electron-impact. 
Consequently, the degree of fragmentation which occurs 
under Cl conditions is generally much less than that 
which occurs under El conditions.
The degree of fragmentation which occurs 
can be controlled further by the choice of reagent gas.
For example, isobutane as reagent gas will give rise 
to MH+ ions which undergo far less fragmentation than is 
observed when methane is used as reagent gas. This is 
because the dominant ionic species produced from isobutane 
is the t-butyl ion which is a far weaker proton donor 
than the CH^+ ion. The use of ammonia as reagent gas 
results in still milder ionisation conditions and hence 
less fragmentation. In addition to the MH+ ion the 
adduct ion [M + NH4) + is also occasionally observed, its 
appearance being dependent upon the conditions employed and 
the basicity of the sample (Keough and DeStefano, 1981) .
The Cl mass spectra have been described for 
some phosphonates using hydrocarbons as reagent gases 
(Sass and Fisher, 1979) and this study extends these
initial experiments to esters and amides of other oxyacids 
of phosphorus using ammonia as reagent gas.
AI.2 EXPERIMENTAL
Unless otherwise stated, all compounds were commer­
cially available. Tetra-isopropyl esters of halogenated 
methylenebisphosphonates were prepared by the method of 
Quimby et al. (1967). Diethyl phosphonoacetic acid was 
prepared by the method of Clayton et al. (1979).
Mass spectra were obtained using an MS80 mass 
spectrometer with a DS55 data system (Kratos Analytical
Instruments). Cl mass spectra were recorded using
-4ammonia as reagent gas at a pressure of 2 x 10 Torr 
in the source housing (equivalent to approximately 0.1 Torr 
in the source). Electron energy was 55 eV. The ion source 
temperature was 200°C and the emission current 500 pA.
El mass spectra were obtained at 70 eV and a source 
temperature of 200°C. Samples were introduced via a 
solids probe in the usual manner.
Al. 3 RESULTS AND DISCUSSION
Al .3.1 Phosphonates
The Cl spectra obtained for compounds 1-10 
(Table AI.3.1) were similar to those obtained previously 
for phosphonates with hydrocarbons (Sass and Fisher, 1979), 
the major high molecular weight signal being due to the 
protonated molecular ions [M +1) • Useful structural
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Table AI.3.1 Compounds Studied
Name Formula ElementalComposition Hol. Wt.
PHOSPHONATES
1 Tetra-isopropyl methylene 
bisphosphonate
(Me2CH0)2P(0)CH2P(0)(OCHMOj)2 CI3H30°6P2 344
2 Tetra-isopropyl monochloromethylene 
blsphosphona te
(MejCHO)P(O)CHCIP(O)(COCHMe2>2 C|3H29C1°6P 378380
3 Tetra-isopropyl monobromomethylene 
bi sphosphona te
(MejCHO)P(O)CHBrP(O)(OCHMe2>2 CllH29*r°6P 422424
4 Tetra-isopropyl dibromomethylene 
bisphosphonate
(M#2CH0)P(0)CBr2P(0)(OCHMSjlj Cl3H28,r2 V 2 500502.504
5 Triethyl phosphonoacetate (EtO)2?(0)CH2C00Et C.".7“i' 224
6 Triethyl 2-phosphonopropionate (EtO)2P(O)CHMeCCOE t V l 9 0SP 238
7 Diethyl phosphonoacetonitrile (EtO)2P(0)CH2CN V l 2 " ° 3 P 177
8 Diethyl allylphosphonate (EtO)2P(0)CH2CH-CH2 ^7PI3°3P 178
9 Benzyl diethyl phosphonoformate (EtO)2P(OJCOOCHjPh C1jH„05p 272
10 Diethyl phosphonoacetic acid (EtO)2P(0)CH2CCOH C6HI3°SP 196
PHOSPHATES
11 Trim#thylphosphate (MeO) 3PO C3H9°4P 140
12 Triethyl phosphate (EtO) jPO V i*°«p 182
13 Tri-isopropyl phosphate (H«2CHO)3po C9H2I°«P 224
14 Tri-n-butyl phosphate (•uOj) PO CI2H27°4P 266
15 Triphenyl phosphate (PhO)3P0 CI."|S°4P 326
PHOSPHITES
PHOSPHORAMIDATES
19 Di-isopropyl phosphoramidate (MSjCHO)jP(0)NH2 C4B|4N03P 181
20 Hexamethyl phosphoramide («•jH)jPO V l . M3OP 179
16 Trimethyl phosphite (HeO) 3P C3K9°3P 124 I
17 Triethyl phosphite CEtO) 3P C."|»°3P 166 I
18 Triphenyl phosphite (PhO)jP CI."|J°3P 310 1
- ******
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data could be obtained from ammonia Cl spectra. For 
example, the spectrum of tetra-isopropyl methylenebis- 
phosphonate (1) (Fig. AI.3.1) contained peaks at 
m/z 345 (6.6%), 303 (4.0%), 261 (6.2%), 219 (3.2%) and 
117 (3.5%), indicating the successive loss of C-jH^  (42 u) 
and confirming the presence of a tetra-isopropyl ester 
(Table AI.3.11). The corresponding signals were scarcely 
discernible in the El spectrum of 1. The Cl spectra of 
the tetra-isopropyl esters of monochloro-(2>, monobromo-(3) 
and dibromo-(4)-methylenebisphosphonates all showed 
similar families of peaks consisting of the protonated 
molecular ion and ions derived from the successive loss 
of propene residues. As might be expected, owing to 
the presence of halogen atoms, the protonated molecular 
ion and related ions in 2 were doublets (ratio 1:2:8), 
doublets (ratio 1:1) for 3 and triplets (ratio 1:2:1) 
for 4 (Table AI.3.ii).
Structural information could also be obtained 
from the Cl mass spectra of the ethyl esters 5-10. In 
addition to the protonated molecular ion, other major 
ions corresponding to the successive loss of 28 u 
(presumably ethene) were present, confirming the 
presence of P-0-C2H5 residues. The Cl mass spectra of 
5 and 6 also showed ions corresponding to the loss of 
ethanol from the protonated molecular ion. This loss 
must involve the COOC2H5 group as this fragmentation 
does not occur in compounds 7-10. The Cl mass spectrum 
of the carboxylic acid diethyl phosphonoacetic acid (10) 
showed a peak due to (M + NH^I m/z 214 (4.2%) as well
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Table AI.3.11 Principal Ions and % Total Ion Current Carried in Ammonia Cl Mass 
Spectra of Esters and Amides of Oxyacids of Phosphorus
PHOSPHONATES
1 345 (6. 6%) , 303 (4.0) , 261 (6.2) , 219 (3. 2), 177 (3.5)
2 381 (2. 3%) » 379 (6.6) , 345 (3.2), 339 (1.9) , 337 (5.3) # 297 (1 .2) #295 (3 .6)255 (0. 6) , 253 (1.7), 213 (0.3) , 211 (1.0)
3 425 ( 1 .3%) . 423 (1. 3) , 383 (1 .3), 381 (1. 3) , 345 (2.9) 341 (0 .8) 339 (0 .8)
299 (0. 3) , 297 (0. 3) , 257 (0.3) , 255 (0. 3)
4 505 ( 1. 7%) , 503 (3. 4) « 501 (1 .8), 463 (2.6) , 461 (5.2) t 459 (2 .8) t 421 (1 .8)
lit (3. 5) , 417 (1.9) , 379 (0.6), 377 (1. 2) , 375 (0 .8)
5 225 (42 .0%) , 197 (9.5) , 179 (5.3), 151 (3.9)
6 239 (29.6%) , 211 (3.6) , 193 (8.0), 183 (1 .2)
7 195 (16 .8%) , 178 (52.0) , 150 (34) , 122 (1 .1)
8 180 (11 .3%) , 179 (17.0) , 178 (6.2) , 167 (8.6) , 151 (4. 4) , 134 (3. 3) , 123 (2.
9 273 (13 .3%) , 245 (0.3) , 229 (12.6) , 217 (0.2) , 181 (8.8) • 91 (29. 3)
10 214 (4. 2%) , 197 (29 .5) , 183 (5.8) , 169 (1 .9) , 153 (11. 7)
PHOSPHATES
11 141 (23.. 3% ) , n o (6. 1) • 94 (1.6) * 79 (0.6)
12 183 (38.,9%) , 155 (20 .0) , 127 (5. 4) • 99 (0.6)
13 225 (22.,8%) , 183 (14 .4) , 141 (8.2) , 99 (1. 1)
14 267 (34. 4%) , 211 (14 .8) , 155 (8.0) , 99 (1.6)
15 327 (40.. 3%) , 233 (1. 8) , 170 (2.0)
PHOSPHITES
16 125 (10..8%) , 111 (11 .4) , 94 (1.9)
17 167 (47..2%) , 139 (20 .9) , 121 (2 .5) , 111 (2..2)
18 311 (10. 4«) , 235 (8.0) , 217 (10 .1) » 153 (2..9)
PHOSPHORAMIDATES
19 182 (33. 5%) , 140 (14.6),, 124 (3. 9) , 98 (14.9)
20 180 (22. 3%) , 136 (5.9) , 135 (10,.0) , 92 (1.8)
94 (8.5)
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Table AI.3.11 Principal Ions and % Total Ion Current Carried in Ammonia Cl Mass 
Spectra of Esters and Amides of Oxyacids of Phosphorus
PHOSPHONATES
1 345 (6.6%), 303 (4.0), 261 (6.2), 219 (3.2), 177 (3.5)
2 381
255
(2.3%), 379 
(0.6)* 253
(6.6), 
(1.7),
345 (3.2), 
213 (0.3),
339 (1.9), 
211 (1.0)
337 (5.3), 297 (1.2) . 295 (3.6) ,
3 425
299
(1.3%), 423 
(0.3), 297
(1.3), 
(0.3),
383 (1.3), 
257 (0.3),
381 (1.3), 
255 (0.3)
345 (2.9), 341 (0.8) , 339 (0.8) ,
4 505
419
(1.7%), 503 
(3.5), 417
(3.4), 
(1.9),
501 (1.8), 
379 (0.6),
463 (2.6), 
377 (1.2),
461
375
(5.2), 459 
(0.8)
(2.8) , 421 (1.8) ,
5 225 (42.0%), 197 (9.5), 179 (5.3), 151 (3.9)
6 239 (29.6%), 211 (3.6), 193 (8.0), 183 (1.2)
7 195 (16.8%), 178 (52.0) , 150 (34), 122 (1.1)
8 180 (11.3%), 179 (17.0) , 178 (6.2) , 167 (8.6) , 151 (4.4), 134 (3. 3), 123 (2.1)
9 273 (13.3%), 245 (0.3), 229 (12.6) , 217 (0.2) , 181 (8.8), 91 (29. 3)
10 214 (4.2%), 197 (29.5), 183 (5.8), 169 (1.9), 153 (11.7)
PHOSPHATES
11 141 (23..3%) . 110 (6. 1) , 94 (1 .6) * 79 (0.6)
12 183 (38..9%) , 155 (20 .0) , 127 (5. 4) , 99 (0. 6)
13 225 (22. 81) , 183 (14 .4) ,' 141 (8. 2) , 99 (1. 1)
14 267 (34..4%) , 211 (14 .8) ,' 155 (8. 0) , 99 (1.6)
15 327 (40..3%) , 233 (1.8) , 170 (2.0)
PHOSPHITES
16 125 (10..8%) , 111 (11 ■ 4), 94 (1. 9)
17 167 (47..2%) , 139 (20 121 (2 .5), 111 (2..2)
18 311 (10..4%) , 235 (8.0) . 217 (10 .1) » 153 (2..9)
P H O SP HO R A M ID A T E S
19 182 (33.,5%), 140 (14.6),. 124 (3..9)
20 180 (22.. 3%) , 136 (5.9), 135 (10..0)
94 (8.5)
92 (1.8)
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as a large peak due to the protonated molecular ion 
(29.5%). Peaks due to loss of carbon dioxide (m/z 153, 
11.7%) and ethene (m/z 169, 1.9%) from the protonated 
molecular ion were also present.
AI .3.2 Phosphates
Previous Cl studies (Sass and Fisher, 1979) did 
not include phosphate esters although their El mass spectra 
have been studied extensively (Occolowitz and Swan,
1966). For phosphate esters, as might be expected, the 
major high molecular weight ion in their Cl mass spectra 
was [M + 1]+ . Again families of peaks could be observed 
in the Cl spectra from which information could be deduced 
as to the nature and number of groups bonded to phosphorus. 
Thus, the trialkyl esters 12-14 gave [M + 1] and ions 
due to the successive loss of three molecules of olefin 
(ethene, propene and butene respectively) (Fig. AI.3.2). 
Trimethyl (11) and triphenyl (15) phosphates showed little 
fragmentationin their Cl mass spectra. The fragmentation 
of the trialkyl phosphates could be observed in their El 
mass spectra. However, as the ion current carried by 
the molecular ion was less than 1% of the total ion current 
in all cases, the fragmentation patterns were much more 
difficult to observe than in the Cl mass spectra.
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Fig A l.3 .2 . Am m onia Cl m ass spectrum of tri-n-butyl phosphate 
(13).
AI. 3.3 Phosphites
Ammonia Cl mass spectrometry was also useful 
for the detection of esters of oxyacids of trivalent 
phosphorus. In the three compounds tested (16-18), the 
protonated molecular ion carried at least 10% of the total 
ion current. For triethyl phosphite (17) peaks correspond­
ing to the loss of two and not three molecules of ethene 
could be observed. There was little fragmentation observable 
in the Cl mass spectrum of trimethyl phosphite (16), while 
the major fragmentation in the Cl mass spectrum of 
triphenylphosphite (18) corresponded to the loss of 
phenol (m/z 94) from the protonated molecular ion.
AI. 3.4 Phosphoramidates
The two phosphoramidates examined (19 and 20) 
showed strong peaks in their Cl mass spectra due to 
protonated molecular ions. The major features in the Cl 
mass spectrum of di-isopropyl phosphoramidate (19) were 
m/z 140 (14.6%) and 98 (14.9%) corresponding to the 
successive loss of two molecules of propene. In this 
case, the protonated molecular ion carried 33.5% of 
the ion current carried by the sample, whereas in 
the El mass spectrum the protonated molecular ion (the 
major, high molecular weight ion) carried only 0.3% of the 
total ion current. The Cl mass spectrum of hexamethyl 
phosphoramide (20) showed only one major peak, in 
addition to [M + HJ+ (22.3%), corresponding to the loss 
of 45 u, presumably Me2NH.
AI.3.5 Methane Chemical Ionisation Mass Spectrometry
For comparison, a representative selection 
of compounds were also studied by methane Cl mass 
spectrometry (Table AI.3.5).
The results show that, as predicted, far 
less fragmentation occurs under methane Cl conditions 
than is observed under El conditions. However, the 
percentage ion current carried by the [M + H)+ ions is 
on the whole much lower than in the comparable ammonia 
Cl mass spectra. Hence, ammonia Cl would appear to be 
the method of choice for the identification and analysis 
of esters and amides of oxyacids of phosphorus.
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Determining the Stability Constant
of a Metal Complex by Gel Chromatography
Let us consider the formation of a 1:1 metal complex, ML, between a metal ion, M, and a ligand, L, according to eqn, 
(1)
M + L e M L (1)
For the sake of simplicity the charge on each species is not presented. The concentration stability constant, K , of the metal complex to be determined is given by
y .  (ML)WIE] (2)
in which [ J represents the molar concentrations of M, L, and ML.Various physiochemical methods, such as spectropho­tometry, potentiometry, ion exchange methods, solvent ex traction methods, solubility methods, etc., have usually been employed to determine the concentration or the activity of M, L, or ML (7,2). If one of these activities or concentrations is experimentally determined, the other two can be calculated, which enables us to evaluate the stability constant of the metal complex. For example, if (ML) is determined spectropho- tometrically, (M) and (L) will then be calculated by
[M| -  [M], -  (MLJ 
[LJ -  [LJ, -  (ML)
in which (M)( and (L)«, the respective total concentrations of metal and ligand, are known.In this paper we describe the principle of a new technique that is based on a gel chromatographic method (3-7) and has been increasingly applied to the characterization of metal- ligand binding in the fields of inorganic (8), bioinorganic (9-/7), and environmental (18) chemistry. This chromato­graphic method has an advantageous and unique character­istic over the conventional static (batchwise) equilibrium methods, in that [M] can be kept at a desired and predeter­mined value, (M)o, throughout the experiment In other words, the equilibrium solution being examined is "buffered** with respect to metal ion, as well as with respect to hydrogen ion, and (ML) and (Ll are then dynamically adjusted to be in equilibrium with [M]o through the process of their chroma­tographic migration. Therefore, [M] is not required to be an­alyzed experimentally and one can evaluate the stability constant of the metal complex according to eqn., (5) by the measurement of (ML) that is in equilibrium with (M)o.
|ML)K  - [ M j o ( | U , - | t o L | ) (5)
in which (M]o and |L]( are known. The only undetermined value, (ML), can be calculated by
|ML) -  (M)i -  |M|.- o ( A + - A m J - a A + - b  (6)
where ¿4<,¿¡8 the observed absorbance, that is the sum of the respective absorbances, Am0 ^ ml> due to free metal ion and metal complex, a and 6 are constants. Equations (5) and (6) indicate that (ML) or K  can be easily determined by measuring ¿«a without any complicated analysis of the ob­served results. The atomic absorption method has been ex­tensively and successfully employed to obtain reproducible results (8 ,1 0 ,1 8 ) . Spectrophotometric methods are powerful if the absorption due to free ligand is negligible. The terms ¿4«*
and j4m0 in eqn. (6) can also be translated into any kind of physicochemical responses of ML and M, such as are based on radioactivity measurement (18).
The most important point in practice of this approach is how to keep the concentration of free metal ion at a constant ' level during the equilibrium experiment It seems very diffi­cult or almost impossible to maintain [M] constant by the conventional static methods in which (M) is usually allowed to be dependent on [M]( and (Lb as indicated in eqns. (3) and (4). As will be mentioned below, however, a simple way to answer this requirement is by use of a gel chromatographic method which was first applied by Hummel and Dreyer (3) to the binding of ^-cytidilic acid with ribonuclease and has subsequently been employed for estimation of the stability constants of various metal complexes (6, 9), with some pro­gressive modification in practical procedure (8, 11). This technique enables us to observe directly the formation of ML complex tha t is in equilibrium with metal ion of the specified concentration, (M)<>.
Gel Chromatography of Metal Ions and Ligands
Before we deal with the detailed discussion on the gel chromatographic determination of the stability constant of metal complex let us review briefly the gel chromatographic behavior of two constituents, a metal ion and a ligand (6, 
19).Gel chromatography is a form of liquid chromatography capable of separating solute molecules according to their size, and its basic principle has been explained in terms of sieving effect or steric exclusion (4-7). The separation of the com­ponents in a sample solution is usually carried out on a column packed with a gel or other porous material. It is a general elution pattern, though not always if there are side effects such as adsorption, that the solute molecules are eluted in the order of decreasing molecular size.Although it was first applied mostly to the separation of very small molecules from very large ones, e.g., desalting from proteins, it has progressively been demonstrated to be widely applicable to the separation of not only a mixture of macro­molecules but also a mixture of lower-molecular-weight species as small as hydrated metal ions. For example, the elution volumes of alkaline earth metal ions on a Sephadex G-15 column (Pharmacia Fine Chemicals AB) increased in the order, Mg < Ca «  Sr < Ba, which could be qualitatively cor­related with the reverse seauence of the radii of these hydrated metal ions, i.e., Mg (4.28 A) > Ca (4.12 A) -  Sr (4.12 A) > Ba (4.04 A) (20).A more pronounced effect of eteric exclusion has been shown for the elution behavior of inorganic polyphosphate anions with different degrees of polymerisation (6, 21). For example, the elution volumee of orthophoephate (Pi), di­phosphate (Pj), triphosphate (P3), tetraphoaphate (P4). end more high polymers (P„) decreased in the order P| > P , > Pj > P4 > P„. A mixture of P|, Pi, and Pj, shown below for their acids, can be easily and completely separated from each
other.
! ? rMO—P—OH MO— O— r —OH
L L Am
<p»> CM
1  ,  I  .  1 «
Am in  oh
For the quantitative expression, the elution volume of a solute molecule, Vt , is represented in terms of some column parameters (6). For very large molecules that are completely excluded from the gel pores, Vm is equal to the interstitial volume of the column, V©. For very small molecules that can penetrate into all parts of the gel pores, Vm is equal to the total liquid volume of the column, V¡ + Vq. For molecules of in­termediate size, the elution volume is given by
V .- V0 + K 4Vi (7)
in which K <j is a distribution coefficient that depends on the molecular size and lies in the range, 0 g  < 1.
Gel Chromatography of Metal Complex
In eqn. (8) a complexation reaction is shown schematically to  illustrate the difference in size among a metal ion, a ligand, and a metal complex (6, 21)
0 +0 s=£@ ( T )  (8)
in which the circle* represent the size* of the free metel ion, the free ligand, and the metal-ligand complex. It is assumed that if the size of the free metal ion is relatively very small compared with that of the free ligand, the size of the metal complex may be primarily determined by the contribution from the size of the ligand. In such a situation, the metal complex is expected to appear at or near the elution position of the free ligand. This speculation teems reasonable to a first approximation for polyatomic ligands such as inorganic po­lyphosphates, EOTA, nucleotides, proteins, etc. The elution volumes of magnesium ion and magnesium polyphosphate complexes, for example, decrease in the order. Mg > MgP2 > MgPj > MgP, > MgP„, which is in accord with the prediction from the increasing order in the ionic sizes, Pj < Pj < P4 < P„, or the decreesing order in the elution volumes, P2 > Pj > P. >  P„, of the corresponding polyphosphate anions (8). The metal complex in some cases tends to be eluted later than the free ligand (6,22,23), for which no satisfactory explanation has been given. It is conceivable that the size reduction of the metal complex, in contrast to the expectation from the mo­lecular weight basis, may be caused by such effects as the chelation and the reduction in charge of the hydration layer.It should be noted that if the ML complex is eluted with an eluent containing neither M or L, it will dissociate successively into its constituents during the passage through the column to give a complicated elution profile of M, L, and ML, de­pending on both the stability constant and kinetic factors (19). On the other hand, if an eluent contain* a constant concen­tration of M and the complexation equilibrium is established rapidly so as not to permit the separation of ML and L. a well-defined peak of ML accompanied by L is expected to appear at the elution position that corresponds to the weighted average of the elution volumes of ML and L.
Determination of Stability Constant
For the sake of clarity in expression, the formation of a magnesium complex, MgL, will be hereafter presented in in­terpreting how one can determine the stability constant of a metal complex (6, 8, 19).A gel chromatographic column packed with a tightly cross-linked gel, such as Sephadex G-10, G-1S, and G-25 (Pharmacia Fjne Chemicals AB) is pra-equilibrated with a buffered eluent containing a known concentration of mag­nesium ion. |Mg)o. A known amount of a ligand. L, is dissolved In a solution of magnesium ion to prepare e sample solution. It is an important prerequisite that the total magnesium concentration in the sample be exactly the same as that in the eluent, if a Hummel and Dreyer pattern (Fig. I) la to be ob­tained. This means that the concentration of free magnesium
Figure 1. A schematic representation of Hummel and Dreyer pattern. According 
to eqn. (6) (M g ), -  a  ^
ion in the sample solution is reduced to a l^vel lower than [Mg]0 by an amount corresponding to the MgL complex formed.An aliquot of t^is sample solution is applied to the pre­equilibrated column and then eluted with the eluent used to preequilibrate the column. The MgL complex, along with L that is in a state'of dynamic equilibrium with ML, migrates down the column more rapidly than the free magnesium ion so as to come out from the zone of magnesium deficiency. L and ML continue their travel through the pre-equilibrated column to be in contact with fresh free magnesium ions in the subsequent plates to form more MgL until a steady state is reached in equilibrium with (Mg)o that is the concentration of free magnesium ion in the mobile phase of the pre-equili­brated column. The resulting elution profile is schematically shown in Figure 1. The absorbance, A «*. corresponding to the total magnesium concentration, (Mg]f -  (Mg] + (MgL), is assumed to be monitored by atomic absorption methods and plotted against the elution volume (see eqn. (7)).When MgL along with L emerges faster, the total concen­tration of magnesium in the effluent rises above the base line level to form a positive peak of MgL. Behind the MgL peak, Aob continues to be constant and then decreases, at the elution position of free magnesium ion, to below the base line level to form a negative peak that corresponds to the amount of magnesium consumed to form MgL. The appearance of a pair of positive and negative peaks in the elution profile therefore provides a criterion of binding of M and L. It is evident that the height of the horizontal base line corresponds to (Mg)© The concentration level of free magnesium in the zone of MgL complex has been interpreted to be equal to that in the hori­zontal region, provided that the sample concentration is rea­sonably low in comparison with the concentration of back­ground electrolyte in the eluent (8, 11). In other words, the peak area of MgL above the base line, S m (l. is » direct mea­sure of the total amount of MgL complex that is in equilibrium with free magnesium whose concentration is (Mg)o- It is also noted that Sm(l should be equal to the area of the negative peak, S Mg- The peak area 5 m«l or S m* can be easily translated into the amount of MgL, QmcL. on the basis of the standard­ized area, So, that is regarded as an internal standard to be calibrated against the known amount of magnesium, AV, (Mg Jo. Equation (5) thus can be rewritten as follows to simplify the calculation of the stability constant
where Ql, represents the toUl amount of L applied.The ratio of Qm, l to Qi„ is designated as 8  and is correlated to K  and (Mg]o by
The Hummel and Dreyer method in Figure I ha* s greal advantage that can be eatimated as well from SM| everwhen S m>l can not be quantitatively determined by lh< spectrophotometric method owing to the interference by 1 that ¡a also at the elution poeilion of MgL. The exact mea aurement of S Mi. however, is often difficult because the neg ative peak of free metel ions tends in general to broaden
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Figure 2. A schematic representation ol an elution profile for a mixed solution 
of magnesium ion and four ligands. I.e.. L. X. V. and Z.
markedly if the metal ions are susceptible to adsorption. Another disadvantage of the S m§ measurement is that S mi can not be directly translated into Qm *l  if more than one li­gand is contained in a sample to form various metal complexes (Fig. 2). To minimize the analytical error resulting from the peak area measurement it is recommended that the relatively well-defined peak of MgL complex be measured by employ­ment of specific methods such as atomic absorption (8) and, for metals such as Zn-65, radioactivity measurement (J8). In such instances the preparation of a sample solution becomes more convenient because magnesium concentration in the sample solution need not be the same as that in the eluent. It is in reasonable excess so as to obtain a positive peak at the elution position of free magnesium ion (Fig. 2), in contrast to the negative peak in Figure 1.A schematic profile to be expected is shown in Figure 2 when a mixed solution (1 ml) containing each 100 nmole of four ligands, i.e., L, X, Y, and Z that are different in size from each other, is assumed to be eluted with an eluent; [Mg)o "  10”5 M . The sample solution also contains 410 nmole of total magnesium that is 400 nmole in excess of that in 1 ml of the eluent If the stability constants of four magnesium complexes are given as 1.0 X 10s for MgL, 1.0 X 104 for MgX, 1.0 X 10® for MgY, and 3.0 X 105 for MgZ, one can expect the amounts of the respective magnesium complexes, Q m kl . Q m « x . Q m « y . and Q m sz . that are numerically (in nmole) shown in Figure 2 for four peaks of magnesium complexes, as well as for a posi­tive peak of free magnesium ion. In other words, one can easily calculate the stability constant, for example, of MgZ complex according to eqns. (9) and (11), if QmrZ »» given.
*-,.ox,o-M»oo-7»)-30xlot
There is an example of the exercise in calculation of this class which is based on the peak area measurement on the chart of a magnesium diphosphate complex (8) whose log K  value obtained by other static methods (24) has been reported to 
be 5.42.Numerical values in Figure 2 also indicate that the peaks for magnesium complexes increase at the expense of the peak of free magpesium ion. It should be noted, however, that the amount of each magnesium complex is dependent on (Mg)0 but does not depend on both the amount of free magnesium ion in the sample or the peak area of free magnesium ion and I the presence of other ligands. Therefore, QmiL values obtained by both methods in Figures 1 and 2 should be, in principle, equal to each other, so long as (Mgjo is the same.According to eqn. (10) Qm *l  or n depends on [Mgjo. If |Mg)0 is lowered fronvl.O X 10"a M  to 1.0 X 10"* M , the values of 
Q m . u  Q m i X i Q m , y . ®nd Q m « z  will accordingly decrease from 50,9.1,91, and 75 to 9.1,1.0,60, and 23, respectively, to result in the increase in the amount of free magnesium ion from 176 
to 317.The ligand concentration is usually requited to be very low, in comparison to the concentration of background electrolyte, to avoid the complexity caused by the Donnan effect (7 7. 13.
2 5 ) .  In the accurate analysis of such a dilute sample solution it is important to know how to choose (Mg]0 for sensitive de­tection and how to minimize the analytical error. It is very convenient in practical use to remember that, if K  [Mg)0 39 1, 50% of the total ligand can be detected as MgL and the relative error in estimating K  can be predicted to be twice the relative error in the measurement of QmiL» which is acceptable. On the other hand, at K|Mg)o 53 10, the advantage that about 90% of the total ligand can be detected as MgL can not overcome the drawback of the unfavorable relative error in K  that amounts to approximately ten times that in Qm*l-Many investigations have been reported on the binding of more than one metal to a ligand (72-/8), including the com­petitive or cooperative binding of more than one kind of metal (77, 26). In order to avoid the complexity in the description of the principle, however, the information from these inter­esting reports can not be presented in this paper.The gel chromatographic method has application from the analytical viewpoint. It is evident from eqn. (10) that Qm*l or SjugL can be calibrated against Q l, to be determined. For example, gel chromatographic technqiue combined with an atomic absorption flow detector has been successfully appliedi to the automatic and sensitive analysis of a mixture of various polyphosphates (8). This method will be in principle appli­cable to the detection of any kinds of ligands which combine with a given metal ion that can be sensitively detected by atomic absorption or other selective methods.
Questions on the Mechanism
We have received many questions about this new technique from those who are familiar with the conventional static equilibrium methods in determining the stability constant. Most of these questions are based on a doubt as to whether or not the equilibrium we can observe in such a dynamic trans­port process can be regarded as the same as that in a static equilibrium system. One of the important questions is how one can realize that MgL and L are in equilibrium with [Mgjo. As has been pointed out in the original paper of Hummel and Dreyer (3) the establishment of a steady state in equilibrium with [Mg)o is visually reflected on the appearance of a base line level corresponding to [Mgjo between the peaks of MgL and Mg.The second question is whether or not this technique is also applicable, as shown in Figure 2, to metal complexes that are not large enough to be completely excluded from the gel phase. This doubt may arise, unfortunately, from the confusing de­scription in the literature by some gel chromatographers who stressed the preferable use of the gel type that permits the complete exclusion of MgL aqd L. As has been noted by Determann and Brewer (5), it is not necessary for the ligand to be excluded completely from the gel phase. A prerequisite is that the degree of separation between the peaks of MgL and Mg be good so as to permit the appearance of a base line cor­responding to [Mgjo between two peaks. This technique, for example, can be successfully applied to  the relatively small ligands such as EDTA and diphosphate anions whose K* values in eqn. (7>are not zero (8, 23).The third question is about the effect of the stationary phase on the complexation equilibrium, which is related in a complicated manner to the above two questions. This question seems out of consideration for MgL and L, whose Ka values are zero, and which is present only in the mobile phase. To be considered is the case for smaller MgL and L that are dis­tributed not only in the mobile phase but also, in part, in the stationary phase. In order to make the answer as simple as possible, let us remember that, according to a random go- and-stop concept in chromatography (27), a solute molecule migrates down the column only when it is in the mobile phase, while its down-stream motion in the stationary phase is halted., This means that the effluent we can analyze contains only the equilibrium components in the mobile phase at the last plate of the column. The stationary gel phase plays an important
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role in separating MgL and Mg to make a steady state in equilibrium but does not affect the complexation equilibrium 
¡ 1 1  the mobile phase that we can determine. The interstitial mobile phase (space) between gel particles may be regarded as a vessel in which a static equilibrium experiment is carried
The author wishes to express his hearty thanks to Professor Shigeru Ohashi for his encouragement during this work.
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APPCNOIX III 
SOURCES or MATERIALS
Adenosine 5'-phosphoromorpholidatc Sigma (London) Chemical Co., Poole, Dorset, U.K.
Adenyly1-(3'-5 *)-guanos Inc Dochringcr, Mannheim, G.F.R.
Adenyly1-imidobiphosphate Bochringer, Mannheim, G.F.R.
3-Amino-l-hydroxy-propane-1,1- 
bisphosphonate
Koch Light Laboratories, Colnbrook, Bucks., U.K.
Bovine pancreatic DNase I Sigma (London) Chemical Co., Poole, Dorset, U.K.
Calf Thymus DNA polymerase I P-L BiochcmicaIs, Milwaukee, Wisconsin, U.S.A.
Cellulose F25< TLC plates E. Merck, Darmstadt, G.F.R.
Chromatography paper (3 MM) Whatman Ltd., Maidstone, Kent, U.K.
DEAE cellulose Whatman Ltd., Maidstone, Kent, U.K.
Dulbeccos Modification of Eagles 
Medium (DMEM x 10)
Flow Laboratories Ltd., Irvine, Ayrshire, U.K.
Dowex 50 Sigma (London) Chemical Co., Poole, Dorset, U.K.
Ethane-1-hydroxy-1,1-bisphosphonate Koch Light Laboratories Ltd., Colnbrook, Bucks., 
U.K.
CF/C discs (2.5 cm) Whatman Ltd., Maidstone, Kent, U.K.
L-Glutamine Flow Laboratories Ltd., Irvine, Ayrshire, U.K.
Glasgow Modification of Eagles Medium 
(GMEM X 10)
Flow Laboratories Ltd., Irvine, Ayrshire, U.K.
V Amcrsham International pic, Amersham, Bucks., U.K.
Imidobisphosphatc Bochringer, Mannheim, G.F.R.
Iodotrimethylsilane Aldrich Chemical Co. Ltd., Gillingham, Dorset, U.K
Newborn calf serum (NCS) Flow Laboratories Ltd., Irvine, Ayrshire, U.K.
Non-essential amino acids (NEAA) Flow Laboratories, Irvine, Ayrshire, U.K.
Nonidct P-40 Sigma (London) Chemical Co., Poole, Dorset, U.K.
(dcoxy)Nucleosido triphosphates Sigma (London) Chemical Co., Poole, Dorset, U.K.
Penid 1lin/Stroptomycin Flow Laboratories Ltd., Irvine, Ayrshire, U.K.
3-Phosphonoproplonic acid Fluorochcm Ltd., Clossop, Derbyshire, U.K
Sainton sperm DNA Calbiochcm, La Jolla, California, U.S.A.
Sephadex G-10 Pharmacia Fine Chemicals, Uppsala, Sweden
Tetraethyl dlmcthylaminomcthylcne- 
bisphosphonatc Lancaster Synthesis Ltd., Morccambc, Lancashire, U.K.
Tetraisopropyl methylenebisphosphonate Lancaster Synthesis Ltd., Morecambc, Lancashire, 
U.K.
Tetrasodium pyrophosphate B.D.II. Chemicals Ltd., Poole, Dorset, U.X.
Triethyl phosphonoacetatc Aldrich Chemical Co. Ltd., Gillinaham, Dorset, U.
Triethyl 2-phosphonopropionate Roche Products Ltd., Welwyn Garden City, Herts., 
U.K.
(Methyl-3»! J Thymidine 5 * -triphosphate 
(42 ci/mmol)
Amcrsham International pic, Amcrsham, Bucks., U.K.
(5,6-3HjUridine 5'-triphosphate Amcrsham International pic, Amcrsham, Bucks., U.K
Zinc chloride {* SpectroSol') B.D.H. Chemicals Ltd., Poole, Dorset, U.K.
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Ammonia Chemical Ionization Mass Spectra of Esters and Amides of Oxyacids of Phosphorus
P. A . ('load and D. W. Hutchinson +
D e p a r t m e n t  o f  C h e m i s t r y  a n d  M o l e c u l a r  S c i e n c e s ,  U n i v e r s i t y  o f  W a r w i c k ,  C o v e n t r y  C V 4  7 A L ,  U K
Chemical ionization mass spectrometry usina a m m o n i a  as the reagent gas has been carried out with esters 
and amides of a variety of oxyacids of phosphorus (phosphates, phosphonates, phosphites and phosphorami- 
dates). In all cases, the protonated molecular ion is a major species in the spectrum and the percentage of the 
total ion current carried by these protonated molecular ions is always considerably greater than that carried 
by the molecular ions in the corresponding electron impact mass spectra. In the chemical ionization mass 
spectra only limited fragmentation of the protonated molecular ion occurs from which useful information on 
the structure of phosphorus derivatives may be inferred.
IN T R O D U C T IO N RESULTS A N D  DISCUSSION
The electron impact (El) mass spectra of esters of 
oxyacids of phosphorus have been widely studied and 
detailed fragmentation patterns for many esters have 
been published.12 However, the ion current carried by 
the molecular ion and other high molecular weight 
ions in the E l  spectra of many phosphorus esters and 
amides is often much less than 1%  of the total ion 
current, making identification and analysis of unknown 
compounds difficult. Chemical ionization (C l) mass 
spectrometry has been suggested as a method to over­
come this problem and C l spectra have been described 
for some phosphonates using hydrocarbons as reagent 
gases.’ We now wish to report work extending these 
initial experiments to esters and amides of other oxy­
acids of phosphorus using ammonia as reagent gas.
E X PE R IM E N T A L
Unless otherwise stated, all compounds were commer­
cially available and were redistilled before use. Tetra- 
isopropyl esters of halogenated methylene bisphos­
phonates were prepared by the method of Ouimby.4 
Diethyl phosphonoacetic acid was prepared by the 
method of Clayton el al.*
Mass spectra were obtained using an MS 80 mass 
spectrometer with a DS 55 data system (Kratos 
Analytical Instruments). C l mass spectra were re­
corded using ammonia as reagent gas at a pressure of 
2 x 10 4Torr in the source housing (equivalent to ap­
proximately O .lTo rr in the source). Electron energy 
was 55 eV. The ion source temperature was 200 °C  
and the emission current 500 |z A. E l mass spectra 
were obtained at 70 eV and a source temperature of 
200 °C . Samples were introduced via a solids probe in 
the usual way.
t  A u t h o r  t o  w h o m  c o r r e » p o m i c n c e  s h o u l d  h e  n d d r c » » e d
Phosphonates
The C l spectra obtained for compounds 1 - 1 0  (Table
1 ) were similar to those obtained previously for phos­
phonates with hydrocarbons,’ the major high molecu­
lar weight signal being due to the protonated molecu­
lar ions [ M + l] ’ . Useful structural data could be ob­
tained from ammonia C l  spectra. For example, the 
spectrum of tetra-isopropyl methylene bisphosphonate 
(1) (Fig. 1) contained peaks at m/z 345 (6.6% ) ,  303 
(4.0%), 261 (6 .2% ), 2 19  (3 .2 % ) and 177 (3 .5 % ),  
indicating the successive loss of C ,H ft (42 u) and con­
firming the presence of a tetra-isopropyl ester (Table
2) . The corresponding signals were scarely discernible 
in the E l spectrum of 1 . The C l spectra of the tetra- 
isopropyl esters of monochloro- (2), monobromo- (3) 
and dibromo- (4> -methylene bisphosphonates all 
showed similar families of peaks consisting of the 
protonated molecular ion and ions derived from the
J
Figur* 1 .  A m m o n i a  C l  m a s s  a p e c t r u m  o f  t a t r a - i s o p r o p y l  
m e t h y l e n e  b i s p h o s p h o n a t e  ( 1 ) .
CCC-0030-493X/83/0018-0057*01.50
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Table 1. Compounds studied
Elemental
Name Formula com position Mol. wt
Phosphonates
1 Tetra-isopropyl methylene (Me2CH0)2P(0)CH2P(0)(0CHMe2)2 C ^ H jo O . P j 344bisphosphonate
2 Tetra-isopropyl monochloromethylene (Me2CHO)2P(OICHCIP(OXOCHMe2)2 C13H20CIO,P2 378bisphosphonate 3803 Tetra-isopropyl monobromomethylene (Me2CH0)2P(0)CHBrP(0X0CHMe2)2 C,3HM BrOBP2 422bisphosphonate 4244 Tetra-isopropyl dibromomethylene ( Me2CH0)2P<0)CBr2P(0)(0CHMe2)2 500bisphosphonate 502,5045 Triethyl phosphonoacetate <EtO)2P(0)CH2COOEt c8h 17o ,p 2246 Triethyl 2-phosphonopropionate (EtO)2P(0)CHMeCOOEt C„H,„OsP 2387 Diethyl phosphonoacetonitrile (EtO)2P(0)CH2CN c„h ,2n o 3p 1778 Diethyl allylphosphonate (EtO)2P(0)CH2CH CH2 c2h ,6o 3p 1789 Benzyl diethyl phosphonoformate (EtO)2P(0)COOCH2Ph C,2H,7OsP 27210 Diethyl phosphonoacetic acid (EtO)2P(OICH2COOH C.H13ObP 196
Phosphates
11 Trimethyl phosphate (MeO)jPO c3h.o 4p 14012 Triethyl phosphate (EtO)3PO cbh ,bo 4p 18213 Tri-isopropyl phosphate (Me2CHO)3PO c„h2,o 4p 22414 Tri-n-butyl phosphate (BuO)3PO c,2h27o „p 26615 Triphenyl phosphate <PhO)3PO c ,.h ,b04p 326
Phosphites
16 Trimethyl phosphite (MeO)jP c3h„o 3p 12417 Triethyl phosphite (EtO)3P c„H,Bo3p 16618 Triphenyl phosphite (PhO)3P c,.h ,bo 3p 310
Phosphoramidates
19 Di-isopropyl phosphoramidate (Me2CHO)2P(OINH2 c,h 10n o 3p 18120 Hexamethyl phosphoramide (Me2N)3PO C.H,bN3OP 179
successive loss of propene residues. This decomposi­
tion presumably arises from the protonation of the 
phosphoryl oxygen followed by elimination of olefin 
(Scheme 1). As might be expected, owing to the 
presence of halogen atoms, the protonated molecular 
ion and related ions in 2 were doublets (ratio 1 : 2 .8), 
doublets (ratio 1 : 1 )  for 3 and triplets (ratio 1 : 2 : 1) for
4 (Table 2).
Structural information could also be obtained from 
the C l mass spectra of the ethyl esters 5-10. In 
addition to the protonated molecular ion, other major 
ions corresponding to the successive loss of 28 u (pre­
sumably ethene) were present, confirming the pres­
ence of P—O —C 2H ,  residues. The C l mass spectra of
5 and 6 also showed ions corresponding to the loss of 
ethanol from the protonated molecular ion. This loss 
must involve the C O O C j H ,  group as this fragmenta­
tion does not occur in compounds 7-10. The C l  mass 
spectrum of the carboxylic acid diethyl phosphonoacetic 
acid (10) showed a peak due to [M + N H 4]4 m lz  214  
(4 .2% ), as well as a large peak due to the protonated 
molecular ion (2 9 .5 % ). Peaks due to loss of carbon
d?»R ohr
C H ^ - r  ----- •  CH,CH—CHj + O— V
CH, X R X R
Sebum* 1. Ducompouition of th* protonated molecular Ion of Isopropyl eater of oxyacld of phosphorus.
dioxide (m/z 153 , 1 1 .7 % )  and ethene (m/z 169, 1 .9 % )  
from the protonated molecular ion were also present.
Phosphates
Previous C l studies’  did not include phosphate esters 
although their E l  mass spectra have been studied 
extensively.6 For phosphate esters, as might be ex­
pected, the major high molecular weight ion in their 
C l mass spectra was [ M +  1]*. Again, families of peaks 
could be observed in the C l spectra from which infor­
mation could be deduced as to the nature and number 
of groups bonded to phosphorus. Thus, the trialkyl 
esters 12-14 gave [M + l ]4 and ions due to the succes­
sive loss of three molecules of olefin (ethene, propenc 
and butene respectively) (Fig. 2). Trimethyl (11) and 
triphenyl (15) phosphates showed little fragmentation 
in their CT mass spectra. The fragmentation of the 
trialkyl phosphates could be observed in their E l mass 
spectra. However, as the ion current carried by the 
molecular ion was less than 1%  of the total ion current 
in all cases, the fragmentation patterns were much 
more difficult to observe than in the C l mass spectra.
Phosphites
Ammonia C l  mass spectrometry was also useful for 
the detection of esters of oxyacids of trivalent phos-
M  ORGANIC MASS SPECTROMETRY, VOL. 11, NO. 2, 1983
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Table 2. Principal inns and %  total ion current carried in Cl mass spectra of esters and amides of oxyacids of phosphorus
Phosphonates
1 345(6.6%), 303(4.0), 261 (6.2), 219(3.2), 177(3.5)
2 381 (2.3%), 379 (6.6). 345 (3.2), 339 (1.9), 337 (5.3), 
297(1.2). 295(3.6), 255(0.6). 253(1.7), 213(0.3), 
211( 1.0)
3 425(1.3), 423(1.3), 383(1.3), 381 (1.3), 345(2.9)
341 (0.8), 339 (0.8), 299 (0.3), 297 (0.3), 257 (0.3), 
255(0.3)
4 505 ( 1.7% ). 503 (3.4), 501 ( 1.8). 463 (2.6), 461 (5.2), 
459(2.8), 421 (1.8), 419(3.5), 417(1.9), 379(0.6). 
377(1.2), 375(0.8)
5 225 (42.0%), 197 (9.5). 179 (5.3), 151 (3.9)
6 239(29.6%), 211 (3.6), 193(8.0), 183(1.2)
7 195(16.8%). 178(52.0), 150(3.4), 122(1.1)
8 180(11.3%), 179(17.0), 178(6.2), 167(8.6), 161 (4.4). 
134(3.3), 123(2.1)
9 273(13.3%), 245(0.3). 229(12.6), 217(0.2), 181 (8.8), 
91 (29.3)
10 214(4.2%), 197(29.5), 183(5.8), 169(1.9). 153(11.7) 
Phosphates
11 141 (23.3%), 110(6.1), 94(1.6), 79(0.6)
12 183 (38.9%), 156 (20.0), 127 (5.4), 99 (0.6)
13 225(22.8%), 183(14.4), 141 (8.2), 99(1.1)
14 267(34.4%), 211(14.8), 155(8.0), 99(1.6)
15 327(40.3%), 233(1.8), 170(2.0)
Phosphites
16 125(10.8%), 111 (11.4), 94(1.9)
17 167(47.2%), 139(20.9), 121(2.5). 111(2.2)
18 311 (10.4%). 235(8.0), 217(10.1), 153(2.9), 94(8.5)
Phosphoramidates
19 1 82(33.5%), 140(14.6), 124(3.9), 98(14.9)
20 180(22.3%), 136(5.9), 135(10.0), 92(1.8)
phorus. In the three compounds tested (16-18), the 
protonated molecular ion carried at least 10%  of the 
total ion current. For triethyl phosphite (17) peaks 
corresponding to the loss of two and not three 
molecules of ethene could be observed. There was 
little fragmentation observable in the Cl mass spec­
trum of trimethyl phosphite (16). while the major 
fragmentation in the Cl mass spectrum of triphenyl
Figure 2. Ammonia Cl mass spectrum of tri-n butyl phosphate (13).
phosphite (18) corresponded to the loss of phenol 
(m/z 94) from the protonated molecular ion.
Phosphoramidates
The two phosphoramidates examined (19 and 20) 
showed strong peaks in their Cl mass spectra due to 
protonated molecular ions. The major features in the 
C l mass spectrum of di-isopropyl phosphoramidate 
(19) were at m/z 140 (14 .6 % ) and 98 (14 .9 % ). corres­
ponding to the successive loss of two molecules of 
propene. In this case, the protonated molecular ion 
carried 3 3 .5 %  of the ion current carried by the sam­
ple. whereas in the El mass spectrum the protonated 
molecular ion (the major, high molecular weight ion) 
carried only 0 .3 %  of the total ion current. The Cl 
mass spectrum of hexamethyl phosphoramide (20) 
showed only one major peak, in addition to [M + H]*’ 
(2 2 .3 %), corresponding to the loss of 45 u, presuma­
bly M ejNH.
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ORGANOPHOSPHORUS COMPOUNDS AS ANTIVIRAL AGENTS
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(  R e c e i v e d  S e p t e m b e r  2 4 ,  1 9 8 2  )
The 5'-triphosphates of 2'-5' linked oligoadcnytic acids are formed in cells which have been exposed to 
interferon and may be involved in the antiviral activity of the latter. The lcad(lt) ion-catalysed 
oligomerisation of adenosine 5'-phosphorimidaaolidatc is a convenient route for the preparation of the 
S'-phosphates of 2*-5* linked oligoadenylic acids. The latter can readily be converted to the triphosphates 
or coupled to the S'-phosphatc of nicotinamide nucleoside to give naturally occurring pyrophosphates 
which may act as reservoirs for the oligoadenylic acids in cells.
Pyrophosphate analogues, eg. phosphonoacetic and phosphonoformic acids or carbon-substituted 
mcthylenebisphosphonic acids are antiviral agents of potential commercial interest as they inhibit the 
replication of a number of viruses including herpes and influença. These pyrophosphate analogues do not 
appear to inhibit virus replication by being incorporated into nucleoside triphosphates which block 
nucleic acid synthesis. Rather the analogues appear to act by forming stable complexes with an essential 
metal ion (probably cine) at the active sites of nucleic acid polymerases of viruses.
At the present time, most bacterial infections can be controlled by chemotherapeutic 
agents as many bacterial enzymes are unlike those of the host organism. On the 
other hand, the enzymes of viruses are often very similar to those of the host 
organism and hence the chemotherapeutic control of viruses is difficult. There arc, 
however, some small differences between host and viral enzymes and these have 
been exploited recently in a number of laboratories. Particular progress in the 
chemotherapy of virus infections has been made in three areas: (a) nucleoside 
analogues, (b) interferon, and (c) low molecular weight inhibitors of viral enzymes. 
Nucleoside analogues arc outside the scope of this review but I would like to 
consider briefly some progress which is being made in the interferon field before 
concentrating on the low molecular weight inhibitors.
Interferon is a naturally occurring glycoprotein which can confer antiviral proper­
ties on cells. When interferon acts on susceptible cells, the synthesis of some unusual 
oligonucleotides, eg. the S'-triphosphate of adcnylyl(2'-5')adenylyl(2'-5')adenosinc 
(I) and higher oligomers is enhanced. This oligonucleotide is unusual as it is the only 
naturally occurring nucleic acid derivative to be discovered at (he present lime which 
contains 2'-S' rather than (he more normal 3'-$' intcrnuclcotide links. These oligomers 
have a powerful inhibitory effect on protein synthesis in cells even when they arc 
present at very low concentrations. One important sequence of events which is 
triggered within the cell by (I) is the phosphorylation of a nuclease and this can then
•To whom correspondence should be addressed
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degrade single stranded RNA. As the m RNA of viruses is single stranded the 
activated nuclease prevents viral replication.
Thus, the oligonucleotide (I) would seem to have potential as an antiviral agent. 
However, at least three problems have to be overcome before (I) can be used. These 
arc (a) the synthesis of substantial amounts of the oligonucleotides, (b) the poor 
uptake of (1) by the cells and (c) their low stability in cells. There are some twenty 
syntheses of (I) in the literature1 but most of these arc complex, multistage 
procedures involving protecting groups and the overall yields are low. An attractive 
method for the synthesis of (I) is based on prebiotic models for oligonucleotide 
synthesis.2 Oligomerisation of the 5'-phosphorimidazolidatc of adenosine in (he 
presence of lead(ll) ions gives the S'-phosphates of predominantly 2'-5' linked 
oligoadcnylic acids. Some 3'-5' linked oligomers are also formed but these are easy 
to remove by enzymic hydrolysis. No protection of (he sugar hydroxyls or the 
adenine residue arc required and reasonable yields of the J'-phosphates of the 2'-$' 
linked oligoadcnylic acids can be obtained in only a few days. The latter can then be 
converted into the corresponding 3'-iriphosphatcs via their phosphoroinorpholidatcs. 
The oligoadcnylic acids are highly charged and are not taken up readily by cells. 
Various methods have been used to overcome this problem, the most successful 
appears to be precipitation as the calcium salts.1 This is feasible as a research 
technique but obviously presents problems for in vivo  work. Even though the 
oligoadcnylic acids related to (I) seem to be unique in possessing 2’-S' internuclco-
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tide links and hence must have a very different shape to the 3'-5' linked isomers, 
there arc enzymes in cells which recognise these compounds and degrade them in 
minutes. One way to stabilise (I) is to block the 2',3'-hydroxyl groups by alkylation 
and this aspect is under investigation in a number of laboratories. We have been 
intrigued by the isolation of a nicotinamide derivative (2) of the oligoadenylic acid 
trimer.4 The biological function of (2) is not known but it has been suggested that it 
may act as a reservoir for ( 1) which can be formed by hydrolysis and further 
phosphorylation. As (2) only occurs in minute amounts in cells we have devised a 
synthesis based on the coupling of nicotinamide ribonuclcoside 5'-phosphate with 
the S'-phosphorimidazolidates of 2'-5' linked oligoadenylic acids prepared by the 
lead(II) ion-catalysed method.
The biological properties of (2) are being investigated at the Imperial Cancer 
Research Foundation in London.
Although oligoadenylic acids related to (I)  have antiviral properties under suitable 
conditions, problems outlined above associated with production, uptake and stabil­
ity do not make them promising antiviral agents for clinical use at the moment. Low 
molecular weight inhibitors of viruses arc more attractive commercially as they
over, it should be possible to introduce variations in structure by synthetic methods 
to overcome problems of uptake, toxicity, stability, etc., without undue difficulty.
One promising class of low molecular weight inhibitors of virus replication which 
we have been studying are analogues of pyrophosphoric acid. Examples of these 
analogues, phosphonoacetic (3, R -  H) and phosphonoformic (4) acids have been 
known for many years and they can be prepared either by the Michaelis Becker3 or 
Arbusov reactions.6 Since (3) and (4) contain both carboxylic and phosphoric acid 
residues it is a simple matter to prepare derivatives modified at either residue.7-* 
Another class of pyrophosphate analogues which we have found to be effective 
antiviral agents are carbon-substituted methylcnebisphosphonic acids (5).
We have prepared a number of derivatives of (3-5) and required a simple way to 
analyse our products. Nuclear magnetic resonance spectroscopy was not very useful 
and hence we turned our attention to mass spectrometry. Electron impact mass 
spectrometry was unsatisfactory as the parent molecule could not easily be detected 
as it carried only a very small percentage of the total ion current. Chemical 
ionisation mass spectrometry using ammonia as the reagent gas gave spectra in 
which the protonaled molecular ion carried 10-30% of the total ion current.* Not 
only were intense molecular ions present but useful structural information could be 
obtained as only limited fragmentation of the protonated molecular ions occurs with
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where R= nicotinamide -I —(3-0-D-ribofuranosyl) 5
should be simple compounds and hence comparatively easy to manufacture. More-
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ammonia as reagent gas. In the ammonia chemical ionisation mass spectrum of 
triethyl phosphonoacetale, the (M + H)* peak appears at m /z  225 and there are 
peaks corresponding to the successive loss of ethylene residues (28 mass units) at 
m / z  197, 169 and 141 confirming the presence of a triethyl ester. The successive 
dealkylation of phosphate esters during ammonia chemical ionisation mass spec­
trometry is quite general and for example, tetraisopropyl methylencbisphosphonatc 
shows a (M + H ) 4 peak at m / z  345 and peaks at m /z  303, 261, 219 and 177 
corresponding to the successive loss of four propylene residues (42 mass units) 
(Figure I). In this manner we have been able to analyse halogcnated and other 
derivatives of (3-5).
The pyrophosphate analogues (3-5) arc effective inhibitors of virus replication 
(Table I).10- 11 They act by inhibiting nucleic acid synthesis and the presence of the 
free carboxylic acid and both phosphoryl hydroxyl groups in (3) and (4) or all 
phosphoryl hydroxyl functions in (5) is essential for antiviral activity. Modification 
of any of the acid functions in these compounds causes almost complete loss of 
antiviral activity. The initial discovery of the antiviral properties of (3) and (4) was 
carried out with herpes virus12 but influenza virus, cytomegalovirus, and a number of 
other viruses, are also inhibited. Nucleic acid synthesis is inhibited by inhibition of 
the nucleic acid polymerases in the viruses but some nonviral polymerases arc also 
sensitive such as D N A  polymerase a  of mammalian cells,12 and reverse transcriptase 
(the RN A dependent DNA polymerase of certain tumour viruses).12
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ammonia as reagent gas. In the ammonia chemical ionisation mass spectrum of 
triethyl phosphonoacctale, the (M + H)* peak appears at m /z 225 and there are 
peaks corresponding to the successive loss of ethylene residues (28 mass units) at 
m /z  197, 169 and 141 confirming the presence of a triethyl ester. The successive 
dealkylation of phosphate esters during ammonia chemical ionisation mass spec­
trometry is quite general and for example, tetraisopropyl methylenebisphosphonate 
shows a (M +  H)'" peak at m /z  345 and peaks at m /z  303, 261, 219 and 177 
corresponding to the successive loss of four propylene residues (42 mass units) 
(Figure I). In this manner we have been able to analyse halogenated and other 
derivatives of (3-5).
The pyrophosphate analogues (3-5) arc effective inhibitors of virus replication 
(Table I).l0-M They act by inhibiting nucleic acid synthesis and the presence of Ihc 
free carboxylic acid and both phosphoryl hydroxyl groups in (3) and (4) or all 
phosphoryl hydroxyl functions in (5) is essential for antiviral activity. Modification 
of any of the acid functions in these compounds causes almost complete loss of 
antiviral activity. The initial discovery of the antiviral properties of (3) and (4) was 
carried out with herpes virus11 but influenza virus, cytomegalovirus, and a number of 
other viruses, are also inhibited. Nucleic acid synthesis is inhibited by inhibition of 
the nucleic acid polymerases in the viruses but some nonviral polymerases are also 
sensitive such as D N A  polymerase a  of mammalian cells,11 and reverse transcriptase 
(the RN A dependent DN A polymerase of certain tumour viruses).11
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We have been studying the effect of pyrophosphate analogues on influenza virus 
mainly because of availability and ease of handling of the virus. However, there are 
problems as it is difficult to isolate from influenza virus active RN A polymerase 
which is free from other proteins. The native nucleic acid template must be present 
together with an oligonucleotide promoter which makes interpretation of the enzyme 
kinetics of the polymerase reaction difficult. The inhibition of influenza RNA
TABLE I
Inhibitory effect of pyrophosphate analogues on RNA polymerase 
from influenza virus
Compound
Concentration (j<M) 
Producing 50% 
Inhibition of Polymerase
(H O ),P (0)CII,CO O H 275
(M0),P(0)C0011 35
(ii0 ),P (0 )C it ,c ii,c o o n > 500
(H O),PfO)CH,CON H, > 500
(IIOIjPfOIOItOKOM), 125
(IIO )JP(O)NIIP(OX0H>| 50
<II0),P<0)CH,P(0X0II), > 5(X)
(II0),P(0)CI1CIP(0X0II), 85
(MOl.PtOJCCl.PfOXOII), 75
( 1 tO ), P(0)Cllr j  PfOXOI 1) j 10
(iio ^P fo ico p to x o ii), 20
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polymerase is followed by studying the effect of pyrophosphate analogues on the 
incorporation of radioactivity into acid-insoluble polynucleotide. This is more rapid 
and a much more sensitive assay than ones based on inhibition of viral growth.
There arc two plausible mechanisms for the mode of action of the pyrophosphate 
analogues. Either, (a) they are converted by host or virus into analogues of 
nucleoside triphosphates which inhibit the viral polymerases, or (b) they interact 
directly with the polymerases possibly by coordinating with an essential metal ion. 
We do not believe that these inhibitors act by being incorporated into the fi-y  
positions of a nucleoside triphosphate analogue. We have prepared the ATP ana­
logue of phosphonoacclic acid (6. R -  adenosine-5') and this compound is neither 
an inhibitor of nor a substrate for RN A polymerase from influenza virus. The 
similar thymidine analogue (6, R  -  thymidine-5') is neither an inhibitor of nor a 
substrate for D N A  polymerase from herpes virus.16 Dichloromcthylcncbis- 
phosphonic acid (5, R — R1 — Cl) is a good inhibitor of influenza virus RNA poly­
merase but again its ATP analogue is neither an inhibitor of nor a substrate for the 
polymerase.
The A TP analogue (6, R  — adenosine-5') is easy to prepare by the phos- 
phoromorpholidate route but when we tried to prepare the A TP analogue of 
phosphonoformic acid all we achieved was the rapid conversion of adenosine 
5'-phosphoromorpholidate into AMP. The reaction in pyridine can be followed by 
J,P N M R at 162 M Hz using a Bruker WH400 spectrometer. With phosphonoacetic 
acid there was a steady decay of the phosphoromorpholidate signal at 7.8 ppm 
matched by an increase in intensity of a pair of doublets centred at 5.2 and -9 .7  
ppm due to the formation of the pyrophosphate residue in (6, R -  adcnosine-5'). 
With phosphonoformic acid, the phosphoromorpholidate signal decays as before but 
no new doublets can be delected, only a new singlet at 2.2 ppm due to adenosine 
5'-phosphate. If the C-ethyl ester of phosphonoformic acid is used in place of the 
free acid, signals at 28.2 ppm due to the ester and 7.8 due to the adenosine 
S'-phosphoromorpholidate can be observed at the start of the experiment. With time, 
two doublets centred at 20.2 and -9 .4  ppm appear due to the formation of the 
pyrophosphate. Thus the C-ethyl ester of phosphonoformic acid which is not an 
inhibitor of the viral polymerase does form a nucleoside triphosphate analogue. We 
believe that phosphonoformic acid reacts with adenosine 5'-phosphoromorpholidatc 
to give an A TP  analogue (7) but this breaks down very rapidly in an intramolecular 
reaction to give a mixed anhydride of adenosine 5'-phosphoric and formic acids (8). 
Such mixed anhydrides are considerably more reactive than phosphoric-acetic mixed 
anhydrides”  and would be expected to decompose rapidly in pyridine. With 
phosphonoacetic acid, the nucleoside triphosphate analogue could still decompose 
by an intramolecular reaction but here a six-membered rather than a fivc-membcrcd 
ring would be involved and hence this breakdown should be comparatively slow.
Marked differences between the rates of intramolecular hydrolysis of phosphonatc 
esters have been observed depending on the size of the ring involved in the cyclic 
reaction. Thus, diethyl 2-carboxymethylphenylphosphonate undergoes intramolecu­
lar hydrolysis I0 5 times more slowly than diethyl 2-carboxyphcnylphosphonalc at 
pH 3.0 and 79.5° . 16 The C-cthyl ester of phosphonoformic acid cannot decompose 
via a cyclic reaction as the carboxyl group is blocked. Hence, the formation of the 
pyrophosphate bond in the nucleoside triphosphate analogue can be observed.
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Many DN A  and R N A  polymerases arc zinc-requiring enzymes19,20 and we 
propose that phosphonoacetic, phosphonoformic and methylcnebisphosphonic acids 
act by complexing with this zinc ion preventing the release of pyrophosphate in the 
chain-elongation step of the polymerisation. This proposal is not new21 but so far 
little evidence has been assembled to support it. A study of enzyme kinetics using 
D N A  polymerase from herpes virus shows that both phosphonoacetate and pyro­
phosphate inhibit the enzyme in an analogous manner but that pyrophosphate is the 
less active. Doth are non-competitive inhibitors of deoxyribonuclcoside triphosphates 
in the polymerase reaction. In addition, phosphonoacetate is a competitive inhibitor 
of pyrophosphate in the pyrophosphate r=* deoxyribonucleosidc triphosphate ex­
change reaction which is catalysed by the polymerase.22 This evidence suggests that 
phosphonoacetale blocks a site on the enzyme which binds pyrophosphate. Further 
support for the chelation mechanism of inhibition is the observation that batho- 
cuproin (9) and 2-acelylpyridine thiosemicarbazone (10), both good chelating agents 
for “soft" metal ions such as zinc, inhibit influenza virus replication by inhibiting 
the RNA polymerase of the virus.21
Little has been published on the melal-chclaling properties of pyrophosphate 
analogues but one study24 does show that phosphonoacelatc chelates zinc strongly.
We are investigating the metal chelating properties of our antiviral compounds 
and hope to see a correlation between the stability constants of the zinc complexes 
with antiviral activity.
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Thus, from in vitro studies, pyrophosphate analogues appear to have promise as 
chemotherapeutic agents. Those simple derivatives tested so far appear to suffer 
from one drawback. Since they arc good chelators of divalent metal ions they also 
complex strongly with calcium ions and arc deposited in the bone. The methylene- 
bisphosphonate (5, R  -  R' — Cl) has been proposed for the treatment of Paget’s 
disease of the bones. Pharmaceutical companies are naturally wary of marketing an 
antiviral which may affect the composition of bones, although there has been a 
suggestion that phosphonoformic acid may find use as an anti-herpes ointment for 
topical application. Our research into the mode of action of pyrophosphate ana­
logues may lead to the development of other, active compounds which do not have 
unfortunate side effects.
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ABSTRACT
Substituted methylene diphosphonates are effective 
inhibitors of the RNA polymerase of influenza A virus causing 50% 
inhibition of the polymerase activity when they are present in 
the concentration range 10-85 uM. The inhibitory power of the 
methylene diphosphonates appears to be related to their ability 
to chelate with metal ions.
INTRODUCTION
Influenza A virus has associated with its core an RNA- 
dependent RNA polymerase activity which differs from the 
polymerases of host cells1. Any differences in properties 
between the two classes of polymerase activity might be useful 
for chemotherapeutic exploitation. Pyrophosphate analogues (eg, 
phosphonoacetate (1) or phosphonoformate (2)) have been shown to 
inhibit the RNA polymerase of influenza virus3. We now wish to 
report that substituted methylene diphosphonates, another class 
of pyrophosphate analogues, inhibit this RNA polymerase activity 
under conditions when DNA polymerase a is little affected.
MATERIALS AND METHODS 
Reagents
Adenylyl(3'-5')guanosine and trisodium phosphonoformate (2) 
(Sigma Chemical Co), imidodiphosphonate (8) (Boehringer 
Corporation) and 3-phosphopropionic acid (3) (Fluka AG) were 
available commercially. [5-3H)UTP (42 Ci/mmol) and 3H2 Û (100 Ci/ 
mol) were obtained from Amersham International. Phosphonoacetic 
(1) and 2-phosphonopropionic (4) acids were prepared by hydro* ia 
of their triethyl esters4. Diethyl phosphonoacetic acid (6) was
€> IRL Press Limited, Oxford, England. 5021
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prepared by the method of Clayton et al^. Methylene diphosphonic 
(9)6 and substituted methylene diphosphonic acids (10-13)7 were 
synthesised as described. The C-amide of phosphonoacetic acid 
(5) was prepared by the action of ammonia on the corresponding 
ethyl ester.
Virus Type and Preparation
The influenza virus A/X49 was a cross between A/England/864/ 
75 and A/PR/8/34 with the H3N2 surface antigens of the A/England 
strain. The virus was grown in the allantoic sac of fertileg
hens' eggs and was isolated essentially as described . Eleven 
day old embryonated hens eggs were inoculated with infected 
allantoic fluid (0.1 ml of a 10~3 dilution in phosphate buffered 
saline), the eggs were incubated (33°C/48 hrs) and then chilled 
(-20°C/2 hrs). The allantoic fluid was collected, and 
centrifuged (3000 rpm/20 min) to remove unwanted egg membranes, 
from this point onwards all procedures were carried out at 0 to 
4°C. The supernatant was removed and the virus was pelleted by 
centrifugation (21,000 rpm/ 90 min, 6 x 250 ml rotor). The 
supernatant was discarded and the virus pellet was allowed to 
soak overnight in PBS. The pellet was then resuspended in PBS 
and layered on to a velocity gradient of 10 to 40% (w/v) sucrose 
in buffer ( 30 ml, 10 mM tris-HCl, pH 7.4) and centrifuged 
(22,000 rpm/1 hr, 3 x 65 ml swing-out rotor). The diffuse virus 
band was collected by bottom puncture and the sucrose was diluted 
out with PBS to a final volume of 30 ml. The virus suspension 
was layered on to an equilibrium gradient of 30 to 70% (w/v) 
sucrose in buffer (30 ml, 10 mM tris-HCl, pH 7.4) and centrifuged 
(20,000 rpm/overnight, 3 x 65ml swing out rotor). The virus band 
was collected, diluted with PBS and the virus pelleted by 
centrifugation (30,000 rpm/2 hrs, 8 x 50 ml rotor). The super­
natant was discarded and the pellet was allowed to soak overnight 
in PBS. The virus was then resuspended in buffer (3 ml, 400 uM 
tris-HCl, pH 8.0) and frozen as aliquots at -70°C and thawed once 
prior to use.
RNA Polymerase Assay
The standard reaction mixture contained in 200ul*50 mM fcris- 
HCl, pH 8.0; 5 mM magnesium acetate; 150 mM potassium chloride;
5 mM dithiothreitol; 0.4 mM ApG; 0.25% (v/v) Nonidet P-40; 0.4 mM
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each of ATP, CTP, GTP and [3HJ UTP (5 pCi) and purified virus 
(10 ul, 2000 Haul. Mixtures were kep' at 4°C until zero time of 
reaction, polymerisation being initiated by addition of virus.
The mixture was kept at 30°C for 1 hour during which time the 
incorporation of tritium into acid-precipitable material increased 
in a linear fashion. After 1 hour, cold saturated sodium pyro­
phosphate solution (200 pi) followed by cold TCA (2 ml, 10% w/v) 
were added and the mixture kept on ice for 15 minutes after 
thorough agitation. Precipitated material was collected on 
Whatman GF/C discs which were washed several times with 10% TCA, 
once with ethanol and dried. The radioactivity of material 
precipitated on the discs was then determined by scintillation 
counting using a toluene-based medium. Pyrophosphate analogues 
were added to the reaction mixtures before addition of virus.
The concentration of analogue which inhibited by 50% the incor-3
poratlon of [ H)uridine into acid insoluble material was derived 
from the dose-response curve for each compound.
DNA Polymerase a Assay
The enzyme from calf thymus was obtained from Worthington 
and was assayed as described by Matsukage et al9.
[3H]-Labelled Phosphonoacetic Acid (1)
To anhydrous phosphonoacetic acid (1) (5 mg) dissolved in
carrier free 3H20 (25 pi) was added concentrated HC1 (1 pi) and
the mixture heated at 70°C for 5 hours. Excess 3H20 was removed 
under pressure and exchangeable tritium removed by repeated add­
ition and evaporation of water. The residue, which co-chromato- 
graphed on paper with unlabelled (1) in EtOHil M ammonium acetate 
(5s2 v/v), was dried in vaouo over PjO^ to give (2-3H]-phosphono­
acetic acid, specific activity 12 pCi/pmole).
Recovery of [2-3H)-Phosphonoacetate (1) from RNA Polymerase Assay
To the standard assay solution (1 ml), containing 0.4 mM UTP 
in place of [3h )-UTP, was added 12-3H)-(1) (0.5 pmole) and puri­
fied virus. The reaction was Incubated at 30°C for 1 hour then 
EDTA was added to a final concentration of 20 mM. The reaction 
mixture was applied to a DEAE DE-52 column (OAc'form, 0.6 x 14 cm) 
which was washed with water and then eluted with a linear grad­
ient of triethylammonlum acetate (O.SpM, pH 4.7, 100 ml). The 
radioactivity of the fractions (1.5 ml) was then determined by
6623
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liquid scintillation counting, the recovery of radioactivity from 
this experiment was almost 90%. The relative positions of elution 
of I3HJ-(1) and adenyl phosphonoacetate (AMPPAA)10 were determined 
in a separate experiment.
Determination of Pyrophosphate Analogue - Zinc Ion Stability 
Constants
The stability constants were determined by the method of 
Hummel and Dreyer11, using a column of Sephadex G-10 (1.6 x 92 cm) 
which had been equilibrated with zinc chloride (10 yM) in tri- 
ethanolamine-HCl buffer (0.1 M, pH 8.0). The analogues (100 
nmole) were; added in triethanolamine/zinc buffer ( 1 ml) and the 
column eluted with the same buffer at a flow rate of 0.4 ml/min. 
The zinc content of individual fractions (2 ml) was determined by 
atomic absorption spectrometry and the stability constants deter­
mined as described11.
RESULTS AND DISCUSSION
Substituted methylene diphosphonates (10-13) are effective 
inhibitors of the RNA polymerase activity of influenza virus A 
(Table), causing 50% inhibition of the polymerase at concentra­
tions at which mammalian DNA polymerases (represented by calf 
thymus DNA polymerase a) are not affected. It has been reported 
that both (1) and (2) inhibit influenza RNA polymerase3 and we 
have observed that both these compounds are potent inhibitors of 
DNA polymerase a. Compounds (1) and (2) are effective antiviral 
agents against Herpes viruses and It has been suggested12 that 
they are active by virtue of their ability to chelate with an 
essential metal ion in the Herpes DNA polymerase and hence inhibit 
DNA synthesis. We propose that the methylene diphosphonates (10- 
13) act in a similar manner against influenza virus A. The RNA 
polymerase activity of influenza viruses is zinc-requiring13 and 
can be inhibited by compounds, eg, 2-acetylpyridine thiosemicarb- 
azone, which can chelate with 'soft' heavy metal ions. The pyro­
phosphate analogues (10-13) do not appear to exert their inhibi­
tory effect by removing from solutions magnesium ions which are 
essential for the RNA polymerase as magnesium ions are present in 
the polymerisation reaction at a concentration of 5 mM while the 
analogues are effective inhibitors of the polymerase at concen­
trations around 50 yM. The pyrophosphate analogues do not appear
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TABLE
INHIBITORY EFFECT OF PYROPHOSPHATE ANALOGUES ON 
RNA POLYMERASE FROM INFLUENZA VIRUS AND 
CALF THYMUS DNA POLYMERASE a
Concn. (yM) producing
pKd .*
50% inhibition
Compound •flu RNA DNA polymer-
polymerase ase a
(1) r c h2cooh 5.5 275 45
(2) RCOOH 5.6 35 35
(3) r c h2c h 2cooh < 4 > 500 > 500
(4) RCHMeCOOH 'v 5 > 500 > 500
(5) r c o n h2 < 4 > 500 > 500
(6) (EtO)2P(0)CH2COOH < 4 > 500 > 500
(7) ROR 5.7 125 > 500
(8) RNHR 5.7 50 > 500
(9) r c h 2r 5.3 > 500 > 500
(10) RCHC1R > 6 85 > 500
(11) r c c i2r > 6 75 > 500
(12) RCBr2R > 6 10 350
(13) RCOR 5.4 20 100
where R * (HO)2P(0)
^Dissociation constant of complex formed with zinc 
ions, measured at pH 8.0 as described in text.
to inhibit the RNA polymerase activity of influenza by being 
converted into analogues of nucleoside triphosphates before act­
ing on the enzyme. Adenyl phosphonoacetate10 is neither a sub­
strate for nor an inhibitor of the polymerase activity. Further 
more, when (2-3H)-phosphonoacetate was incubated with the stan­
dard polymerase assay mixture, all the radioactivity receoverd 
from the assay was in the form of starting material, none could 
be detected in the form of nucleoside triphosphate analogues.
Little data on the metal chelating properties of pyrophos­
phate analogues have been published. We have, therefore, deter­
mined by gel filtration a dissociation constant Kd , (Table) for
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have relatively high pKd ,g and are inhibitors of the polymerase, 
whereas (3)-(6) have lower pKd ,g and are ineffective inhibitors. 
Steric factors may also be important and (2) which can form a 
metal chelate with a 5-membered ring is a more effective inhibi­
tor than (1) which forms a chelate with a 6-membered ring. There 
is a correlation between pKd, and polymerase inhibitors for 
methylene diphosphonates, and (9) which has a lower pKd , chan the 
halogenated analogues (10)-(12) is an ineffective inhibitor of 
the polymerase. On the other hand the analogues (10)-(12) are 
good inhibitors. Interestingly, carbonyl diphosphonate (13) is a 
more effective inhibitor of the RNA polymerase activity than (9) 
though it has a similar pKd ,. Here, again, steric factors may be 
important as the P-C-P angle in the two compounds should be very 
different. Inorganic pyrophosphate (7) and imidodiphosphonate 
(8) have high pKd ,g and are inhibitors of the polymerase. 
Presumably the inhibition of the polymerase activity by inorganic 
pyrophosphate is due to suppression of the dissociation of the 
enzyme-inorganic pyrophosphate complex which is present after the 
formation of the internucleotide bond. The kinetics of the in­
hibition of influenza virus RNA polymerase activity by the pyro­
phosphate analogues are difficult to follow owing to the complex­
ity of the enzyme system (for example, Lineweaver-Burk plots of 
the inhibition of this enzyme activity by pyrophosphate analogues 
are curved). Furthermore, the polymerase activity is inhibited 
by excess zinc, making it difficult to determine whether the in­
hibition of the enzyme activity by the pyrophosphate analogues 
can be reversed by the addition of an excess of zinc ions.
We suggest that the evidence presented above supports the 
hypothesis that pyrophosphate analogues inhibit the RNA polymer­
ase activity of influenza virus by complexing with an essential 
zinc ion at the active site of the enzyme and preventing the 
binding of nucleoside triphosphates or preventing the release of 
Inorganic pyrophosphate once the internucleotide bond has been 
formed by the enzyme. One reason for the difference in sensitiv­
ity of different polymerases (eg, DNA polymerase o) to these 
analogues may be that the environment around the essential zinc 
ion is such that an effective inhibitory complex cannot be formed 
in the insensitive enzymes. Investigations on other strains of
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FIGURE
Relationship between K ., (the ability of pyrophosphate 
analogues to bind zinc ion 8t pH 8) and their effectiveness as 
inhibitors of the RNA polymerase activity of influenza A virus.
PAA phosphonoacetate (1), PFA phosphonoformate (2), 3PPA 3- 
phosphonopropionate (3), 2PPA 2-phosphonopropionate (4), PP, 
pyrophosphate (9), C1MDP monochloromethylene diphosphonate (10), 
C12MDP dlchloromethylene diphosphonate (11), Br2MDP dibromomethy- 
lene diphosphonate (12), CDP carbonyl diphosphonate (13).
complexes formed between zinc ions and pyrophosphate analogues at 
pH 8.0, the pH at which the RNA polymerase assays are carried 
out. We do not attempt to specify which ligand species are in­
volved in complex formation as more than one species may be 
present and K^, is merely an indication of the strength of the 
Interaction between the analogues and zinc ions at this pH. How­
ever, our pKd , values do not differ markedly for the pKd values 
reported for the fully ionised compounds (1) (5.3)1*, and (11) 
[6.7] . We find that there is a correlation between the pKd, of
an analogue and its effectiveness as an inhibitor of the RNA 
polymerase activity of Influenza (Figure). Thus, (1) and (2)
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have relatively high pKd ,g and are inhibitors of the polymerase, 
whereas (3)-(6) have lower pKd ,g and are ineffective inhibitors. 
Steric factors may also be important and (2) which can form a 
metal chelate with a 5-membered ring is a more effective inhibi­
tor than (1) which forms a chelate with a 6-membered ring. There 
is a correlation between pKd , and polymerase inhibitors for 
methylene diphosphonates, and (9) which has a lower pKd , than the 
halogenated analogues (10)-(12) is an ineffective inhibitor of 
the polymerase. On the other hand the analogues (10)-(12) are 
good inhibitors. Interestingly, carbonyl diphosphonate (13) is a 
more effective inhibitor of the RNA polymerase activity than (9) 
though it has a similar pKd ,. Here, again, steric factors may be 
important as the P-C-P angle in the two compounds should be very 
different. Inorganic Dyrophosphate (7) and imidodiphosphonate 
(8) have high pKd ,g and are inhibitors of the polymerase. 
Presumably the inhibition of the polymerase activity by inorganic 
pyrophosphate is due to suppression of the dissociation of the 
enzyme-inorganic pyrophosphate complex which is present after the 
formation of the internucleotide bond. The kinetics of the in­
hibition of influenza virus RNA polymerase activity by the pyro­
phosphate analogues are difficult to follow owing to the complex­
ity of the enzyme system (for example, Lineweaver-Burk plots of 
the inhibition of this enzyme activity by pyrophosphate analogues 
are curved). Furthermore, the polymerase activity is inhibited 
by excess zinc, making it difficult to determine whether the in­
hibition of the enzyme activity by the pyrophosphate analogues 
can be reversed by the addition of an excess of zinc ions.
We suggest that the evidence presented above supports the 
hypothesis that pyrophosphate analogues inhibit the RNA polymer­
ase activity of influenza virus by complexing with an essential 
zinc ion at the active site of the enzyme and preventing the 
binding of nucleoside triphosphates or preventing the release of 
inorganic pyrophosphate once the internucleotide bond has been 
formed by the enzyme. One reason for the difference in sensitiv­
ity of different polymerases (eg, DNA polymerase ™) to these 
analogues may be that the environment around the essential zinc 
ion is such that an effective inhibitory complex cannot be formed 
in the insensitive enzymes. Investigations on other strains of
5627
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influenza virus are in progress.
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